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Preface  
This Ph.D. thesis is the result of various experiments conducted through three good years on the 
island of Lindholm.  The laboratory is a part of the National Veterinary Institute within the Technical 
University of Denmark (DTU Vet). The studies were conducted under the supervision of my main-
supervisor Professor Graham J. Belsham and co-supervisor Senior Researcher Thomas Bruun 
Rasmussen. The studies were supported by core funds from within DTU Vet. Furthermore, a short 
research stay at the Pirbright Institute (United Kingdom) was supported by a Short Term Mission 
from Epizone.   
 
This Ph.D. thesis is divided into four main chapters. Chapter 1 describes the current knowledge 
about foot-and-mouth disease virus (FMDV), including the status of foot-and-mouth disease (FMD) 
and the FMDV life-cycle at a molecular level. It focuses on the processing of the capsid precursor 
and the assembly pathway to generate virus particles.  
 
Chapter 2 briefly describes the aim of the three different manuscripts. Furthermore, it also provides 
the reader with a short summary of the manuscripts. Chapter 3 is presented as three manuscripts 
listed below. In this chapter, the results are described and discussed.  
 
1. Kristensen T., Normann P., Gullberg M., Fahnøe U., Polacek C., Rasmussen T. B. 
and Belsham G. J. (2016). Determinants of the VP1/2A junction cleavage by the 3C 
protease in foot-and-mouth disease virus-infected cells. Journal of General 
Virology, 98 (385-395). 
 
2. Kristensen T., Newman J., Guan S. H., Tuthill T. J. and Belsham G. J. (2018). 
Cleavages at the three junctions within the foot-and-mouth disease virus capsid 
precursor (P1-2A) by the 3C protease are mutually independent. Virology, 522 
(260-270). 
II 
 
 
3. Kristensen T. and Belsham G. J. Identification of a short, highly conserved, motif 
required for picornavirus capsid precursor processing at distal sites. Manuscript 
submitted.  
 
Chapter 4 provides the overall conclusions of the results obtained and discussed in the three 
manuscripts. It also provides future perspectives for research resulting from the three manuscripts.   
 
  
III 
 
Acknowledgements 
My time as a Ph.D. student at Lindholm is something that I will always remember and look back at 
with extreme joy. The time has been both interesting and good, and I feel that I have learned a lot 
during the last three years. No doubt, there has also been times of frustrations, when things 
(especially experiments) did not go as planned. The work leading up to this thesis would not have 
been possible without the support from many people two whom I am very grateful.  
 
First, I would like to thank my two supervisors, Professor Graham J. Belsham and Senior Researcher 
Thomas Bruun Rasmussen for giving me the opportunity to carry out this Ph.D. project. It has been 
three wonderful years and I have learned so much from both of you. I would like to express my 
gratitude to my main supervisor Professor Graham J. Belsham. We have had so many good talks and 
scientific discussions. Thank you for always answering your emails within seconds and for always 
providing good and constructive feedback on manuscripts and presentations. You have always 
supported and guided me when I came with new ideas for new experiments. Numerous times, I 
have entered your office to discuss some new results or new ideas, left five minutes later, and then 
an hour has passed. So thank you for always taking your time and always keeping your door open. I 
also wish to acknowledge my co-supervisor, Senior Researcher Thomas Bruun Rasmussen. You have 
always kept your door open, and been available when I needed to discuss something with you, from 
the project economy to troubleshooting about a mutagenic PCR, so thank you.  
 
Special thanks also go to Laboratory technician Preben Normann who has assisted me in the lab 
when time was limited. You have been an incredible help, especially in the creation and sequencing 
of new constructs and you have impressed me every time you managed to create 15 new constructs 
at your first go. I also wish to thank Laboratory technician Jani Christiansen, Jane Borch and Hanne 
Petersen for their assistance in reading plates, performing ELISAs and virus titrations. Special thanks 
also go to the laboratory technicians in the cell-lab, Lone Koch Nielsen, Dorota Wolkanowska, Hanne 
Egelund Hansen and Hanne Petersen. You have provided me with so many cells, and every cell has 
always been of first class quality!  
IV 
 
 
I also wish to thank all of the Ph.D. students who are, and have been, employed during my time at 
Lindholm. I wish to thank Ph.D. Jonas Kjær, who was also in the FMDV group at the time of my 
employment. We have had so many good talks about FMDV, but certainly also about everything 
else. I also wish to thank my good friend and colleague Ph.D. student Ann Sofie Olesen. You have 
been by my side since we conduced our master thesis at University of Copenhagen and I am so glad 
that we had the opportunity to follow each other through our Ph.D. studies as well.  
 
I also wish to acknowledge all of the incredible people working at Lindholm. I have been so pleased 
to work there during the last three years. There is an amazing work environment and a nice and 
relaxed atmosphere. In relation to this, I especially want to thank the Head of the Virology group, 
Professor Anette Bøtner. You have contributed very much for maintaining this good environment, 
even though the future for Lindholm has been uncertain. I have always felt comfortable coming to 
you, no matter the reason. The list is too long to mention all of your names, but you should know, 
that you have all contributed to making this a fantastic place to work! Huge thanks also goes out to 
the card-playing club on the ferry. I have so many good memories from the mornings and afternoons 
with many good games, wonderful talks and incredibly many laughs. I still find it very incredible that 
I have managed not to lose a single time in this game during the last three years (even though some 
of you might think that I did)!   
 
I also wish to thank Dr Tobias J. Tuthill for letting me work in his lab at the Pirbright Institute (United 
Kingdom). It was a very pleasant stay, and everyone in the group was so friendly and welcoming. 
Special thanks also goes out to Ph.D. student Chris Neil, for helping to arrange the practical stuff 
associated with my stay. Furthermore, I also wish to thank Postdoc. Joseph Newman for assisting 
me in the laboratory and for helping me successfully accomplish the objective of my stay. 
Furthermore, I would like to thank Epizone for the funding of this stay.  
 
V 
 
Finally, I would like to thank my family and friends who have supported me in fulfilling this journey. 
I wish to thank my dad, who has always been very interested and asked questions about my research 
but far from always understood the answers. My deepest thanks goes to my boyfriend Jonas 
Pedersen, for always believing in me and supporting me through the last ten years, and in particular 
the last three.        
 
  
VI 
 
List of abbreviations 
 
17-AAG  17-allyl-17-demethoxygeldanamycin 
17-DMAG  17-desmethoxy-17-N,N-dimethylaminoethylaminogeldanamycin 
3Cpro  3C protease 
3Dpol  3D polymerase 
aa   Amino acids  
BEV  Bovine enterovirus 
cDNA  Complementary DNA 
CHIP  Carboxyl terminus of Hsp70-interacting protein 
CPE  Cytopathic effect 
cre   cis-acting replication element 
DI  Defective interfering 
DNA  Deoxyribonucleic acid 
dsRNA   Double stranded RNA 
eIF  Eukaryotic translation initiation factor  
ELISA  Enzyme linked immunosorbent assay 
ER  Endoplasmic reticulum 
EMCV  Encephalomyocarditis virus 
FMD  Foot-and-mouth disease 
FMDV  Foot-and-mouth disease virus 
GAO  United States Government Accountability Office 
GA  Geldanamycin 
HAV  Hepatitis A virus 
HRV  Human rhinovirus 
Hsp  Heat-shock protein 
Ig   Immunoglobin 
IFN  interferon 
IRES  Internal ribosome entry site 
VII 
 
ISG  interferon-stimulated genes 
Lpro  Leader protease  
MKS  Mund- og klovsyge (Danish FMD) 
MKSV  Mund- og klovsyge virus (Danish FMDV) 
mRNA  Messenger ribonucleic acid 
nm   Nano meters  
nt   Nucleotides  
O1K  O1 Kaufbeuren 
O1M  O1 Manisa 
OIE  Office International des Épizooties (World Organisation for Animal 
Health) 
ORF Open reading frame 
p.i. Post infection 
PCBP2  Poly-r(C)-binding Protein 2 
PCR  Polymerase chain reaction 
PV  Poliovirus 
RNA  Ribonucleic acid 
RT-PCR  Reverse transcription-polymerase chain reaction 
SVD  Swine vesicular virus 
UK  United Kingdome 
UTR  Untranslated region 
US  United States  
VNT  Virus neutralization test 
wt   wild type 
 
 
  
VIII 
 
Objectives and summary 
Foot-and-mouth disease (FMD) is caused by a highly contagious virus (FMDV) that infects cloven-
hoofed animals, including both domesticated and wildlife. FMD is one of the most important threats 
to the agricultural industry. Europe is usually free of FMD, however sometimes outbreaks occur and 
can result in large productivity losses and severe trade restrictions. One example of such an 
outbreak of FMD occurred in the United Kingdom (UK) in 2001, where the total costs were estimated 
to around 8 billion pounds. An outbreak of FMD has not occurred in Denmark since 1983. However, 
introduction of the disease back into Denmark would have huge consequences for the Danish 
industrialized pig production, and remains a continuing threat.  
 
FMDV belongs to the picornavirus family. The virus particles consist of a capsid surrounding a single-
stranded, positive sense genomic RNA of approximately 8,400 nucleotides. The capsids consist of 
60 copies of four different structural proteins, termed VP1, VP2, VP3 and VP4. These capsid proteins 
are generated by cleavage of the capsid precursor P1-2A into VP0, VP3, VP1 and a short 2A peptide 
by the viral encoded 3C protease (3Cpro). The 2A peptide is not included in the virus particle. During 
assembly of the capsid proteins, VP0 is cleaved to generate VP4 and VP2 by a process that is 
currently unknown. The processing of the capsid precursor into the capsid proteins is necessary for 
virus capsid assembly, and thus essential in the virus life cycle. Blocking the processing of the 
junctions between the capsid proteins, might be fatal for the virus, and thus might be a possible 
antiviral target.   
 
The focus of this Ph.D. thesis has been to determine the importance of the amino acid sequences 
flanking the junctions within the FMDV P1-2A precursor in relation to correct processing by the 
3Cpro. Furthermore, studies have also been performed on analyzing a specific motif within VP1, 
which is important for correct capsid precursor processing.   
 
Manuscript 1: In an earlier study it was found that the VP1 K210E (the P2 position in the VP1/2A 
junction) in FMDV O1 Manisa, blocked cleavage of this junction. The mutant virus acquired a second 
site mutation, VP1 E83K. Introduction of this VP1 E83K alone caused the virus to generate a new 
second-site mutation near the VP1/2A junction, at the 2A L2P (the P2´ position). Interestingly, this 
IX 
 
substitution also severely inhibited cleavage of this junction. In this manuscript virus adaptions 
within these two mutant viruses (e.g. FMDV VP1 K210E and FMDV VP1 E83K) were analyzed by next 
generation sequencing. This identified variants within the FMDV VP1 E83K, where the VP1 K210N 
was observed. To identify which amino acids could be tolerated at this site for processing of the 
VP1/2A junction, various alternative amino acids (aa) were introduced at VP1 K210 in the FMDV A22 
Iraq. Interestingly, only the presence of a positively charged aa (e.g. lysine or arginine) at this 
position permitted efficiently cleavage of the VP1/2A junction by the 3Cpro, whereas the presence 
of either an aa with neutral or negative charge severely blocked cleavage of this junction.  
 
Manuscript 2: In this manuscript, the impact of different substitutions near the junctions separating 
the capsid proteins within the capsid precursor, was investigated. The VP0/VP3- and the VP3/VP1 
junctions were modified with different aa substitutions within a construct encoding the P1-2A area. 
These constructs were expressed in a transient expression assay in either the presence or absence 
of 3Cpro.  The VP2 K217R and the VP3 I2P (2 aa upstream and downstream the VP0/VP3 junction 
respectively), strongly reduced cleavage of this junction. The VP2 K217E substitution completely 
prevented cleavage of this junction by the 3Cpro. Both the VP3 Q221P and the VP1 T1P (1 aa 
upstream and downstream the junction) each severely inhibited cleavage of the VP3/VP1 junction. 
Interestingly, blocking either of these junctions, did not prevent processing of any other junction 
within the capsid precursor. Thus, it seems that there is no strict order of 3Cpro processing of the 
capsid precursor. The modifications were also introduced into full-length FMDV RNA. However, only 
the wt and the mutant having the VP2 K217R substitution could be rescued as infectious virus. 
Higher levels of the VP0-VP3 intermediate were observed within cells infected with the mutant 
virus. The VP0-VP3 intermediate was not incorporated in either empty capsids or virus particles. 
Thus, processing of this junction seems necessary for capsid assembly.     
 
Manuscript 3: This manuscript identified a short motif required for correct FMDV capsid precursor 
processing. Various modifications were introduced into the VP1-coding region of FMDV P1-2A 
cDNA. Truncations removing the 2A peptide and 27 aa of the C-terminus of VP1, resulted in severe 
blocking of the processing of both the VP0/VP3- and VP3/VP1 junctions within the capsid precursor. 
Introducing small deletions identified the region VP1 185-190, as being necessary for correct 
X 
 
processing by the 3Cpro. Five of these aa (YCPRP) are highly conserved among all seven serotypes of 
FMDV. Furthermore, these residues are also conserved in many other picornaviruses, including 
poliovirus. Single aa substitutions in the motif revealed that VP1 Y185A and VP1 R188A individually 
impeded cleavage of both the VP0/VP3- and the VP3/VP1 junctions, which are more than 400 aa 
and around 200 aa away from the site of modification. Interestingly, this conserved motif can also 
explain earlier observations on the poliovirus capsid precursor, which is highly resistant to cleavage 
following truncation (which removed this motif). The results suggest that the identified motif, is 
important for correct folding of picornavirus capsid precursors and their subsequent processing.       
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Formål og resumé (objective and summary in Danish) 
Mund- og klovsyge (MKS) forårsages af en meget smitsom virus (MKSV), som inficerer klovbærende 
dyr, heriblandt både vilde dyr og produktionsdyr. MKS er en af de værste infektiøse sygdomme i 
forhold til landbrugets produktionsdyr. Europa har været fri for MKS i mange år, dog kommer der 
indimellem udbrud, hvilket forårsager store økonomiske tab for erhvervet i forbindelse med 
aflivning og restriktioner for handlen med produktionsdyr. I 2001 havde England et alvorligt udbrud 
af MKS, hvilket blev estimeret til at have kostet i omegnen af 67 milliarder DKK. Siden 1984 har der 
ikke været nogen udbrud af MKS i Danmark, dog udgør et potentielt udbrud stadig en kæmpe 
trussel, da det ville have store konsekvenser for det danske landbrug.     
 
MKSV tilhører familien Picornaviridae. Viruspartiklen består af en proteinskal, også kaldet et kapsid, 
som indeholder et positivt enkelstrenget RNA-genom på ca. 8.400 nukleotider. Kapsidet består af 
60 kopier af 4 forskellige strukturelle proteiner: VP1, VP2, VP3 og VP4. Disse 4 kapsidproteiner samt 
et kort 2A-peptid, som ikke inkorporeres i viruspartiklen, bliver dannet ved kløvning af 
kapsidprecursoren. Denne kløvning foretages af et af virussens egne enzymer, 3C proteasen (3Cpro). 
Under dannelsen af viruspartiklen bliver VP0 kløvet til VP4 og VP2, ved en, indtil videre, ukendt 
proces. Kløvningen af kapsidprecursoren er nødvendig i dannelsen af nye viruspartikler, og derfor 
også afgørende for virussens livscyklus. Blokering af et af disse kløvningssteder mellem 
kapsidproteinerne er højst sandsynligt fatalt for virussen, og de kunne derfor være oplagte mål for 
antivirale midler.                 
 
Formålet med denne ph.d. afhandling har været at undersøge aminosyresekvensen nær forskellige 
kløvningssteder i MKSV kapsidprecursoren i forhold til korrekt kløvning. Derudover har der også 
været fokus på at identificere en region i VP1, som er vigtig for korrekt kløvning af 
kapsidprecursoren.    
 
Manuskript 1: Et tidligere studie har vist, at en aminosyreændring, VP1 K210E, (P2 positionen i 
VP1/2A kløvningsstedet) i MKSV O1 Manisa forhindrede kløvning af VP1/2A. Denne mutantvirus 
XII 
 
viste sig at have genereret yderligere en mutation i VP1 E83K. VP1 E83K mutationen blev 
introduceret alene i MKSV, og denne virus genererede en mutation nær VP1/2A kløvningsstedet, i 
2A L2P (på P2´positionen). Også denne mutation viste sig at blokere kløvningen af VP1/2A 
kløvningsstedet. I dette manuskript, har vi brugt next generation sequencing til at identificere 
adaptioner i disse to virusmutanter (MKSV VP1 K210E og MKSV VP1 E83K). MKSV VP1 E83K 
mutanten viste sig at have genereret en mutation i VP1 K210N. Forskellige aminosyrer blev 
introduceret i MKSV A22 Iraq på VP1 K210 positionen for at identificere, hvilke der kunne tolereres 
i forhold til korrekt kløvning af VP1/2A kløvningsstedet. Kun positivt ladede aminosyrer på denne 
position resulterede i at 3Cpro kunne kløve dette kløvningssted. Både negativt og neutralt ladede 
aminosyrer blokerede kløvningen af kløvningsstedet. 
 
Manuskript 2: I dette manuskript har vi undersøgt effekten af forskellige substitutioner nær de to 
kløvningssteder som adskiller kapsidproteinerne. Forskellige aminosyresubstitutioner blev 
introduceret enkeltvis nær VP0/VP3- og VP3/VP1 kløvningsstederne i et konstrukt som kodede for 
P1-2A kapsidprecursoren.  Disse konstrukter blev udtrykt i celler både alene og sammen med 3Cpro. 
Substitutionerne VP2 K217R og VP3 I2P (2 aminosyrer før og efter VP0/VP3 kløvningsstedet), 
reducerede individuelt kløvningen af dette site. Substitutionen VP2 K217E blokerede kløvningen af 
VP0/VP3 kløvningsstedet. Substitutionerne VP3 Q221P og VP1 T1P (1 aminosyre før og efter 
kløvningsstedet) blokerede individuelt kløvningen af VP3/VP1 kløvningsstedet. Blokering af ét af 
disse kløvningssteder forhindrede ikke kløvning af andre kløvningssteder i kapsidprecursoren. De 
forskellige modificeringer blev også genereret i fuld-længde MKSV RNA. Dog var det kun vildtypen 
(wt) og mutanten MKSV VP2 K217R der genererede infektiøs virus. Der blev observeret et højere 
niveau af et mellemprodukt bestående af VP0-VP3 i celler inficeret med denne mutantvirus 
sammenlignet med celler inficeret med wt virus. Dette VP0-VP3 mellemprodukt blev ikke 
inkorporeret i hverken tomme kapsider eller i viruspartikler, og det virker derfor sandsynligt, at 
kløvning af dette VP0/VP3 kløvningssted er nødvendig for dannelsen af kapsidet i viruspartiklen.   
 
Manuskript 3: I dette manuskript har vi identificeret en kort region, som er nødvendig for korrekt 
kløvning af MKSV kapsidprecursoren. Forskellige modificeringer blev genereret i VP1 regionen i et 
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konstrukt som indeholdt MKSV P1-2A cDNA. Fjernelsen af 2A peptidet og 27 aminosyre af VP1 C-
terminalen resulterede i, at kapsidprecursoren ikke kunne kløves af 3Cpro. Ved at introducere små 
deletioner i dette område blev det tydeligt, at regionen VP1 185-190 var nødvendig for korrekt 
kløvning af kapsidprecursoren. Fem af disse aminosyrer (YCPRP) viste sig at være meget 
konserverede i alle syv serotyper af MKSV. Derudover viste det sig, at dette motiv også var meget 
konserveret i mange andre picornavirus som fx poliovirus. Enkeltvise aminosyresubstitutioner i 
dette område afslørede, at VP1 Y185A og VP1 R188A hver især kunne forhindre kløvning af både 
VP0/VP3- og VP3/VP1 kløvningsstedet. Disse to kløvningssteder ligger hver især henholdsvis mere 
end 400 aminosyrer og omkring 200 aminosyrer væk fra den modificerede region. Identificeringen 
af dette konserverede motiv kan forklare tidligere observationer, hvor trunkation af poliovirus 
kapsidprecursoren (inklusiv fjernelse af det konserverede motiv) resulterede i, at denne ikke kunne 
kløves. Det virker sandsynligt, at dette nyligt identificerede motiv er vigtigt for korrekt foldning af 
kapsidprecursoren og for kløvningen af denne.           
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1.   Introduction 
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1.1.   Introduction to and status of foot-and-mouth disease 
Foot-and-mouth disease virus (FMDV) infects cloven-hoofed animals including both domesticated 
animals and wildlife (Alexandersen & Mowat, 2005; Jamal & Belsham, 2013). FMDV infections result 
in high productivity losses and, as the disease is extremely contagious, it is considered a very 
important animal health concern worldwide (Grubman & Baxt, 2004). Foot-and-mouth disease 
(FMD) is one of the most important threats to the agricultural industry as outbreaks are difficult to 
control, result in trade restrictions and hence have huge economic impact. 
 
The mortality resulting from FMDV infection is low in adult animals but due to the rapid spread, high 
morbidity and huge devastating economic impact, the disease is one of the listed infectious diseases 
of the World Organisation for Animal Health (Office International des Épizooties (OIE))  (Grubman 
& Baxt, 2004). Countries that are a member of the OIE are classified with a particular FMD status, 
and the FMD control strategy depends on the status of the country. FMDV is able to spread via 
transport of milk or other animal products and thus disease-free countries have strict controls on 
imports of such products to prevent entry of the disease to the country (Grubman & Baxt, 2004). 
 
FMD has been eradicated from Europe but it is still endemic in many parts of Africa and Asia 
(Alexandersen et al., 2003), see Fig. 1. Sometimes outbreaks of FMD occur in previously disease-free 
areas. The United Kingdom (UK) experienced a huge outbreak of FMD in 2001. More than 10 million 
cattle, sheep and pigs were slaughtered and burned. The direct cost in compensation to farmers 
that had lost their animals were estimated to around 1.1 billion pounds, whereas the total costs 
were estimated to around 8 billion pounds, since the associated effects on trade in the agriculture 
industry and tourism were also very costly and long lasting (Rowlands, 2017). This outbreak brought 
FMD back into focus, for at least Europe, which had been free of the disease for many years. Other 
massive outbreaks of FMD include Taiwan in 1997 where around 40% of the pig population was lost, 
and Argentina which also had a huge outbreak in 2000-2001 (Rowlands, 2017). The trauma 
associated with these FMD outbreaks has caused a higher focus on FMDV research, surveillance and 
control. Indeed, new high containment facilities for working with FMDV have been built in several 
places around the world, e.g. at The Pirbright Institute in the UK, at DTU National Veterinary 
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Institute, Lindholm, in Denmark and at Plum Island in the United States (US) (Rowlands, 2017). 
However, both Denmark and the US are now planning on moving their facilities to the mainland i.e. 
Copenhagen (Vilhelmsen, 2017) and Kansas respectively (Kingsbury, 2008). However, in 2008 the 
US Government Accountability Office (GAO) stated that evidence was lacking to conclude that FMD 
research could be carried out safely on the US mainland. The GAO pointed out that data from earlier 
releases of FMD from laboratory facilities had not been proper examined. This raised numerous 
concerns about the danger related to having such facilities on the mainland close to susceptible 
animals (Kingsbury, 2008). Later on, the National Academy of Sciences suggested that the possibility 
of FMD release from the laboratories in Kansas was estimated to be around 70% over the next 50 
years, most likely due to human error (Walsh & Yeibio, 2010). However, the plan is still for the new 
FMD facilities in Kansas to open in 2022.   
 
Figure 1 shows the geographical distribution of foot-and-mouth disease virus (FMDV) divided into 
seven pools. Countries, which are normally free of disease, are marked in beige (Jamal & Belsham, 
2013). 
 
FMDV is a small, non-enveloped, single-stranded positive-sense RNA virus belonging to the genus 
Aphthovirus within the large family of picornaviruses. The FMDV RNA genome is about 8,400 
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nucleotides (nt) in length and is surrounded by a protein shell (capsid), which is roughly spherical 
and around 25-30 nm in diameter. The capsids consist of 60 copies of four different structural 
proteins, termed VP1, VP2, VP3 and VP4. Seven different serologically distant serotypes of FMDV 
exist, namely O, A, C, SAT1, SAT2, SAT3 and Asia-1 (Jamal & Belsham, 2013). There is no cross-
protection between these serotypes due to huge sequence diversity and thus significant antigenic 
variation especially within the capsid coding regions.  
 
Since FMDV is extremely contagious and has huge economic impact, effective surveillance is very 
important. The first step in good surveillance is based on the observation of clinical symptoms, 
which include high temperature, excessive salivation, vesicles in and around the mouth and on the 
feet, resulting in loss of appetite and lameness (Jamal & Belsham, 2013; Nfon et al., 2017). In cattle 
these symptoms are normally very easy to recognize, whereas it can be rather difficult to detect the 
disease in sheep due to mild or unapparent signs of infection (Grubman & Baxt, 2004). Furthermore, 
other diseases such as swine vesicular disease (SVD) and vesicular stomatitis can cause similar 
symptoms in certain species (Jamal & Belsham, 2013). Upon observation of clinical signs, samples 
from the suspected cases must be tested by various laboratory techniques to diagnose the disease 
and if positive, to determine the serotype of the virus. Some of the most widely used techniques for 
diagnosis include the virus neutralization tests (VNT), enzyme linked immunosorbent assay (ELISA) 
(for antigen or antibody), reverse transcription-polymerase chain reaction (RT-PCR) and virus 
passage on cells. The antigen ELISA can be used with an integrin as the capture reagent, since this is 
able to capture all FMDV serotypes (Rowlands, 2017). Moreover, the primers used in the RT-PCR 
have to be complementary to the genome of all serotypes. To ensure that the virus concentration 
is high enough to detect, it sometimes has to be propagated in susceptible cell cultures (Jamal & 
Belsham, 2013).       
 
FMDV can cause persistent infection in cattle, sheep and goats (i.e. so called carrier animals). Pigs 
on the other hand, do not become carriers since they clear the infection within 3-4 weeks 
(persistence is defined as animals being positive for virus for at least 28 days after infection) 
(Alexandersen et al., 2002). Cattle frequently continue to shed virus after clinical symptoms have 
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disappeared. In wildlife animals, the African buffalo has been reported to “carry” the virus for up to 
5 years (Alexandersen et al., 2002). There has been some controversy over whether FMD is 
transmissible from long-term carriers. The virus shed from persistently infected animals is often 
present as virus-antibody complexes. However, infectious virus can be isolated from such samples 
by removing antibodies with organic solvent (Rowlands, 2017). Over time, there have been a few 
observations in southern Africa indicating the possibility of transmission from persistently infected 
buffalo into herds of cattle. However, several controlled experiments were unable to show that the 
virus could spread to another animal from a persistently infected animal (Sutmoller & Olascoaga, 
2002). However, a recent study has shown that exposure of susceptible cattle to oropharyngeal fluid 
(collected from the throat and then deposited in the pharynx, not injection) from persistently 
infected cattle caused clinical FMD (Arzt et al., 2018). However, neither this fluid nor tissues 
harvested from the cattle were able to transmit the infection to pigs. 
Another issue is that some vaccinated animals do not show clinical signs following exposure to 
FMDV but their immune status might not prevent them from becoming carriers. The carrier-issue, 
with vaccinated animals, has intensely influenced the decisions about not using vaccines unless an 
outbreak occurs (Alexandersen et al., 2002; Rowlands, 2017). However, in countries where the 
disease is endemic and control is by vaccination, it is important to be able to discriminate between 
vaccinated animals and potential carriers. One strategy is to remove epitopes from the vaccine virus 
without interrupting its protective ability (Fowler et al., 2010, Fowler et al., 2014). Antibodies against 
the deleted epitope would thereby indicate that the animal had been infected with the wildtype 
(wt) virus. 
 
1.2.   Foot-and-mouth disease virus – a member of the picornavirus family 
Picornaviruses are a large family of non-enveloped RNA viruses that includes significant human and 
animal pathogens. Clinically important picornaviruses in humans include poliovirus, rhinovirus 
(causing the common cold), echovirus 71 (causing hand, foot and mouth disease and severe 
neurological disease in children), hepatitis A virus, Coxsackievirus A (also causing hand, foot and 
mouth disease) and Coxsackievirus B (causing pain and inflammation in the chest), the last two 
infections can also lead to meningitis or myocarditis. Picornaviruses affecting animals include swine 
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vesicular virus and foot-and-mouth disease virus (FMDV). The picornavirus family is still growing, 
and in 2014 consisted of 46 species grouped into 26 genera, the best known being Enterovirus (e.g. 
poliovirus (PV), rhinovirus and coxsackievirus), Aphthovirus (e.g.  FMDV), Cardiovirus (e.g. 
encephalomyocarditis virus (EMCV) and Theiler’s murine encephalitis virus) and Hepatovirus (e.g. 
hepatitis A virus (HAV)) (Jiang et al., 2014). See Fig. 2 for an overview of the picornavirus family, 
illustrated by a phylogenetic tree.   
 
 
Figure 2 shows a phylogenetic tree of the major genera within the picornavirus family. The tree is 
based on the amino acid sequence relationships for the capsid precursor. The branch length 
corresponds to the amino acid substitutions per position (King et al., 2011). 
 
Picornaviruses are approximately 25-30 nm in diameter, and have a capsid with an icosahedral 
symmetry surrounding a single-stranded, positive sense genomic RNA of approximately 7,100-8,900 
nt. Both the 5´ and 3´ terminus of the RNA contain an untranslated region (UTR). A virus-encoded 
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protein, VPg (3B) is covalently linked to the 5´ terminus. The capsid is comprised of 60 copies of each 
of the four capsid proteins VP4 (also designated 1A), VP2 (1B), VP3 (1C) and VP1 (1D) with the 
exception of parechoviruses and kobuviruses in which the VP0 (the precursor of VP2 and VP4) 
remains uncleaved (Jiang et al., 2014). The capsid proteins VP1, VP2 and VP3 are exposed on the 
outside surface of the particle while VP4 is located internally (Hogle et al., 1985; Rossmann et al., 
1985; Acharya et al., 1989; Jiang et al., 2014).  
 
The receptors used for entering host cells by different picornaviruses are very diverse. PV, Coxsackie 
B virus and certain rhinoviruses use the immunoglobin (Ig)-like domains as receptors. Other 
picornaviruses are known to use heparan sulfate, low-density lipoproteins and integrins (Tuthill et 
al., 2010; MacLachlan & Dubovi, 2017). In addition, the pathway for releasing the RNA into the 
cytoplasm of the host cell also varies among different picornavirus genera. For instance, when PV 
interacts with its receptor it causes structural changes in the virus particle, which results in the 
release of the internal VP4 and the N-termini of the VP1s are re-localized to the surface of the 
particle. The N-terminus of VP1 is hydrophobic and is (perhaps together with VP4) involved in 
forming a pore in the cell membrane through which the viral genome can enter the cytoplasm 
(Tuthill et al., 2010). The FMDV VP1 protein lacks the equivalent N-terminal region present in PV, 
and thus the entry mechanism for FMDV is different (Tuthill et al., 2010). FMDV enters the host cell 
through an endosomal pathway by a docking mechanism. The mildly acidic pH within the 
endosomes causes the capsid to disassemble into pentameric subunits and releases the viral 
genome (Tuthill et al., 2010) (described in further detail in section 1.5.1.). The specific pathways 
used by different genera within the picornavirus family might reflect their differences in pH stability, 
i.e. PV is stable at low pH while FMDV is not (MacLachlan & Dubovi, 2017).           
 
Only the virus genome needs to enter the cell cytoplasm as the RNA is infectious, and can initiate 
the infection alone. After reaching the cytoplasm, the RNA genome is translated in a cap-
independent mechanism in which the ribosome binds via the translation initiation factors, to the 
internal ribosomal entry site (IRES) within the 5′ UTR of the viral RNA (Martinez-Salas & Belsham, 
2017). The RNA contains a single, large, open reading frame that is translated and processing of the 
encoded polyprotein occurs both during and after translation (Jiang et al., 2014). Three or four 
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proteins are formed rapidly after the translation, the Leader (not in all picornaviruses), the capsid 
precursor P1 or P1-2A (depending on the genus), also referred to as the structural protein precursor, 
and P2 and P3 (the non-structural protein precursors). Many picornaviruses, e.g. members of the 
Cardiovirus, Hepatovirus and Aphthovirus genera, have a Leader protein at the N-terminus of the 
polyprotein. In the Aphthovirus genus, the Leader protein is a protease (Lpro), which is responsible 
for cleavage at its own C-terminus, thereby separating itself from the P1-2A capsid precursor. 
Separation of the structural and non-structural proteins in the cardio- and aphthoviruses is 
mediated at the 2A/2B junction in a protease independent manner during translation, by a process 
termed “ribosomal skipping” (Donnelly et al., 2001) or “StopGo” (Atkins et al., 2007). In contrast, 
the 2A protein in enteroviruses is a chymotrypsin-like protease, and is responsible for cleavage at 
its own N-terminus (at the VP1/2A junction) to separate the capsid precursor from the non-
structural proteins (Toyoda et al., 1986; Sommergruber et al., 1989). 
 
The P2-P3 junction and most other protein junctions within these three precursors (P1/P1-2A, P2 
and P3) are cleaved by 3Cpro to produce the mature proteins. However, the P1 capsid precursor of 
enteroviruses is processed by the 3CD protease (3CDpro) (Jore et al., 1988; Ypma-Wong et al., 1988) 
whereas the 3Cpro is responsible for cleavage of the P1-2A precursor of cardio- and aphthoviruses 
into three structural proteins (VP0, VP3 and VP1) plus 2A (Belsham, 2005; Gullberg et al., 2013a). 
During capsid assembly and usually encapsidation of the viral RNA, VP0 is cleaved (in most 
picornaviruses) to generate VP2 and VP4 by a process that is currently unknown.  
 
The non-structural proteins, especially the 2C and the 2BC precursor, are involved in relocation of 
cellular membranes into structures that are essential for the formation of RNA replication 
complexes (Jiang et al., 2014). The positive sense RNA is used as the template for the synthesis of a 
negative sense RNA, which in turn is used as template to synthesize more positive sense RNA. The 
RNA is synthesized by the 3D polymerase (3Dpol) and requires the uridylylation of a free VPg protein, 
to function as a primer for both the synthesis of positive- and negative-sense RNA (Belsham, 2005). 
The newly made positive sense RNA can either be used for translation, as the template for RNA 
synthesis or as the viral genome in  new virus particles (Jiang et al., 2014).    
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Many picornaviruses are relatively heat stable and may survive for several weeks if protected by 
saliva or feces and shielded from strong sunlight. The stability of the capsids among different genera 
are affected differently by pH, and thus certain disinfectants are suitable for some genera but not 
for other, i.e. sodium carbonate is an effective disinfectant for FMDV but not for SVD virus 
(MacLachlan & Dubovi, 2017).  
 
1.3.   FMDV genome organization 
The FMDV particle has a protein shell (capsid) that consists of 60 copies of the four different capsid 
proteins, VP1, VP2, VP3 and VP4. The VP1, VP2 and VP3 are exposed on the outside of the virus 
shell, whereas VP4 is internal (reviewed by Jiang et al., (2014)). The capsid serves to protect the viral 
genome and to deliver it to the cytoplasm of a cell. Each particle contains a single stranded positive-
sense RNA genome, which has structures that resemble cellular mRNAs, i.e. with one long open 
reading frame (ORF) and a poly(A) tail at its 3´-terminus. However, unlike cellular mRNAs, the FMDV 
RNA has no cap structure at its 5´-terminus. The large ORF encodes a large polyprotein that is rapidly 
processed, mostly by virus-encoded protease to generate four primary protein precursors, namely 
the leader (Lpro), the capsid precursor (P1-2A) and the two non-structural protein precursors (P2 and 
P3). These precursors are processed to generate some 15 mature proteins (Belsham, 2005). For an 
overview of the genome organization, see Fig. 3. 
 
1.3.1.   The 5´-untranslated region (5´-UTR) 
The 5´-UTR of FMDV is extraordinarily long compared to other picornaviruses, comprising ca. 1,300 
nucleotides, whereas PV 5´-UTR only comprises approximately 740 nt and EMCV 5´-UTR around 830 
nt (Belsham, 2005). The 5´-UTR can be divided into five different regions, namely the S-fragment, 
the poly(C) tract, several pseudoknots, the cis-acting replication element (cre) and the internal 
ribosome entry site (IRES). An overview of the different regions can be seen in Fig. 4.  
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Figure 3 shows the genome organization of FMDV. The RNA genome encodes a large polyprotein. 
The Leader protease (Lpro) cleaves at its own C-terminus. The capsid precursor P1-2A is separated 
from the non-structural proteins by a mechanism referred to as ribosomal skipping at the 2A/2B 
junction. The 3C protease (3Cpro) is responsible for cleavage of all other junctions with the exception 
of the maturation cleavage of VP0 into VP4 and VP2 (adapted from Jamal & Belsham (2018)). 
 
The first region is the S-fragment, which is around 360 nt and is predicted to fold into a large hairpin 
structure (Clarke et al., 1987; Escarmís et al., 1992). It is assumed that the S-fragment is required for 
the viral RNA replication, since the initiation of the positive strand RNA replication will initiate at the 
S-region complement on the negative strand. It has also been reported that the S-fragment interacts 
with the cellular RNA helicase A (involved in alterations of RNA secondary structures) and that 
reducing the level of this protein inhibited FMDV replication (Lawrence & Rieder, 2009). It has earlier 
been suggested that the S-fragment was involved in host-species specificity. A recent study provided 
evidence that the S-fragment was involved in the host innate immune response. Interestingly they 
found that a FMDV-S4 A24 mutant, having a 164 nt deletion in the S-fragment was highly attenuated 
in mice. The mice were given a dose 1,000-fold higher than the one causing lethality by the FMDV 
A24 wt, and all of these animals survived. Additionally, mice given the high dose of FMDV-S4 A24 
were protected when challenged with FMDV A24 wt (Kloc et al., 2017). Furthermore, this study 
found a correlation between the size of the deletion within the S-fragment in different FMDV 
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mutants and the mutant’s ability to cause an increase in the level of interferon-β (IFN-β) mRNA and 
several interferon-stimulated genes (ISG) mRNAs within infected cells. Moreover, infection of cells 
with the FMDV-S4 A24 mutant caused a higher upregulation of cytokines in comparison with 
infection with the wt virus (Kloc et al., 2017). Together these results suggest that the innate immune 
response and the virus pathogenesis in animals is highly affected by the S-fragment. 
 
Figure 4 shows the structural elements within the FMDV 5´UTR. From the 5´-terminus, these are: 
poly(C) tract, pseudoknots (PKs), cis-acting replication element (cre)/ 3B-uridylylation site (bus), 
internal ribosome entry site (IRES), the polypyrimidine tracts (PPTs) and the two different initiation 
codons that give rise to Lab and Lb (Belsham, 2005). 
 
The next region is the poly(C) tract. This is a contiguous stretch of cytidines that varies in length 
among different FMDVs ranging from around 80 nt to 420 nt (reviewed by Martinez-Salas & Belsham 
(2017)). In general, the shorter regions are found in laboratory strains, whereas field strains typically 
have a longer poly(C) tract. The exact function for this region is not known, however there is a strong 
selection pressure for the poly(C) tract in cell cultures (Rieder et al., 1993). A study has introduced 
infectious RNA transcripts only containing between 6 and 35 C residues into cells, and interestingly 
upon rescue the poly(C) tract in the replicated RNA had increased to contain around 75 to 140 C 
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residues. In contrast, RNA transcripts only containing two C residues, did not increase the number 
of C residues upon RNA rescue; however this virus grew much slower in cell culture compared to 
the wt. Interestingly, all of the mutant viruses, with various lengths of Poly(C) tract, were equally 
virulent in mice (Rieder et al., 1993).  
 
The third region of the 5´-UTR is around 250 nt in length, and is believed to contain a variable 
number of pseudoknots in different FMDVs. One pseudoknot is predicted to be 43 nt in length and 
interestingly different isolates have been reported to have deletions of either 43 nt or 86 nt within 
this region, thus it seems that deletions or additions in this specific area always include a full-length 
43 nt pseudoknot (Escarmís et al., 1995).  
 
The fourth region is called the cis-acting replication element (cre), which is a specific stem-loop 
structure and is required for RNA replication. The stem-loop structure, includes a conserved AAACA 
motif within the loop, and functions as a template for the uridylylation (attachment of U) to the VPg 
(3B) (Paul et al., 2000; Gerber et al., 2001; Nayak et al., 2005). The uridylylation generates the 
primers (VPgpU and/or VPgpUpU) for viral RNA synteses. Interestingly, the cre structures are 
located within different regions of the genome among different picornaviruses, i.e. in the coding 
regions for VP1, 2A, VP2 and 2C in HRV-14, HRV-2, cardioviruses and PV respectively (Mcknight & 
Lemon, 1998; Lovert et al., 1999; Goodfellow et al., 2000; Gerber et al., 2001). An earlier study 
showed that PV bearing lethal mutations in the native structure of the cre in the 2C coding region 
could be restored to replication competency by the introduction of the cre at another site within 
the genome (Goodfellow et al., 2000). The FMDV cre is, in contrast to other picornaviruses, located 
within the 5´-UTR just upstream of the IRES (Mason et al., 2002). Similarly, to PV, the position of the 
cre within the FMDV genome was not found to be important (Mason et al., 2002). Moreover, it was 
later shown that the cre did not have to function in cis, since a mutant FMDV with a critical mutation 
in the cre structure could be complemented in trans by co-infection with other FMDVs having 
defects elsewhere in the genome (Tiley et al., 2003).     
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The fifth region is the IRES, which is responsible for the initiation of translation on the FMDV 
genome. The IRES is approximately 450 nt in length and is predicted to contain several complex 
stem-loop structures. The initiation of translation on the FMDV genome occurs by a cap-
independent mechanism in contrast to cellular mRNAs that use a cap-dependent mechanism. The 
cellular mRNAs have a cap structure (m7GpppN), which is recognized by the initiation factor complex 
eIF4F and this is necessary for translation initiation. The eIF4F complex comprises other translation 
initiation factors, i.e. eIF4E (that binds to the cap), eIF4A (an RNA helicase) and eIF4G (involved in 
binding the small ribosomal subunit to the mRNA). It has been suggested that the small ribosomal 
subunit interacts with the eIF4F complex and then scans the mRNA until an AUG codon (in a suitable 
context) is reached. At this point, the large ribosomal subunit joins and translation starts. The 
scanning can be affected by complex RNA structures and by the presence of other AUG codons. This 
mechanism is in contrast to the initiation of translation mediated by the FMDV IRES, where the 
translation machinery is directly recruited to an internal position in the RNA. Due to the properties 
of the cap-independent translation initiation, FMDV can continue polypeptide translation when cap-
dependent translation is inhibited following cleavage of the eIF4G by the Lpro (reviewed by 
(Martinez-Salas & Belsham, 2017)). The IRES-dependent initiation of translation of the FMDV 
genome does not require the N-terminus of the eIF4G and its associated eIF4E (cap binding protein). 
The translation is described in further detail in section 1.5.2.             
 
1.3.2.   The Leader protease 
The Leader protease (Lpro) is responsible for cleavage between its own C-terminus and the N-
terminus of VP4, i.e. at the L/P1-2A junction. This viral protease is required not only to process the 
viral polyprotein but also to cleave certain host proteins such as the eIF4G to impair protein 
synthesis from capped mRNA in the infected cell (Devaney et al., 1988; Gradi et al., 2004). Many 
other picornaviruses also induce cleavage of the eIF4G during infection, but the cleavage is here 
mediated by the 2A protease i.e. for entero- and rhinoviruses (reviewed by Belsham (2005)). Two 
forms of the Lpro (Lab and Lb) exist, having different initiation sites (84 nt apart) and thus differing 
by 28 amino acids in length, see Fig. 4. The exact reason for this is still unclear, however many 
ribosomes fail to initiate translation at the first AUG codon and are then believed to scan along the 
FMDV genome to the second AUG codon (Belsham, 1992). Both the Lab and Lb forms of protease 
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are able to cleave the L/P1-2A junction within the polyprotein and also the eIF4G (Medina et al., 
1993). The Lpro also stimulates the activity of the IRES, however it has yet not been determined 
whether this is a direct effect of cleavage of the eIF4G or if the Lpro also cleaves other proteins that 
modify the IRES activity (reviewed by Martinez-Salas & Belsham (2017)).     
 
Another advantage of shutting down host cell protein synthesis, besides taking over the translation 
machinery, may be the reduction of antiviral response. During an FMDV infection, the α/β interferon 
mRNAs are induced, likely due to the presence of dsRNA. The blocking of host cell protein synthesis 
will inhibit synthesis of the α/β interferons and thereby reduce the antiviral response (Chinsangaram 
et al., 1999).   
 
The Lbpro is not needed for virus viability. A study has shown that it is possible to delete the Lb coding 
sequence and the mutant FMDV could still replicate in cattle, but displayed reduced pathogenicity 
(Brown et al., 1996). In contrast to this, FMDV was not viable when the whole Lab encoding 
sequence was removed. However, removing the 84 nt (between the two initiation sites of Lab and 
Lb) still produced viable virus, and thus the whole leader encoding sequence can be removed, but 
not at the same time (Belsham, 2013).  
    
1.3.3.   The capsid proteins 
The P1-2A is the precursor of the structural (capsid) proteins. The precursor is separated from the 
rest of the polypeptide at the N-terminus of P1-2A by the Lpro (see above). The processing of the P1-
2A/P2 junction is mediated by a mechanism that occurs in a co-translational manner, known as 
“ribosomal skipping” (Donnelly et al., 2001) or “StopGo” (Atkins et al., 2007) (for further details see 
next section). The 3Cpro is responsible for cleavage of the P1-2A precursor to generate three mature 
structural proteins (VP0, VP3 and VP1) and a short 2A peptide. The capsid proteins VP0, VP3 and 
VP1 remain associated with each other (in a protomer) and assemble into pentamers. Twelve of 
these pentamers can then assemble around a single RNA molecule to form a virus particle. During 
this process, the VP0 is cleaved to generate VP2 and VP4 by a mechanism that is currently not 
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understood. The VP1, VP2 and VP3 proteins are exposed on the capsid surface, contributing to the 
antigenic properties of the virus and are responsible for interacting with cell surface receptors to 
promote virus entry into cells (Jackson et al., 2000). The VP4 protein is entirely internal within the 
virus particle. The pentamers are also able to assemble into empty capsid particles (a particle not 
containing any RNA) (Abrams et al., 1995; Gullberg et al., 2013b). In empty capsid particles, cleavage 
of VP0 into VP2 and VP4 can also occur, however unprocessed VP0 is also present in the empty 
particles (Curry et al., 1997; Gullberg et al., 2013b). The properties of the capsid precursor, the 
processing of this and the capsid assembly process are described in more detail in section 1.6.     
 
1.3.4.   The 2A peptide 
Cleavage of the junction between the structural and non-structural proteins, at either the VP1/2A 
or the 2A/2B junction, is usually mediated by the 2A protein, but the function of the 2A protein 
varies between the picornavirus genera (Luke et al., 2008). In entero- and rhinoviruses, the 2A 
protein is a protease, referred to as the 2Apro, which cleaves at its own N-terminus, i.e. at the P1/2A 
junction (Toyoda et al., 1986; Sommergruber et al., 1989).  In the cardio- and aphthoviruses 
“cleavage” occurs at the C-terminus of 2A i.e. at the 2A/2B junction. This process is protease 
independent and happens during translation by a process termed “ribosomal skipping” (Donnelly et 
al., 2001) or “StopGo” (Atkins et al., 2007). In this case, the 2A protein remains attached to the 
capsid precursor, as P1-2A, until it is removed by the 3Cpro. The 2A peptide in FMDV is only 18 
residues long, in contrast to the 2A protein of cardioviruses, which is ca. 150 residues long. The C-
terminus of the 2A proteins from cardio- and aphthoviruses are highly conserved and contain the 
motif D(V/I)E(T/S)NPG/P (Palmenberg et al., 1992). When the elongating ribosome reaches the end 
of 2A it skips the synthesis of the peptide bond between the glycine and proline. The eukaryotic 
translation release factor 1 and 3 are believed to release the protein from the ribosome thereby 
creating the cleavage between 2A and 2B (Doronina et al., 2008a, Doronina et al., 2008b). A recent 
study showed that substitutions could be tolerated by the FMDV at the E14, S15 and N16 residue 
within the 2A sequence, even though cleavage activity for these mutant was only around 30-50% 
compared to the wt. No FMDV mutants containing substitutions at the P17, G18 and P19 (first amino 
acid in the 2B protein) could be rescued (Kjær & Belsham, 2018a). In addition to this study it was 
investigated which amino acids and nucleotides that could be tolerated at these highly conserved 
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codons for the residues P17, G18 and P19. Each codon was changed to NNN (encoding all different 
nucleotides thus providing the possibility of different amino acids) in separate constructs. 
Interestingly, only the wt amino acids were tolerated by the virus at these specific sites, and 
furthermore there was a clear selection towards the wt codons through several passages (Kjær & 
Belsham, 2018b). Interestingly, earlier studies has shown that cleavage of the FMDV VP1/2A 
junction, i.e. at the N-terminus of 2A, is not necessary for capsid assembly and for virus viability 
(Gullberg et al., 2013a, Gullberg et al., 2014; Kristensen et al., 2016). 
 
1.3.5.   The 2B, 2C and the 2BC precursor 
Different genera of the picornavirus family have very different 2B proteins, thus it is unlikely that 
they share similar functions (Martinez-Salas & Belsham, 2017). The 2B protein from PV has been 
described as a hydrophobic transmembrane protein, which can increase cell membrane 
permeability and thereby induces the release of virus particles from the host cell (Doedens & 
Kirkegaard, 1995; Agirre et al., 2002). It has been suggested that 2C is involved in viral RNA 
replication, as mutations that overcome the RNA replication inhibitory action of guanidine are 
located in this protein (Saunders & King, 1982). However, exactly how 2C is related to the replication 
complex is not understood.  
 
The 2B and 3A proteins of PV have individually been reported to block trafficking of proteins to the 
cell surface (Doedens & Kirkegaard, 1995). Immunofluorescence microscopy showed that the PV 3A 
protein caused the secreted proteins to be associated with the endoplasmic reticulum (ER), whereas 
the PV 2B protein caused the secreted proteins to be associated with the Golgi apparatus. Thus, it 
seems that these two PV proteins inhibit the protein secretory pathway by different mechanisms 
(Doedens & Kirkegaard, 1995). In contrast to PV 3A, the FMDV 3A protein does not prevent 
trafficking to the cell surface, but inhibition was observed when the FMDV 2BC precursor was 
expressed in cells (Moffat et al., 2005). This effect could also be achieved by the co-expression of 2B 
and 2C. Interestingly, the 2B and the 2C proteins were not individually able to block the trafficking, 
indicating the importance of the intermediate precursors within a FMDV infection. It is likely that 
the FMDV 2BC precursor plays a similar role as the PV 2B and 3A protein, which is able to block the 
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secretory pathway. This will prevent trafficking of interferons and other cytokines and also prevent 
the presentation of viral peptides on the cell surface, thereby inhibiting immune defenses and 
contributing to persistent infections (Doedens & Kirkegaard, 1995; Moffat et al., 2005).  
 
1.3.6.   The 3A protein 
The 3A protein has hydrophobic sequences that enables binding to membranes, which might explain 
why RNA replication complexes are associated with membrane vesicles. Moreover, the 3A protein 
has also been suggested to be involved in transporting the 3B peptides to the RNA replication 
complex (reviewed by Martinez-Salas & Belsham (2017)). The FMDV 3A protein also seems to be 
involved in virulence and host specificity, since the FMDV strain that caused the outbreak in Taiwan 
in 1997, which interestingly only infected swine and also had an exceptionally high mortality rate, 
was found to have a 10 amino acid deletion and several substitutions within the 3A coding region 
(Knowles et al., 2001).  Subsequently, it has been shown that the strain with this deletion grows 
preferentially in porcine cells and has restricted growth in bovine cells (Pacheco et al., 2003).  
  
1.3.7.   The three 3B proteins 
The FMDV 3B coding region is unique in that it encodes three non-identical copies of the 3B (termed 
3B1, 3B2 and 3B3), whereas other picornaviruses only have one copy. The 3B (VPg) peptide, following 
uridylyation, serves as a primer for viral RNA synthesis and is attached to the 5´-terminus of both 
positive and negative sense FMDV RNA. Interestingly all three copies are used equally in the 
initiation of viral RNA replication (Nayak et al., 2005), but it is not certain whether they have 
different roles besides initiation of RNA replication. It has been suggested that the VPg3 may be 
involved in encapsidation (Arias et al., 2010). However, FMDVs that have had one or even two copies 
of VPg deleted are still able to replicate in cells, but with a lower efficiency than wt virus (Pacheco 
et al., 2003). Furthermore, the  mutant FMDVs, with just a single VPg, produced only a mild disease 
in pigs, indicating that the copy number of 3B is important in relation to virulence (Pacheco et al., 
2003). Furthermore, it was recently shown, using a replicon system that 3B1 and 3B2 could be 
deleted, whereas deletion of 3B3 alone was detrimental to replication (Herod et al., 2017). However, 
mutating the uridylated tyrosine residue of 3B3 Y2F had no significant effect on replication. This 
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suggested that the 3B3 might have an important role in FMDV replication besides its role as a primer 
for RNA synthesis. The study demonstrated that 3B3 were able to direct the processing of the P3 
precursor and thereby control the release of the 3Dpol (Herod et al., 2017).   
 
1.3.8.   The 3C protease 
The function of the 3Cpro is well described. It is responsible for cleavage of most of the junctions 
within the polyprotein, thereby generating the precursors, processing intermediates and mature 
proteins. The structure of FMDV 3Cpro closely resembles the conformation of chymotrypsin (Allaire 
et al., 1994), and indeed, it belongs to the family of chymotrypsin-like serine proteases, although 
the serine in the active site is replaced by a cysteine, and thus has Cys-His-Asp/Glu at the active site 
(Gosert et al., 1997; Birtley et al., 2005; Sweeney et al., 2007). The active site is responsible for the 
substrate binding and is located between two six-stranded β-barrels (Matthews et al., 1999). The 
amino acid residues near the cleavage sites are designated as P4 P3 P2 P1 / P1´ P2´ P3´ P4´. In many 
picornaviruses (e.g. the enteroviruses), the cleavage sites always contain a glutamine residue (Q) at 
the P1 residue, however FMDV 3Cpro is able to process junctions containing either a glutamate (E) 
or a glutamine at the P1 position. The active site is responsible for recognition of the different side 
chains of the amino acids near the cleavage site. The correct binding and orientation of the 
polyprotein in the active site are determined by the side chains of the amino acids. During this 
binding, hydrogen bonds are formed between the substrate and the protease. The S1 pocket of the 
FMDV 3Cpro is responsible for binding to the side chain of the P1 residue  of the polyprotein (Birtley 
et al., 2005). The side chains of both E and Q bind in almost the same manner, thus making the 
FMDV 3Cpro able to process junctions containing either of these amino acids at this position. 
 
Besides acting as a protease, the FMDV 3C protein also displays an RNA binding function, which is 
important in relation to the uridylylation of VPg. It was earlier shown that the VPg uridylylation 
required the 3Dpol, the 3CD protein and the RNA template containing the cre (Nayak et al., 2005). 
Later on, it was found that the FMDV 3C protein was able to replace the 3CD protein for the VPg 
uridylylation, although the efficiency of the 3C protein was lower than with the 3CD protein (Nayak 
et al., 2006).   
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1.3.9.   The 3D RNA polymerase 
The FMDV 3D protein is an RNA-dependent RNA polymerase. The FMDV has a positive-sense RNA 
genome, and thus this RNA acts as a template for the initial synthesis of a negative-sense RNA, which 
is then used for the synthesis of new positive-sense RNA genomes. The 3D polymerase has a 
preference for the negative-sense RNA template, which might explain the excess of positive-sense 
RNA over negative-sense RNA within infected cells (Belsham, 2005). The 3´-terminus of the positive-
sense RNA is the poly(A) tail, whereas the 3´-terminus of the negative-sense is the S-fragment. The 
3D RNA polymerase requires uridylylated 3B (VPg) as a primer to initiate replication (reviewed by 
Martinez-Salas & Belsham (2017)). The replication mechanism is described in further detail in 
section 1.5.3.  
 
1.3.10.   The 3´-untranslated region (3´-UTR) 
The FMDV 3´-UTR contains two components, a heteropolymeric region of around 100 nt and a 
poly(A) tail. Within the heteropolymeric region, there exist two stem loops that are involved in 
FMDV replication. Furthermore, deletion of this sequence blocks infectivity of FMDV RNA (Sáiz et 
al., 2001). Interaction between the two stem loops and sequences within the 5´-UTR has been 
suggested, the hypothesis is that they contribute to genome circularization during replication 
(Serrano et al., 2006).  
 
1.4.   Quasispecies  
The rapid evolution of RNA viruses, including FMDV, is mainly because these viruses replicate with 
extremely high mutation rate due to the properties of their RNA-dependent RNA polymerases. The 
RNA polymerase lacks proofreading capabilities in contrast to the mammalian DNA-dependent RNA 
polymerase that has several different features for proofreading. Continuous error-prone replication 
leads to extensive genetic heterogeneity of the virus within a single host cell. These mutant-
populations are similar but not identical, and are called a quasispecies (Lauring & Andino, 2010). 
The significant mutation rate allows the virus to adapt more easily to the environment, escape the 
immune response and evolve resistance towards vaccines and antiviral drugs, a process known as 
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positive selection. This, in turn, complicates the management and control of the diseases caused by 
these RNA viruses. In contrast, there is also a risk for the virus, that important biological information 
gets lost due to these mutations, this process is referred to as negative selection (Domingo et al., 
2012).  
 
Viral RNA polymerases have a mutation rate of approximately 10-4 (Lauring & Andino, 2010), which 
means that on average, for every 10,000 nucleotides that are synthesized, one mutation will be 
introduced. Since the FMDV genome is around 8,400 nucleotides, there will be introduced 
approximately two new mutations every time the genome is replicated, since synthesis of negative-
sense RNA needs to occur, before the synthesis of a new positive-sense RNA. Due to the large virus 
population in both cell cultures and natural infections, it is estimated that at every site within the 
genome every possible mutation is generated upon just one passage of the virus in cell culture, and 
thus will be present within the virus population (Lauring & Andino, 2010). 
 
Thus, RNA viruses exist as a cloud of similar variants that is constantly changing due to new 
mutations. This also means that the introduction of a defined RNA transcript derived from a unique 
clone into cells, will quickly evolve into a collection of related viruses. These viruses are the 
quasispecies, and is based around the consensus sequence. Several rounds of replication can result 
in a more complex mutant distribution with mutants giving rise to higher levels of variation (Lauring 
& Andino, 2010), see Fig. 5.  
 
The high mutation rate and the resulting heterogeneity has huge consequences in relation to the 
virus generating resistance against vaccines or antiviral drugs (Gerrish & García-Lerma, 2003). 
However, some useful information can also be obtained from this high mutation rate. For instance, 
in PV a mutation encoding a substitution that causes the capsid to become more unstable has been 
introduced into a PV clone and introduced into cells. After harvest of the new virus population, 
several secondary mutations within the capsid-coding region were identified. These new secondary 
mutations were found to increase capsid stability and were used to increase capsid stability of 
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empty capsids in relation to a potential vaccine production (Fox et al., 2017). Another study has 
taken advantage of the high mutation rate to identify a genetic link between two distant sites. In 
this study, a lysine residue (K) was substituted by a glutamate (E) at residue 210 in VP1 (the P2 
residue in the VP1/2A junction) which blocked processing of this junction, and a secondary mutation 
was observed at VP1 E83K in the rescued virus. Interestingly, introducing this latter substitution 
alone, caused a new secondary mutation at the P2´ residue in the VP1/2A junction (2A L2P), which 
also blocked the processing of the VP1/2A junction (Gullberg et al., 2014). The basis for this linkage 
is still unknown. 
 
Figure 5 shows an illustration of quasispecies. FMDV replicates with a high mutation rate, which 
generates a cloud of diverse mutants. Within a few generations there will be a high number of 
different variants that originate from the first original virus (Lauring & Andino, 2010). 
 
1.5.   The FMDV life cycle 
FMDV has a relatively short life cycle of around 4-6 hours within cultured cells. The virus causes 
morphological changes, which include cell rounding and redistribution of internal cellular 
membranes together referred to as cytopathic effect (CPE) (Grubman & Baxt, 2004). An important 
feature of the FMDV RNA is that it is infectious (e.g. see Belsham & Bostock, 1988), hence, no viral 
protein is necessary for the viral RNA to initiate the infection. Thus, the first step after entering into 
the cytoplasm is to take over the cellular translation machinery to start producing the viral proteins 
that are required for virus replication. The RNA genome encodes a large polyprotein that is co- and 
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post- translationally processed into some 15 mature proteins and a variety of precursors. Besides 
acting like an mRNA for synthesis of the polyprotein, the RNA genome also has to act as template 
for RNA replication. Initially, negative-sense RNA strands are synthesized, using the positive-sense 
genome as template. Afterwards, new positive-sense RNA genomes are produced, using the 
negative-sense RNA molecules as template. The processed capsid proteins assemble around a single 
infectious RNA genome to produce a new virus particle. Roughly, the infectious cycle can be 
considered in four steps: 
• Attachment and entry  
• Translation of the FMDV genome  
• Replication of the FMDV RNA 
• Encapsidation, maturation and release 
An overview of the FMDV life cycle can be seen in Fig. 6 
 
Figure 6 shows the lifecycle of FMDV. The virus can attach to an integrin receptor or the heparan 
sulfate (HS) receptor. It enters the cell via endocytosis. Within the endosomes there is a mildly acidic 
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environment, which causes the capsid to disassemble and releases the RNA genome and it enters 
the cytoplasm. The viral genome is translated and the encoded polyprotein is processed to generate 
the structural (capsid) proteins and the non-structural proteins (NSPs). The RNA is replicated, and 
the capsid proteins can assemble around a single stranded positive sense viral RNA genome to form 
new virus particles. These virus particles are released upon cell lysis (Gao et al., 2016). 
 
1.5.1   Virus attachment and entry into cells 
The choice of receptors play a role in tissue and cell tropism and thereby in disease pathogenesis 
for all viruses. The FMDV can use several receptors from within the large family of transmembrane 
glycoproteins called integrins (Grubman & Baxt, 2004). These receptors consist of two subunits (α 
and β) bound to the cell surface and are involved in cell adhesion and lymphocyte interactions. The 
region of the FMDV capsid involved in attachment to the integrins is present on the VP1 capsid 
protein. This region is called the G-H loop because it exists as a surface exposed loop connecting the 
G and H stands of the protein. Within this loop, the sequence is highly variable except for a highly 
conserved tripeptide sequence, Arg-Gly-Asp (RGD), involved in the interaction with the integrin 
receptors (Pierschbacher & Ruoslahti, 1984). The first indication that this sequence might be 
involved in the attachment to the integrins came from a study showing that small peptides, having 
the RGD motif inhibited virus adsorption in a dose-dependent manner (Fox et al., 1989). Moreover, 
substitutions within these peptides of any of the three amino acids (RGD) lowered the inhibitory 
effect (Baxt & Becker, 1990). Later on, it was shown that amino acid substitutions within the RGD 
motif of FMDV O1 Kaufbeuren (O1K) resulted in FMDV particles that were noninfectious in 
susceptible cells (Leippert et al., 1997). Another study showed that transfection of an RNA 
transcript, derived from a full-length cDNA of FMDV A12 with a deletion of the sequence encoding 
the RGD motif did not result in CPE upon passage on BHK cells. However, some virus particles could 
be isolated directly from the transfected cells. These virus particles were used to vaccinate steers 
intramuscularly. Neither of the animals developed any clinical signs of FMD but were protected from 
FMD upon subsequent virus challenge (McKenna et al., 1995). 
 
Within the family of 24 known integrin receptors, only 8 recognize the RGD motif. However, so far 
only 4 integrins (αvβ1, αvβ3, αvβ6 and αvβ8) have been confirmed to bind to FMDV (Grubman & Baxt, 
2004). FMDV can use a co-receptor, depending on the passage history of the individual virus strain; 
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specifically, field strains of foot-and-mouth disease virus bind to integrins, whereas cell-culture-
passaged virus can also use heparan sulfate as a receptor (Jackson et al., 1996).  
 
A study showed that a variant of the serotype O virus having a positively charged Arginine as residue 
56 of VP3 could grow in CHO cells that lack the integrin receptors for FMDV. Interestingly this virus 
was highly attenuated in cattle. However, viruses recovered from animals inoculated with high 
doses of this virus had lost their ability to grow in CHO cells. Sequencing revealed that the VP3 R53 
had been changed to an un-charged amino acid or that a closely positioned residue VP2 134 had 
been changed from the positively charged lysine to the negatively charged glutamate (Sa-carvalho 
et al., 1997). Comparison of these animal-derived viruses to other viruses showed that positively 
charged amino acids were required at both VP2 134 and VP3 53 in order for the virus to bind to the 
heparan sulfate receptors (Sa-carvalho et al., 1997). Later on, it was shown that another cell-culture-
adapted B64 strain of the O1 Kaufbeuren virus (O1K B64), which has had 64 passages in cell-culture 
was highly attenuated in cattle. However, replacing the surface exposed capsid proteins with those 
from field strains  either the O/UKG/34/2001 (O-UKG), from the outbreak in the UK in 2001, or the 
A/Turkey 2/2006 (A-TUR), resulted in FMD in the inoculated cattle (Bøtner et al., 2011).  
 
FMDV can also enter cells via Fc receptors if the virus exists as virus-antibody complexes with non-
neutralizing IgG molecules. This pathway is of unknown significance, but may be important in the 
long-term carrier state, where the virus sometimes is shed as virus-antibody complexes 
(Alexandersen et al., 2002; MacLachlan & Dubovi, 2017).  
 
Upon interaction with one of the integrin receptors, the FMDV can enter the cell through clathrin-
mediated endocytosis. The FMDV particle is delivered to the early endosome where they are 
exposed to a mildly acidic environment. This drop in pH is crucial for the FMDV particle to 
disassemble into pentamers and thereby release the RNA genome into the cytoplasm (Carrillo et al., 
1984). The pentamer interfaces of the FMDV particle are stabilized by β-sheet interactions, which 
bind the subunits together. The acidic environment within the early endosome changes the 
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ionization state of the histidine residues at the pentamer interfaces and this, most likely, disturbs 
the β-sheet interactions causing the FMDV particle to disassemble (Curry et al., 1995). The FMDV 
particle disassembles into pentameric subunits comprising five copies of VP2, VP3 and VP1. This releases 
the RNA and the internally located VP4. Pentamers formed during disassembly therefore differ from 
those formed during the assembly pathway as they lack the VP4 protein (present within VP0 in the 
assembled pentamers) (Fry et al., 2005). 
 
1.5.2.   Translation of the FMDV genome 
The FMDV RNA genome is, by itself, infectious and does not bring with it any viral proteins used for 
either translation or replication. Thus, after the uncoating and release into the cytosol, the first step 
is for the RNA-genome to associate with the cellular translation system. As mentioned above, the 
FMDV genome lacks the typical cap-structure at its 5´-terminus, but uses instead the IRES for 
initiation of proteins synthesis. The IRES is an RNA sequence that consists of complex three-
dimensional structures that can function in both cis and trans (Drew & Belsham, 1994) and recruits 
the cellular translation machinery. Normally, the cellular capped mRNA is recognized by a trimeric 
complex of initiation factors called eIF4F that consists of eIF4A (an RNA helicase), eIF4E (a cap-
binding protein) and eIF4G (a scaffold protein). Nearly all cellular translation initiation factors are 
required for the translation initiation of the FMDV genome, with the exception of eIF4E. The Lpro 
and the 3Cpro induce the cleavage of eIF4G and remove the N-terminus of this protein, which is the 
binding site for eIF4E (Devaney et al., 1988; Belsham et al., 2000). Thus, translation of the FMDV 
genome eventually leads to shut down of the cap-dependent translation, and thus the FMDV is able 
to take over the translation machinery without competing with the cellular mRNA. The C-terminus 
of eIF4G is not affected by the cleavage and thus retains the binding sites for eIF4A and the 40S 
ribosomal subunit via eIF3, that is required for IRES-dependent translation initiation, see Fig. 7. 
During translation initiation on cellular mRNAs, the translation initiation complex scans along the 
mRNA until it reaches an initiation (usually AUG) codon at which the 60S ribosomal subunit is 
recruited and protein synthesis starts. In the FMDV genome, translation can start at two separate 
in-frame start codons, resulting in two different size forms of the Lpro (for more details, see section 
1.3.2). The full-length polyprotein is never observed within infected cells, as the protein is rapidly 
processed both co- and post-translationally by the viral encoded proteases, Lpro and 3Cpro, and by 
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the ribosomal skipping process at the 2A/2B junction (this mechanism is described in further detail 
in the section 1.3.4). The Lpro is responsible for the cleavage at its own C-terminus, i.e. at the L/P1-
2A junction, while the 2A peptide is required for the “cleavage” at the 2A/2B junction and the 3Cpro 
is responsible for the cleavage of the P2/P3 junction. The cleavage of the polyprotein results in four 
primary products: the Lpro, P1-2A precursor, the P2 precursor and the P3 precursor. After this initial 
processing, all other cleavages are mediated by the 3Cpro, except for cleavage of VP0 into VP2 and 
VP4. The processing of the P1-2A precursor by the 3Cpro is explained in detail in section 1.6.2. 
 
Figure 7: a) intact eIF4G is required for its interaction  with the eIF4E cap-binding protein. The cap-
binding protein is required for the initiation of cap-dependent protein translation of cellular mRNA. 
b) IRES dependent translation does not require the cap-binding protein, eIF4E, and can thus initiate 
translation when eIF4G is cleaved (Gao et al., 2016). 
 
1.5.3.   Genome replication 
Picornavirus infection causes huge rearrangements of cellular membranes to form replication 
complexes and the 2BCATPase and 2CATPase are very active in this rearrangement. The replication of 
viral RNA takes place within these replication complexes that are assembled from several of the viral 
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encoded non-structural proteins and cellular membranes i.e. the ER and Golgi apparatus. These 
FMDV replication complexes form in the cytoplasm adjacent  to the nucleus and appear to be 
present in lower numbers compared to other picornaviruses, such as PV (Monaghan et al., 2004).  
 
The FMDV particle has a positive-sense RNA genome and thus the first step in RNA replication is the 
synthesis of a minus-strand RNA molecule. The switch from translation of the RNA genome to RNA 
replication, has not been extensively studied in FMDV. However, translation needs to occur prior to 
synthesis of the negative strand RNA, due to the need for the viral proteins required for the RNA 
replication. Translation take place from the 5´-end towards the 3´-end and replication vice versa, 
and it has been shown that the passage of the ribosome along the RNA prevents RNA replication 
(reviewed by Belsham, (2005)). Thus, it is believed that the translation of the input RNA must be 
stopped in order for replication to occur. However, the exact mechanism is not known. It is likely, 
that this switch from translation to replication is mediated by blocking the IRES function of the initial 
RNA. Once new RNA molecules are generated, these can again function as template for translation. 
Thus, only a one-way switch is required. It is likely that the translation and replication are separated 
in the cell in different compartments to limit the amount of competition between the two processes 
(Belsham, 2005).       
 
In PV the Poly-r(C)-binding Protein 2 (PCBP2) is involved in both replication and translation. The 
PCBP2 acts as a sequence specific RNA-binding protein to regulate the translation and stability of 
the target sequence. To make the switch from translation to replication, it has been suggested that 
the polymerase precursor (3CD) cleaves the PCBP2, which inhibits interaction with the IRES, but 
does not affect viral RNA replication (Grubman & Baxt, 2004; Chase et al., 2014). However, the 
FMDV IRES does not seem to require the PCBP2 protein for translation (Grubman & Baxt, 2004), and 
thus it is likely that other factors contributes to the inhibition of the FMDV IRES.  
 
FMDV RNA replication is initiated at the 3´-terminus of the template RNA strand in a primer-
dependent manner. The VPg (3B) protein is uridylylated by the 3Dpol using the cre as a template and 
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functions then as a primer for the 3Dpol to initiate replication. Both the FMDV genome and cellular 
mRNAs have a poly(A) tail  at their 3´ termini, and thus the 3Dpol must be able to distinguish between 
them. The discovery of the cre (cis-acting replication element) provided a possible explanation for 
the ability of the viral polymerase to distinguish between cellular and viral RNA. The conserved motif 
AAACA within the stem loop of the cre is required for entero- and rhinovirus minus-strand synthesis, 
where the two first A’s serves as a template for the uridylylation of VPg (Mcknight & Lemon, 1998; 
Goodfellow et al., 2000).  
 
1.5.4.   Capsid assembly and RNA packaging 
The final step in the FMDV life cycle is the encapsidation of a positive-sense RNA molecule by the 
viral capsid proteins and the maturation of VP0 into VP2 and VP4. It has been suggested that there 
exists a cis-acting packaging signal within the positive-sense RNA molecule that is involved in the 
encapsidation (Grubman & Baxt, 2004). This will be described in further detail in section 1.6.5. 
 
The P1-2A precursor is cleaved by the 3Cpro into the structural proteins VP0, VP3, VP1 and a short 
2A peptide. The VP0, VP3 and VP1 remain associated with each other in a protomer containing one 
copy of each of the capsid proteins. Five protomers then combine to form a pentamer and 12 
pentamers can them assemble into the mature capsid. The 12 pentamers either assemble around a 
single RNA molecule to form a virus particle or they assemble into empty capsid particles without 
any RNA (Abrams et al., 1995; Gullberg et al., 2013b). One of the final steps that happens during the 
assembly of the pentamers into a virus particle, is the cleavage of VP0 to generate VP2 and VP4. The 
VP4 is entirely internal within the virus particle, whereas VP1, VP2 and VP3 are exposed partly on 
the capsid surface. In FMDV empty capsid particles, cleavage of VP0 into VP2 and VP4 can also occur, 
however unprocessed VP0 is also present (Curry et al., 1997; Gullberg et al., 2013b; Kristensen et 
al., 2018). The maturation of VP0 to VP2 and VP4 is important for FMDV particle stability and is 
required for generation of infectious virus (Knipe et al., 1997). After assembly and maturation of 
VP0, the host cells are lysed and the newly produced viruses are released. Polyprotein processing 
and capsid assembly is described in further detail in section 1.6. An overview of the FMDV capsid 
assembly is shown in Fig. 8. 
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Figure 8 shows an overview of the FMDV capsid assembly process. The P1-2A capsid precursor is 
processed by the 3Cpro to generate VP0 comprising VP2 and VP4 (internal), VP3 and VP1, which stay 
together as a protomer. Five protomers assembles to one pentamer, and 12 of these pentamers can 
assemble around a viral RNA genome or they can form empty capsids (Jamal & Belsham, 2013).  
 
1.6.   FMDV – from polyprotein to virus particle 
The FMDV genome encodes a single protein produced from one large open reading frame (ORF). 
Nevertheless, the full-length polyprotein is not observed within infected cells due to rapid co- and 
post-translational processing. The separation of the FMDV capsid precursor (P1-2A) from the non-
structural proteins occur co-translationally by ribosomal skipping at the 2A/2B junction (Donnelly et 
al., 2001). The 2A peptide is removed from the P1-2A precursor by the 3Cpro, however removal of 
the 2A peptide is not necessary for capsid assembly (Gullberg et al., 2013a). The Lpro cleaves itself 
from the N-terminus of the P1-2A precursor. The free N-terminus of the P1-2A precursor contains a 
myristoylation signal sequence (G X X X S/T) and is myristoylated by a cellular enzyme (Towler & 
Gordon, 1988). 
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The cleavage of the capsid precursor into the structural proteins (VP0, VP3 and VP1) is necessary for 
virus assembly and maturation, however the products never separate but stay together as a 
protomer. Five of these protomers make up the pentamer subunits, and twelve of these can 
assemble into either a proviron (contains RNA but still uncleaved VP0) or empty capsids (no RNA). 
The final event of virus maturation is the processing of VP0 into VP2 and VP4. All of these steps will 
be described in detail in the next sections.  
 
1.6.1.   Myristoylation  
The N-myristoylation of the P1-2A occurs co-translationally after the auto proteolytic cleavage by 
the Lpro. The Lpro cleaves at either K/G or R/G and thus exposes  a glycine at the N-terminus of VP4. 
In picornaviruses that do not produce a leader protein, i.e. entero- and rhinoviruses, a cellular 
aminopeptidase removes the initiator methionine residue, which exposes a glycine at the N-
terminus of VP1. A 14-carbon saturated fatty acid myristate is covalently attached to the glycine by 
the host N-myristoyl-transferase.  
 
The myristoylation of proteins is important to determine subcellular targeting, protein-protein and 
protein-membrane interactions. Blocking of the FMDV myristoylation site does not prevent 
cleavage of the capsid precursor, but interestingly prevents assembly of empty capsid particles 
(Belsham et al., 1991; Abrams et al., 1995). The myristoylated N-terminus of VP4 in PV has been 
shown to participate in stabilizing interactions between the five protomers in the pentamer (Hogle 
et al., 1985). The lack of myristoylation also reduces the efficiency of receptor binding in FMDV 
(Goodwin et al., 2009). Furthermore, blocking myristoylation of PV P1 alters the late steps of PV 
capsid assembly but does not totally prevent it. These resulting PV particles are not infectious, which 
most likely reflects the inability of un-myristoylated VP4 to penetrate the membrane (Marc et al., 
1990). These findings suggest that myristoylation of the capsid precursor and the VP4 N-terminus 
have an influence on the overall structure of both the precursor, the intermediates and the virus 
particle. Moreover, since myristoylation is important for protein-membrane interaction, the 
myristoylation of the capsid precursor might also be involved in directing the capsid precursors to 
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the membranes where newly synthesized RNA could then associate with the capsid proteins after 
synthesis (Paul et al., 1987).   
 
1.6.2.   FMDV capsid precursor processing by the 3C protease 
The FMDV life cycle is critically dependent on correct processing of the polyprotein by the 3Cpro of 
specific junctions, which contain non-identical sequences. Within the capsid precursor (P1-2A), the 
3Cpro is responsible for cleavage at the VP0/VP3-, VP3/VP1- and VP1/2A junctions. The cleavages at 
these junctions occur at different rates, most likely determined by the amino acids flanking the 
junctions (Zunszain et al., 2010), these amino acids are designated P5 P4 P3 P2 P1/ P1´ P2´ P3´ P4´ 
P5´.  
 
The FMDV 3Cpro shows greater diversity in sequence recognition in comparison to many other 
picornavirus 3C proteins. The FMDV 3Cpro is able to cleave junctions containing either a glutamine 
(Q) or a glutamate (E) at the P1 position in contrast to the 3Cpro from other picornaviruses  (like PV 
and human rhinovirus (HRV)), which only cleave junctions with a Q at the P1 position. The two types 
of junctions that can be cleaved by the FMDV 3Cpro are designated as the Q/x and the E/x group, 
where x is any amino acid. The Q side chain of the P1 residue binds in almost the same manner as 
the alternative E side chain to the FMDV 3Cpro, thus making the protease able to process both types 
of junctions (Birtley et al., 2005). The P1 and the P1´ residues are considered the most important for 
correct processing, however several residues are required for recognition by the 3Cpro, since several 
P1-P1´ sites that are not cleaved are present within the polyprotein. The specificity of junction 
recognition is important since slower processing of some sequences, such as the 2B/2C junction, 
allows intermediate proteins to perform specific functions, which is not possible as mature proteins 
(Gao et al., 2016). In one study, junctions cleaved by the 3Cpro have been compared from more than 
100 FMDV strains (Carrillo et al., 2005). These junction sequences were, later on, divided into two 
groups according to their P1 residue (E or Q) (Curry et al., 2007), see Fig. 9, which gave an indication 
of the important amino acids for each junction group.  
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Figure 9 shows a logo plot of the amino acid sequences cleaved by the FMDV 3C protease. 
Sequences from over 100 FMDV strains (Carrillo et al., 2005) were aligned and split into two groups 
according to the nature of the P1 residue (i.e. the Q/x- and the E/x groups) (Curry et al., 2007).  
 
The binding of a short peptide corresponding to the VP1/2A junction to the 3Cpro, revealed that the 
alanine (A) positioned at residue P5 is largely solvent exposed. The sidechains of this residue point 
towards residue 143 methionine (M) of the 3Cpro, but is not close enough to make contact. 
Substituting this P5 A to either arginine (R) or proline (P) only caused a two-fold reduction of 3Cpro 
activity, whereas substituting the P5 A to a leucine (L) did not have any major effect. The lack of 
contact most likely accounts for the finding, that this residue only had modest effect on the peptide 
cleavage activity (Zunszain et al., 2010).   
 
In the Q/x group sites (e.g. at the VP1/2A junction), 3Cpro seem to have a preference for either a P, 
A or isoleucine (I) at the P4 position (Curry et al., 2007). The binding of a short peptide corresponding 
to the VP1/2A junction, which has a P at the P4 residue, to the 3Cpro, revealed that this residue is 
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partly buried in the peptide binding grove, only exposing one C atom. This residue interact with 
sidechains from  3Cpro L142 (residue cysteine (C) 142 from the wt was substituted to L to make the 
3Cpro more soluble), valine (V) 140 and tyrosine (Y) 190 (Zunszain et al., 2010). Interestingly, 
substituting the P4 P, to either a V, Y or L, completely prevented cleavage by the FMDV 3Cpro using 
a peptide cleavage assay. This was a bit surprising because these amino acids have sidechains of 
similar size and also because A and I are both found in the P4 position in other junctions belonging 
to the Q/x group. However, removing or introducing a P within a peptide/protein often results in a 
drastic change due to the very different structure of P compared to other amino acids.  Furthermore, 
V is found at this position in several junctions belonging to the E/x group (Birtley et al., 2005; 
Zunszain et al., 2010).  
 
 A wide variety of amino acids (V, Q, E, histidine (H), phenylalanine (F), serine (S), R and A) are 
present as the P3 residue both within the Q/x and E/x groups (Curry et al., 2007). In common for all 
of these are that they most likely are able to make hydrophobic contacts with the side chain of 3Cpro 
M143 located within the β-ribbon (Zunszain et al., 2010). However, variation from a P3 A to either 
a Q, E or V (which is tolerated at this site in other FMDV junctions, including the Q/x group), within 
a short peptide corresponding to the VP1/2A junction, reduced the cleavage activity 5-10 fold. This 
might be due to the larger side chains of these amino acids, compared to the A, which might affect 
the positioning of the β-ribbon, thereby affecting interaction with other substrate residues 
(Zunszain et al., 2010). These findings indicate that correct cleavage is dependent on the amino acid 
sequence flanking the junction, and that one amino acid can have a huge impact on cleavage activity 
even though it is tolerated at other junctions belonging to the same group.  
 
The grouping of the Q/x and E/x junctions revealed that junctions with a Q at the P1 position typically 
also had a lysine (K) at the P2 position (Curry et al., 2007). Using a short peptide corresponding to 
the VP1/2A junction revealed that the K at the P2 position made contact to the H46, L142 and M148 
of the 3Cpro. Moreover, the K also made salt bridges from the amine group to the side chains of 
aspartic acid (D) 144 and D146 within the 3Cpro. The formation of one of the pockets within 3Cpro, 
seems to be dependent on substrate binding, since L142, D144 and D146 within the 3Cpro, adjust 
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their position upon binding to the substrate. Substitution of the P2 K to norleucine, which is similar 
to K but lacks the amine group prevented cleavage. Substitution of the P2 K to an R reduced cleavage 
by around 4-fold (Zunszain et al., 2010).    
 
The P1 Q, of the VP1/2A junction forms three hydrogen bonds to the S1 pocket of the 3Cpro (Zunszain 
et al., 2010). Interestingly, the P1 Q, which is found in many other FMDV junctions, binds in 
approximately the same manner as the P1 E, thereby explaining the tolerance of FMDV 3Cpro for 
either amino acid at this specific site. Indeed, the Q in a short peptide corresponding to the VP1/2A 
junction can be substituted to E, which only reduced cleavage activity by two-fold (Birtley et al., 
2005; Zunszain et al., 2010). Changing the P1 Q to either R or D completely prevented cleavage 
(Zunszain et al., 2010).  
 
Large hydrophobic amino acids (i.e. L, I or threonine (T)) at the P1´ within the Q/x junction group 
(Curry et al., 2007) also seem to be of high importance for cleavage activity. Substituting the P1´ L 
to either glycine (G) or C, in the Q/x group, using a peptide cleavage assay, reduced cleavage activity 
of FMDV 3Cpro to around 10% and 50% respectively (Zunszain et al., 2010). Interestingly, the FMDV 
often has a G at the P1´ position when the P1 residue is E. Thus, also this amino acid seems to be 
affected by the overall sequence flanking the junction for correct positioning in regard to 3Cpro 
cleavage. The binding of the P1´ leucine in a short peptide corresponding to the VP1/2A junction 
binds in an unusual manner. Upon binding of the 3Cpro to the peptide, a pocket is formed where the 
P1´ leucine is incorporated. This pocket in 3Cpro is only present upon binding to the substrate 
(Zunszain et al., 2010).    
 
There is a high variability of the amino acids at the P2´ positon within both the Q/x and the E/x 
groups, see Fig. 9 (Curry et al., 2007). The P2´ L in the short peptide corresponding to the VP1/2A 
junction binds at one end of the peptide-binding grove (Zunszain et al., 2010). The E/x group often 
has a P at the P2´ residue, but interestingly substituting the P2´ L to a P within the VP1/2A junction 
(Q/x group) within full length FMDV completely prevented cleavage of this junction (Gullberg et al., 
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2014). However, it should be noted that a P is never present at this residue within the Q/x group, 
see Fig. 9.  
 
Also the P3´ residue has a high sequence variation within both the Q/x and the E/x group, see Fig. 
9. In the case of the short peptide corresponding to the VP1/2A junction, the P3´ L is almost 
completely exposed on the surface of the enzyme. However, it is positioned to form hydrogen bonds 
with residue E50 of the 3Cpro surface (Zunszain et al., 2010). However, several of the other amino 
acids found at this position would not be able to maintain the interaction with residue E50 of the 
3Cpro (Zunszain et al., 2010), and thereby, it is unlikely that this interaction is of high importance for 
cleavage activity.  
 
Also the P4´ residue has a high sequence variation within the two groups of junctions, see Fig. 9. In 
a short peptide corresponding to the VP1/2A junction the P4´ F is highly solvent exposed, with the 
exception of a small apolar contact with the upper surface of the C-terminus of one of the β-barrels. 
Moreover, substituting the P4´ F to R, P or A, which all have apolar features, only had a small effect 
on the cleavage activity (Zunszain et al., 2010).  
 
The conformation of FMDV 3Cpro closely resembles the structure of chymotrypsin (Allaire et al., 
1994), and indeed, it belongs to the family of chymotrypsin-like serine proteases. However, the S in 
the active site is replaced by a C, and thus has C163-H46-D84/E at the active site (Gosert et al., 1997; 
Birtley et al., 2005; Sweeney et al., 2007). The active site is located between two six-stranded β-
barrels and binds to the polyprotein junction (Matthews et al., 1999). A two-strand β-ribbon 
structure folds over the peptide binding cleft, where it makes important interactions with the 
substrate, thereby contributing to substrate specificity (Matthews et al., 1999; Sweeney et al., 
2007). The C142 within the 3Cpro, which is located at the tip of the β-ribbon, seems to have a 
significant effect on the catalytic activity of the 3Cpro.  
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The FMDV 3Cpro C142 maps closely to the position in the structure of the HRV2 3C residue L127. This 
suggests that these two amino acids in the different picornavirus genera play a very similar role. 
Indeed, both amino acids have a hydrophobic functional group, and it is suggested that this side 
chain is involved in positioning the substrate via interactions with the sidechains of the P2 and P4 
residues (Sweeney et al., 2007). This hypothesis was further strengthened by the finding that 
substituting the P2 L to either T or R remarkably reduced cleavage, and substituting the P4 P to 
either V, L or I completely blocked the cleavage of these peptides (described as unpublished data in 
Sweeney et al. (2007)). Furthermore, substituting the FMDV 3C 142C to a S had no effect on 
substrate specificity in small peptide cleavage assay but caused a significant downregulation of 3Cpro 
activity (around 1% of wild type activity) (Sweeney et al., 2007). However, substitutions to other 
amino acids such as T, A or V, which are more apolar compared to the S had less effect on the 
proteolytic activity of the 3Cpro. Interestingly, substituting this residue to an L, which is highly 
hydrophobic enhanced the catalytic activity of the 3Cpro compared to the wt (Sweeney et al., 2007). 
Later, studies have used the 3C C142S substitution in transient assays for cleavage of the P1-2A 
precursor, where the reduced activity of this mutant 3Cpro was verified (Polacek et al., 2013).   
 
The peptide sequences flanking the junction are highly important for correct processing by the 3Cpro, 
however the overall structure of the P1-2A precursor is also highly important for correct processing. 
Truncating the P1-2A precursor, by removing the 2A and 42 residues of the C-terminus of VP1 
blocked the processing of both the VP0/VP3- and the VP3/VP1 junction, even though the sequence 
flanking the junctions were un-modified (Ryan et al., 1989). Similarly, truncating the P1-precursor 
of PV also blocked the processing of the mature capsid proteins by the PV 3CDpro (Ypma-Wong & 
Semler, 1987). We recently showed that processing of the three junctions were mutually 
independent (Kristensen et al., 2018), see result section publication 2, indicating that the blocking 
of the cleavage at these two junctions, observed in the earlier studies, was likely due to an overall 
structure change in the precursor, rather than blocking of one junction thereby affecting the other 
junction. This observation will be further addressed in the result section in publication 3.  
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1.6.3.   Assembly of the 5S protomers into the 12S pentamer 
After the processing of the P1-2A precursor into VP0, VP3, VP1 and the short 2A peptide, the 
structural proteins (excluding the 2A peptide) remain together as a 5S protomer. Five of these 
protomers then assemble to form a 12S pentamer. Pentamers from different picornaviruses migrate 
with different rates through a sucrose gradient i.e. FMDV pentamers migrate at 12S while PV 
pentamers migrate at 14S. Myristoylation of the capsid precursor in many picornaviruses (with the 
exception of hepato- and parechoviruses) seems to stabilize the structure at the 5-fold axis 
symmetry of the virus particle. Interestingly, blocking myristoylation of the PV P1 precursor, by 
changing the G at VP4 residue 2 to an A prevents the formation of the PV pentamers (Ansardi et al., 
1992). The assembly of correct FMDV 12S pentamers is also dependent on N-terminal 
myristoylation of the P1-2A precursor, as abnormal pentameric assembly (approximately 17S) 
occurred upon lack of myristoylation (Goodwin et al., 2009). In infected cells, incompletely 
myristoylated pentamers are believed to be excluded from virus particles.  
 
The C-terminus of the capsid precursor of different genera within the picornavirus family differ 
regarding the presence, or absence, of the nonstructural protein 2A. In the enteroviruses, such as 
PV, the 2A protein is not included in the capsid precursor P1. In contrast, in other picornavirus 
genera, i.e. aphtho-, cardio- and hepatoviruses the 2A protein remains attached to the capsid 
precursor as P1-2A. The 2A protein plays an important role in hepatovirus capsid assembly. The HAV 
P1-2A precursor is cleaved by the HAV 3Cpro to generate VP0, VP3 and VP1-2A, which associate into 
pentamers. In HAV empty capsids and immature virus particles, the 2A is exposed on the surface of 
the particle, while in the mature HAV particle that contain the RNA, almost all 2A proteins have been 
removed by an unidentified cellular protease. Interestingly, deleting approximately 40% of the N-
terminus 2A protein abolished HAV infectivity (Cohen et al., 2002). Transient expression of this HAV 
P1-2A mutant, revealed that the N-terminus of 2A was required for both efficient cleavage of the 
P1-2A precursor by 3Cpro and for assembling of the protomers into pentamers. These data indicate 
that the 2A protein plays an important role in relation to correct capsid precursor folding, to allow 
efficient processing by the 3Cpro (Cohen et al., 2002). In contrast to HAV, the FMDV P1 does not 
require the 2A protein for association of the protomers into pentamers (Goodwin et al., 2009). 
However, the formation of pentamers is not affected upon blocking of this junction (Goodwin et al., 
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2009), and indeed, the pentamers containing the uncleaved VP1-2A junction can assemble to form 
infectious virus particles (Gullberg et al., 2013a).    
   
1.6.4.   Assembly of the 12S pentamers into 75S empty capsids 
A prominent feature of the many picornavirus infections is the co-occurrence of several kinds of 
intermediate particle assemblies, e.g. protomers, pentamers and empty capsids. Structural studies, 
using x-ray crystallography, has only been reported for few picornavirus genera empty capsids, 
whereas many mature picornavirus structures have been determined. Empty capsids, contain 12 
pentamers, like the virus particle, but no RNA genome. Empty capsids have been identified in cells 
infected by several picornavirus infections including entero- and aphthoviruses (Maizel Jr et al., 
1967; Korant et al., 1975; Rowlands et al., 1975). The empty particles are formed from twelve 
pentamers, and are believed to assemble in a concentration dependent manner (Li et al., 2012). 
Interestingly, some FMDVs are more likely to form empty capsid than others i.e. especially the FMDV 
A22 Iraq tends to form many empty capsids (Abrams et al., 1995; Curry et al., 1997). It is generally 
believed that five protomers can self-assemble into a pentamer and that twelve of these pentamers 
can assemble into empty capsids or a virus particle. However, the mechanism governing the self-
assembly leading to an empty capsid is poorly understood.  
 
The myristoylation state also seems to be important for the FMDV empty capsid formation. 
Expression of the FMDV P1-2A (wt) precursor and the 3Cpro generated empty capsid particles. 
However, substituting the S to an A within the myristoylation signal sequence (G X X X S) blocked 
the formation of empty capsids even though the P1-2A precursor was efficiently processed by the 
3Cpro (Abrams et al., 1995). However, based on this study, it is not possible to conclude, whether this 
interruption of the myristoylation signal blocked the formation of pentamers or the assembly of 
pentamers into empty capsids.   
 
Using PV and bovine enterovirus (BEV), particles sedimenting at 45S have been reported, it is not 
clear whether these 45S particles are intermediates between the 14S pentamers and the 80S empty 
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particles (Su & Taylor, 1976; Rombaut et al., 1985). Although BEV is extremely cytopathogenic in cell 
cultures, the number of mature virus particles produced are relatively low. The study by Su & Taylor 
(1976) showed that the BEV infection resulted in the production of a high amount of 80S empty 
capsids, and a lesser amount of 160S mature virus particles, 130S provirons, 45S particles, 14S 
pentamers and 5S protomers. Interestingly, at high ionic strength the 45S particles were 
transformed into the 80S empty capsids, using pulse-chase experiments. In contrast, no precursor-
product relationship was established from the 45S and 80S to the mature virus particles (Su & Taylor, 
1976).   
 
Several alternative hypotheses have been proposed for the presence of empty capsids. One 
hypothesis suggests that empty capsids are a precursor to the mature virus (Jacobson & Baltimore, 
1968), into which the RNA can be inserted, as is the case for many bacteriophages (Black, 1989). 
Other studies have reported that the empty capsids can disassemble into pentamers, which led to 
the hypothesis that empty capsids are a storage form of pentamers, which are the direct precursors 
that assemble to form the virus particle (Nugent & Kirkegaard, 1995). One study has shown in a cell-
free replication system, that only PV pentamers can interact with newly synthesized RNA to form 
mature virus particles (Verlinden et al., 2000). This suggest that empty capsids are just an excess of 
capsid proteins and thus a dead end product, that is formed when there is a temporary or continuing 
lack of newly produced viral RNA (Verlinden et al., 2000).    
 
The true role of empty capsids within infected cells remains unknown. However, these empty 
capsids has proven useful for the formation of recombinant vaccines against FMDV (and other 
picornaviruses). For these vaccines, the capsid precursor, P1-2A, has been expressed together with 
the virus encoded protease, 3Cpro (Roosien et al., 1990; Lewis et al., 1991; Abrams et al., 1995; 
Gullberg et al., 2013b, Gullberg et al., 2016; Polacek et al., 2013; Porta et al., 2013). In addition, PV 
has been of interest with regard to the production of empty capsids for a vaccine. However, due to 
insufficient stability of the PV empty capsids, a possible vaccine using this strategy has only recently 
been achieved (Fox et al., 2017). This study took advantages of a known substitution in the type 3 
Sabin vaccine strain that destabilizes capsid assembly intermediates, including the empty capsids, 
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without affecting stability of the mature PV (Macadam et al., 1991). Thus, the candidate residues 
for stabilizing the empty capsids were chosen based on observed secondary mutations in this strain, 
which increased the stability of assembly intermediates including empty capsids. Similarly, 
stabilizing mutations in type 1 and 2 strains were identified following introduction of this 
destabilizing mutation. This study was able to generate stable empty capsids for all three serotypes, 
which each generated high levels of protective antibodies in animal models (Fox et al., 2017).          
 
1.6.5.   RNA encapsidation - assembly of twelve pentamers into the proviron  
Two different mechanisms for RNA encapsidation has been suggested. One is that pentamers 
assemble around a single RNA genome and form the proviron, and the other is that the RNA genome 
is inserted into an empty capsid (Jiang et al., 2014). One study that supports this first mechaninsm 
has shown that pentamers have RNA binding activity and that the binding of RNA to the pentamers 
alters their conformation. In addition, the same study showed that the empty capsids did not display 
any RNA binding activity (Nugent & Kirkegaard, 1995). These findings clearly supported the theory 
that the pentamers were the direct precursor for the proviron for RNA encapsidation. The theory 
was further strengthened when another study showed that both PV 5S protomer and 14S 
pentamers could be cross-linked with viral RNA associated with the PV replication complex (Pfister 
et al., 1995). Later on, a study showed that only PV pentamers interact with the newly synthesized 
RNA to form virus particles (Verlinden et al., 2000). 
 
The exact mechanism of packaging of picornavirus RNA is still unclear, and especially the issue of 
which signals are necessary for RNA encapsidation remains unsolved. The picornavirus capsid, only 
encapsidates positive-sense RNA, linked to a VPg, thereby excluding all cellular RNAs (Nomotot et 
al., 1977; Grubman & Baxt, 2004). Moreover, only newly synthesized PV RNA genomes are 
encapsidated (Nugent et al., 1999), thereby also explaining the close association of capsid 
pentamers with the replication complex (Pfister et al., 1995). It is generally believed that there is 
one, or more, cis-acting packaging signal(s) present within the positive-sense RNA genome to enable 
encapsidation. For PV, the packaging signal does not appear to be present within the P1 coding area, 
since this region could be deleted (in defective interfering (DI) particles) and the RNA genome was 
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still packaged into PV capsids within co-infected cells (Kajigaya et al., 1985; Hagino-Yamagishi & 
Nomoto, 1989). In contrast, no DI particles have been detected in FMDV infected cells  (Clarke & 
Spier, 1983). However, the complete P1 coding region from a number of picornaviruses, including 
FMDV can be replaced with a reporter gene, thus generating a replicon (McInerney et al., 2000). In 
this study, trans-encapsidation of this RNA lacking the FMDV P1 coding region, was also 
investigated, and found to be extremely inefficient (McInerney et al., 2000). Interestingly, the PV 
replicons (lacking the P1 coding area) can be encapsidated when capsid proteins are provided by 
transfecting the cells with a recombinant vaccinia virus that expresses the PV capsid protein P1 
(Ansardi et al., 1994). Moreover, another study pointed out that a PV replicon (encoding firefly 
luciferase instead of the VP2-VP3-VP1 area) could be encapsidated by PV P1 from all subtypes (type 
1, 2 and 3), but were not encapsidated when capsid proteins were provided from another 
picornavirus, i.e. BEV, coxsackievirus A21 or B3, or enterovirus 70 (Porter et al., 1998). These data, 
suggest that the packaging signal does not exist within the P1 coding area of PV RNA and that specific 
packaging signals are present for individual picornaviruses.  
 
The first study to report a cis-acting encapsidation region within the picornavirus family, identified 
a stem-loop structure located in the 5´ end of the genome of a newly discovered picornavirus, Aichi 
virus. This stem-loop was shown to be highly important for encapsidation of the viral RNA (Sasaki & 
Taniguchi, 2003). PV is one of the most studied viruses within the picornavirus family but, as yet, no 
such RNA packaging signal has been identified within the PV genome. In addition, the 2CATPase (part 
of the replication complex) has been suggested to be implicated in the insertion of RNA into PV 
particles, via protein-protein interactions with the VP3 capsid protein (Liu et al., 2010). However, 
recently a study identified contacts between the RNA genome and the capsid of human 
parechovirus from the crystal structures, and these areas within the RNA genome have been 
confirmed as RNA packaging signals (Shakeel et al., 2017). Interestingly, a recent study has identified 
several places within the FMDV genome that might be important for RNA encapsidation (Logan et 
al., 2018). This study took advantage of the properties of the FMDV RNA-polymerase, which lacks 
proof-reading function and thereby introduces errors, resulting in a virus population with closely 
related RNA molecules. Cells infected with the FMDV were lysed to generate a sample containing 
both packaged and unpackaged genomes. From a portion of this sample, virus particles were 
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purified by ultracentrifugation through a sucrose gradient to obtain a sample of only packaged 
genomes. Deep sequencing was applied for both the total population of viral genomes (both 
packaged and un-packaged genomes) and for the purified virus particles, only containing the 
packaged genomes. Comparing these data, made it possible to identify several places in the RNA 
genome that might be important for RNA packaging. Three specific areas, within the Lpro and P1 
coding sequence were chosen for further investigation. Interestingly, introducing silent mutations, 
which altered predicted stem loop structures within all three areas, significantly reduced the yield 
of FMDV. In contrast, no reduction was observed for the yield of empty capsids and 
protomers/pentamers, indicating that these areas of the genome are important specifically for RNA 
packaging (Logan et al., 2018).       
  
1.6.6.   The maturation cleavage of VP0 into VP4 and VP2 
As with the empty capsids, the relevance of the proviron in relation to the virus assembly process is 
not completely elucidated. Early observations with PV had suggested that the proviron was an 
intermediate precursor of the mature virus (Fernandez-Tomas & Baltimore, 1973). However, these 
results has proven difficult to reproduce, and it is still not clear whether these particles are actual 
intermediates or are dead-end products in the assembly pathway.    
 
The cleavage of VP0, also referred to as the maturation cleavage, to generate VP4 and VP2 is usually 
considered to occur during or after encapsidation of the viral RNA. However, the cleavage is not 
completely dependent on RNA encapsidation, since VP2 and VP4 are also observed in FMDV empty 
capsids (Curry et al., 1997; Gullberg et al., 2013b). However, a much higher level of cleaved VP0 (i.e. 
as VP2 and VP4) is found in the virus particles containing RNA. In PV particles, containing RNA, one 
or two copies of VP0 are thought to remain uncleaved and are present in the virus capsid as VP0 
(Jacobson & Baltimore, 1968).  
 
The outer surface of the protein shell in the empty capsids, provirons and the mature virus particles 
are very similar. The major differences are in the internal structure where many stabilizing 
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interactions that are present in the mature virus particle are missing in the empty capsids and 
provirons. Since the VP4/VP2 cleavage site is located on the internal side of the virus particle, 
thereby isolated from cellular and viral proteases, it is considered an autocatalytic event (Arnold et 
al., 1987).  
 
The cleavage site in PV at the VP4/VP2 junction contains a motif of three amino acids, P, H and Q. 
In PV, the proline has been predicted to cause the amino acid chain to kink at this position, which 
allows water molecules to cause hydrolysis of the scissile band thereby separating the VP4 and VP2 
proteins (Basavappa et al., 1994). In most FMDVs the VP4/VP2 junction has the sequence A-L-L-A/D-
K-K-T (Carrillo et al., 2005), thus there is no proline at this junction, and it seems that processing of 
the FMDV VP2/VP4 junction occurs by a different mechanism than for the one suggested for PV. An 
earlier study suggested that a conserved serine at residue 10 within VP2 was involved in the 
cleavage of VP0 in several picornaviruses (Arnold et al., 1987). However, a couple of years later this 
theory was rejected, since substituting the serine to either a cysteine or alanine within PV did not 
affect VP0 cleavage (Harber et al., 1991). The RNA encapsidation has also been suggested to be 
necessary for cleavage of VP0 (Arnold et al., 1987). However, since  FMDV empty capsids have been 
reported to contain some level of cleaved VP0 as VP2 (and VP4) (Curry et al., 1995, Curry et al., 1997; 
Gullberg et al., 2013b) whereas unassembled material predominatly had the intact VP0. Thus, it 
seems that the RNA encapsidation is not essential for this processing and perhaps it is the assembly 
process itself that is necessary to permit cleavage. So, the exact mechanism of cleavage at the 
VP4/VP2 junction remains unknown. 
 
1.6.7.   The FMDV particle 
The structure of different picornaviruses has been solved by x-ray crystallography, e.g. PV (Hogle et 
al., 1985), HRV (Rossmann et al., 1985) and FMDV (Acharya et al., 1989). The structure is iscohedral 
and has 2-, 3- and 5-fold axes of symmetry (see Fig. 10). The VP2, VP3 and VP1 are located externally 
on the virus particle while VP4 is completely internal. The structures of VP2, VP3 and VP1 are very 
similar to one another and each of these proteins contain eight β-strands that are arranged to make 
up a β-barrel. The mature FMDV particles, containing an RNA genome and processed VP0, i.e. VP4 
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and VP2, are generally more stable than the empty capsids, which mostly contain unprocessed VP0 
(Curry et al., 1995, Curry et al., 1997).  
 
Figure 10 shows the structure of the FMDV A22 Iraq (PDB 4GH4) (Curry et al., 1996). The 2-, 3-, and 
5-fold axes are marked with a red circle and indicated with the respective number. 
 
The structure of the mature virus particles within the different picornavirus genera are very similar 
but clearly differences exist. The VP1 proteins (shown in dark blue)  are clustered around the five-
fold axes of symmetry, while VP2 (shown in light blue) and VP3 (shown in yellow) are clustered 
around the three-fold axes, see Fig. 10 (Hogle et al., 1985; Acharya et al., 1989). In PV, there is a 
sunken area, referred to as the “canyon”, around the five-fold axes below VP1. The canyon is 
involved in receptor binding. In cardioviruses there is a series of smaller sunken areas, referred to 
as “pits”, which also are involved in receptor attachment (reviewed by Tuthill et al., (2010)). The 
FMDV particle has a much smoother surface, and in contrast to several entero- and cardioviruses 
the FMDV has a flexible G-H loop, involved in receptor binding, sticking out from the surface of VP1 
(Acharya et al., 1989; Logan et al., 1993). The structure of the entero-, cardio- and aphthoviruses 
are shown in Fig. 11. The FMDV does not have any major canyon or any pits as observed in the 
45 
 
entero- and cardioviruses. This might be because the structural proteins are substantially smaller in 
FMDV, and thus the protein shell is thinner. The FMDV VP1 protein comprises 211-213 residues 
(depending on serotype), whereas the VP1 of HRV14 and PV comprises 279 and 306 residues 
respectively. 
 
 
Figure 11 shows the structure of a) poliovirus (enterovirus), b) encephalomyocarditis virus 
(cardiovirus) and c) foot-and-mouth disease virus (aphthovirus). The dark blue represents the 
innermost surfaces and the white represents the outermost surfaces (Tuthill et al., 2010). 
 
The pentamer interfaces of picornaviruses are stabilized by β-sheets between subunit junctions. A 
characteristic feature of FMDV is their extreme sensitivity towards low pH. When the pH is reduced 
to below 6.8 the FMDV is inactivated. The inactivation is caused by pentameric subunit dissociation, 
thereby releasing the RNA and VP4 (Brown & Cartwright, 1961; Burroughs et al., 1971). The pH 
sensitivity of FMDV is likely to be governed by the switch of the protonation state of a cluster of 
histidines at the pentameric boundaries (Vlijmen et al., 1998). The protonation, at low pH, of several 
histidine residues, but in particular H142 and H145 within VP3, is believed to disturb inter-pentamer 
interactions thereby causing capsid disassembly (Curry et al., 1995; Vlijmen et al., 1998; Fry et al., 
2005). The location of these two histidine residues, in particular, at the interfaces of the pentameric 
subunits of the particle provides a possible explanation for the high acid sensitivity of the virus.  
 
The knowledge of the structure of the virus has also had benefits in relation to the design of novel 
vaccines since modifications of selected residues at the pentamer boundaries has resulted in viruses 
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with higher thermostability (Mateo et al., 2008). Moreover, the knowledge of the structure has also 
been used to modify the virus by removing specific epitopes to create a marker vaccine (allowing 
discrimination between vaccinated and previously infected animals) (Fowler et al., 2011).  
 
1.6.8.   The involvement of cellular chaperones in the viral life cycle 
Chaperones, including heat shock proteins (Hsps) exist in different cellular compartments, where 
they assist in protein folding, maturation, protein complex assembly and protein trafficking. The 
ability of cellular proteins to carry out specific functions is highly dependent on their correct folding. 
Furthermore, the correct folding is also necessary to prevent the proteins from degradation by the 
proteasome that removes misfolded proteins (reviewed by Geller et al. (2012)).  
 
Proteins in the Hsp90 family are highly abundant within cells. There exist two mammalian 
cytoplasmic Hsp90 isoforms, one is the stress-induced Hsp90α, and the other one is the Hsp90β, 
which is constitutively expressed. In the ER, there is a Hsp90 homologue, called Grp94 and another 
homologue called TRAP1 is present within the mitochondria (reviewed by Geller et al. (2012)). 
Hsp90 is an ATPase, meaning that it accomplishes its role through a complex cycle regulated by the 
breakdown of ATP into ADP and a free phosphate ion as well as by interaction with numerous co-
chaperones. The hydrolysis of ATP releases energy that is used to drive  the folding of the target 
protein (Jhaveri et al., 2012). In the cytoplasm, the Hsp90 is involved in the maturation, folding and 
localization of a large set of proteins. In contrast to other chaperones, Hsp90 does not appear to 
interact with newly translated proteins (Geller et al., 2012). Instead, Hsp90 receives the target 
protein from other chaperone systems, where the protein has already been partially folded. For 
instance, protein kinases first interact with the Hsp90 co-chaperone Cdc37 (Pearl, 2005), and for 
steroid receptors, Hsp70 binds first and then another co-chaperone transfers the target protein to 
Hsp90 by interacting with both chaperone systems (Kimmins & MacRae, 2000; Geller et al., 2012). 
Besides being involved in the maturation and folding of various target proteins, Hsp90 and Hsp70 
have also been shown to be important in relation to degradation of some proteins. Protein 
homeostasis depend on a balance between correct protein folding and protein degradation. The 
ability of chaperones to facilitate protein degradation is mediated by interactions with co-
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chaperones such as the carboxyl terminus of Hsp70-interacting protein (CHIP). CHIP binds to both 
the Hsp70 and Hsp90 and is able to facilitate the targeting of proteins to the proteasome system 
(Dickey et al., 2008; Edkins, 2015). Thus, it seems that there is a fine line between correct protein 
folding and protein degradation that helps the cells to rapidly remove misfolded proteins. The 
protein substrates for Hsp90 are highly diverse. Hsp90 is required for many proteins and protein 
complexes. The protein targets include proteins involved in transcription, translation, mitochondrial 
function, membrane trafficking, signal transduction and cell division (Geller et al., 2012). Hsp90 is 
thought to be involved in the maturation of proteins that are already partially folded, and may also 
act to stabilize or remodel these proteins. For some protein complexes, Hsp90 appears to facilitate 
their assembly by stabilizing the unstable subunits and to be involved in the incorporation of the 
specific components into the protein complex. For other protein complexes, Hsp90 promotes 
change in the structure of the assembled complex. However, in both cases, Hsp90 does not appear 
to be part of the final assembled protein complex  (Makhnevych & Houry, 2012).   
 
Viral proteins, like cellular proteins need different chaperones to achieve their correct function and 
indeed a wide variety of both DNA and RNA viruses require chaperones to facilitate entry, genome 
replication, translation and assembly (Geller et al., 2012). Viruses have a very limited coding 
capacity, and thus they rely on different cellular factors to complete their replication cycles. 
Furthermore, due to the limited coding capacity of the viral genome, viral proteins often carry out 
several functions, which suggests that they might be structurally complex. The viruses often rapidly 
produce a large amount of these structurally complex proteins and thus it is likely that several 
different chaperones are involved in their folding (Geller et al., 2012). In addition, the viral precursor 
proteins are highly dependent on correct folding to enter a state that makes them accessible for 
processing and to avoid degradation by the proteasome. This has been proven to be essential for 
the P1 capsid precursor of PV, which is rapidly degraded upon inhibition of Hsp90 (Geller et al., 
2007).  
 
Using specific Hsp90 inhibitors has been shown to reduce the replication of diverse viruses in vitro. 
For example,  Hsp90 appears to be important in the regulation of viral polymerase function in the 
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case of herpesvirus (Burch & Weller, 2005) and hepatitis B virus (Hu et al., 1997), whereas it seems 
to be required for capsid processing in different picornaviruses  (Geller et al., 2007; Newman et al., 
2017). The virus capsid is a complex structure and must be stable both within the host and outside 
it. Thus, the virus capsid must tolerate different environmental conditions but also be able to 
disassemble upon entry into cells to initiate new infections. Hsp90 is known to be involved in the 
folding of different picornavirus capsid precursors (Geller et al., 2007; Newman et al., 2017). In PV, 
the P1 capsid precursor has been found to interact with Hsp90 (possibly together with Hsp70), and 
likely in conjunction with its co-chaperone p23, and was found to be required for the processing of 
this precursor into the capsid subunits. Interestingly, neither of the other PV precursors, P2 and P3, 
seemed to interact with Hsp90 and in addition, the inhibition of Hsp90 did not prevent cleavage of 
the other viral protein precursors (i.e. P2 and P3). Thus, it is likely that Hsp90 is required for the PV 
capsid precursor to obtain the complex folding that enables recognition and cleavage by the viral 
protease (Geller et al., 2007). Furthermore, the interaction between Hsp90 and P1 is believed to 
protect the P1 capsid precursor from degradation by proteasomes (Geller et al., 2007). Similarly, it 
has recently been shown that Hsp90 is required for efficient growth of FMDV in cell cultures and for 
the P1-2A capsid precursor processing (Newman et al., 2017). This indicates that the FMDV capsid 
precursor is also highly dependent on this chaperone to obtain the correct conformation. An 
overview of the involvement of Hsp90 in the folding of the capsid precursor is shown in Fig. 12. 
Interestingly, the capsid precursor of HAV is not sensitive to the inhibition of Hsp90 (Aragonès et al., 
2010), which suggest that HAVs might use other mechanisms for correct folding of its capsid 
precursor. 
 
Among the many protein targets of Hsp90 are proteins involved in cell division including proteins 
related to tumorigenesis (Whitesell & Lindquist, 2005). As these cancer-related proteins are highly 
dependent on Hsp90, specific Hsp90 inhibitors have been suggested to act as cancer treatments. 
Several different pharmacological inhibitors of Hsp90 have been identified. These include 
Geldanamycin (GA) and the GA analogues 17-allyl-17-demethoxygeldanamycin (17-AAG) and 17-
desmethoxy-17-N,N-dimethylaminoethylaminogeldanamycin (17-DMAG). These inhibitors function 
by competing with ATP for binding to the ATP-binding domain of Hsp90 (Jhaveri et al., 2012). These 
inhibitors are currently undergoing clinical evaluation for their use as an anticancer treatment and 
49 
 
results indicate that they have potential as cancer therapy against a wide variety of oncogene-
related cancer types (Wang et al., 2016). Furthermore, the involvement of Hsp90 of various virus 
species has raised the possibility of using non-toxic doses of Hsp90 inhibitors as broad-spectrum 
antiviral agents against a variety of human and animal viruses.  
 
 
Figure 12 shows the possible involvement of Hsp90 and its co-chaperones in the folding of the 
picornavirus capsid precursor (in this example for the poliovirus capsid precursor). Hsp90 interacts 
with the P1 precursor, and is required for the precursor to achieve its correct conformation prior to 
its subsequent processing (Geller et al., 2012).   
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2.   Thesis outline and aim 
This Ph.D. study has focused on different factors required for FMDV capsid assembly and in 
particular for capsid precursor processing. The studies leading up to the three manuscripts were 
based on these three aims:  
I. Analysis of role of the sequences flanking the VP1/2A junction in full-lengh 
FMDV A22 Iraq. The aim was to determine the effect of various amino acid 
substitutions at VP1 K210, for correct processing of this junction. The study was 
based on an earlier study, showing that the VP1 K210E substitution in FMDV 
O1 Manisa severely blocked processing of this junction (Gullberg et al., 2013a).    
 
II. Analysis of the role of the sequences flanking the VP0/VP3- and the VP3/VP1 
junctions. The aim of this study was to identify the effect of different amino 
acid substitutions adjacent to the two junctions separating the capsid proteins. 
Moreover, we wished to determine whether there was a strict order for 
processing of the junctions, i.e. the VP0/VP3-, VP3/VP1-, and VP1/2A junction. 
 
III. Based on two earlier studies that showed that C-terminal truncation of the 
capsid precursor in both PV and FMDV, blocked processing at each of the 
junctions between the structural proteins  (Ypma-Wong & Semler, 1987; Ryan 
et al., 1989), we hypothesized that there might be a region within the C-
terminus of VP1, which is of high importance for correct capsid precursor 
processing. The aim of this study was to identify the region(s) that seemed to 
cause this block in protein processing.   
 
In manuscript 1 entitled “Determinants of the VP1/2A junction cleavage by the 3C protease in foot-
and-mouth disease virus-infected cells” the effect of various substitutions at the VP1 K210 for 
correct processing of the VP1/2A junction was investigated. The VP1 K210 corresponds to the 
residue two aa upstream the junction (P2). Using reverse genetics, various substitutions were 
introduced at VP1 K210 in the cDNA encoding the full-length FMDV. These constructs were in vitro 
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transcribed and the RNA transcripts were introduced into baby hamster kidney (BHK) cells. After 
some few passages to obtain a high virus titter, the cleavage of the VP1/2A junction was investigated 
by western blot and immunofluorescence.   
 
In manuscript 2 with the title “Cleavages at the three junctions within the foot-and-mouth disease 
virus capsid precursor (P1–2A) by the 3C protease are mutually independent” the effect of various 
substitutions near the junctions between the capsid proteins, i.e. the VP0/VP3- and VP3/VP1 
junctions were investigated. As it was likely that these substitutions would block cleavage of one of 
the junctions, which might be fatal for the virus, the effect of these changes was first tested using a 
transient expression assay to express the capsid precursor (P1-2A) in the absence and presence of 
3Cpro. Subsequently, the different substitutions were tested in the context of the full-length FMDV, 
however only one of the mutants could be rescued.  
 
In manuscript 3 entitled “Identification of a short, highly conserved, motif required for picornavirus 
capsid precursor processing at distal sites”, we identified a region within the C-terminus of VP1 that 
was required for capsid precursor processing. In this study, we used mutagenic PCR to make 
different constructs encoding the P1-2A area with different modifications. First, we introduced Stop 
codons at different sites within the VP1 coding area, next we introduced small deletions in the area 
identified by the Stop codons. Lastly, we introduced single amino acid substitutions within the 
identified region. These modifications identified a short motif, which was highly conserved among 
many picornaviruses and had a huge impact on capsid precursor processing.  
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Determinants of the VP1/2A junction cleavage by the 3C
protease in foot-and-mouth disease virus-infected cells
Thea Kristensen, Preben Normann, Maria Gullberg, Ulrik Fahnøe,† Charlotta Polacek, Thomas Bruun Rasmussen and
Graham J. Belsham*
Abstract
The foot-and-mouth disease virus (FMDV) capsid precursor, P1-2A, is cleaved by FMDV 3C protease to yield VP0, VP3, VP1
and 2A. Cleavage of the VP1/2A junction is the slowest. Serotype O FMDVs with uncleaved VP1-2A (having a K210E
substitution in VP1; at position P2 in cleavage site) have been described previously and acquired a second site substitution
(VP1 E83K) during virus rescue. Furthermore, introduction of the VP1 E83K substitution alone generated a second site
change at the VP1/2A junction (2A L2P, position P2¢ in cleavage site). These virus adaptations have now been analysed using
next-generation sequencing to determine sub-consensus level changes in the virus; this revealed other variants within the
E83K mutant virus population that changed residue VP1 K210. The construction of serotype A viruses with a blocked VP1/2A
cleavage site (containing K210E) has now been achieved. A collection of alternative amino acid substitutions was made at
this site, and the properties of the mutant viruses were determined. Only the presence of a positively charged residue at
position P2 in the cleavage site permitted efficient cleavage of the VP1/2A junction, consistent with analyses of diverse FMDV
genome sequences. Interestingly, in contrast to the serotype O virus results, no second site mutations occurred within the
VP1 coding region of serotype A viruses with the blocked VP1/2A cleavage site. However, some of these viruses acquired
changes in the 2C protein that is involved in enterovirus morphogenesis. These results have implications for the testing of
potential antiviral agents targeting the FMDV 3C protease.
INTRODUCTION
Foot-and-mouth disease virus (FMDV) is the prototypic
member of the genus Aphthovirus within the family Picor-
naviridae and seven different serotypes (O, A, C, SAT 1–3
and Asia-1) have been identified. All FMDVs have a posi-
tive-sense RNA genome (ca. 8400 nt) that includes a single
large ORF (ca. 7000 nt) encoding a polyprotein [1]. The
full-length polyprotein is never observed since during, and
after, synthesis it is processed, mainly by virus-encoded pro-
teases, to generate 15 distinct mature products plus multiple
precursors. The FMDV polyprotein includes two trans-act-
ing proteases; these are the Leader (L) protease and the 3C
protease (3Cpro). The L protease is only responsible for one
cleavage within the polyprotein that occurs at its own C-
terminus (i.e. the L/P1-2A junction, [2, 3]). However, this
protease also induces cleavage of the translation initiation
factor eIF4G; this results in the inhibition of host cell, cap-
dependent, protein synthesis (reviewed in [1]). The 3Cpro
cleaves all the other junctions within the FMDV polyprotein
except for the VP4/VP2 junction and the 2A/2B junction.
Cleavage of VP0 to VP4 and VP2 occurs on encapsidation
of the viral RNA and also within assembled empty capsid
particles [4–6]. Separation of the 2A peptide from the 2B
protein is dependent on the 2A coding sequence. However,
this region only encodes 18 aa (without any protease
motifs), but its presence results in a break in the polyprotein
during its synthesis; this is described as ‘ribosomal skipping’
[7] or ‘StopGo’ [8].
The FMDV capsid protein precursor, P1-2A (Fig. 1), is pro-
cessed by the 3Cpro to VP0, VP3, VP1 and 2A. The scission
of the VP1-2A junction is the slowest of these cleavages
within cell-free translation systems [9] and within mamma-
lian cells [5, 6] since the uncleaved VP1-2A can still be
detected when all other junctions are fully cleaved (e.g. when
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P1-2A is expressed with a low level of 3Cpro). However, in
peptide cleavage assays, using short synthetic substrates, it
has been found that the peptide corresponding to the VP1/
2A cleavage site was the most rapidly processed [10].
The FMDV 3Cpro cleaves a variety of different junction
sequences (the amino acid residues at the cleavage junctions
are indicated as P4P3P2P1/P1¢P2¢P3¢P4¢). The cleavage sites
recognized by the FMDV 3Cpro have either glutamine (Gln,
Q) or glutamate (Glu, E) at the P1 position [11]. The con-
sensus sequence (in single-letter code) for the VP1/2A junc-
tion in serotype O and A FMDVs is PxKQ/xLNF. The Q
residue at the P1 position, together with the P4-Pro (P), P2-
Lys (K) and P4¢-Phe (F) residues, represent key determin-
ants of 3Cpro specificity at this site [10–12]. Analysis of
aligned FMDV 3Cpro cleavage sites from over 100 strains of
the virus (including representatives of all serotypes) revealed
that sites with P1-Q have a strong selectivity for P2-K, indi-
cating that recognition of the P1 residue by 3Cpro is influ-
enced by the P2 residue [11]. Recently, we have shown that
changing the P2-K residue to E at the VP1/2A junction (i.e.
K210E in VP1), in a serotype O virus, greatly inhibited
cleavage at this junction and resulted in the formation of
infectious virus particles containing the uncleaved VP1-2A
[6]. The ‘self-tagged’ viruses containing this modification
(K210E) also acquired, during the virus rescue procedure, a
second amino acid substitution within VP1 (E83K). Inter-
estingly, introduction of this E83K substitution alone into
the virus generated a second site mutant (L2P, in the 2A
sequence; this is position P2¢ in the VP1/2A junction) that
also blocked cleavage [13]. We have now expanded this
analysis to identify the determinants of cleavage at the VP1/
2A junction within the context of infectious serotype O and
A FMDVs using a variety of different approaches. Within
the serotype A FMDVs, no second site changes in VP1 were
observed in viruses where the VP1/2A cleavage was inhib-
ited, but some evidence for changes in 2C was obtained. For
certain picornaviruses, within the enterovirus genus, inter-
actions between the virus capsid proteins and the 2C non-
structural protein have been implicated in the process of
virus morphogenesis [14–16].
RESULTS
Modification of the VP1/2A cleavage site in a
serotype A FMDV
In order to determine whether the key elements of the
results obtained with the serotype O FMDV sequences [13]
also applied to serotype A FMDV, the effect of modifying
the VP1/2A cleavage site within a serotype A FMDV was
examined. The VP1/2A cleavage site sequence in the A22
strain of FMDV (APAKQ/LLNFD) differs at just one out of
the 10 residues flanking the junction from the serotype O
(strain O1 Manisa, abbreviated throughout as O1M)
sequence (APVKQ/LLNFD) analysed previously [6, 13] (see
Fig. 1). The K210E substitution (at the P2 position) was
pO1K/A22 cDNA
pO1K/A22 wild-type (wt)         
pO1K/A22 VP1 K210E              
pO1K/A22 2A L2P                      
pO1K/A22 VP1 K210E 2A L2P  
APAKQ/LLNFD
APAEQ/LLNFD
APAKQ/LPNFD
APAEQ/LPNFD
APAKQ/LLNFD
APAKQ/LLNFD (reversion)  
APAKQ/LPNFD
APAEQ/LPNFD
Encoded sequence      Rescued virus
VP2 VP3 VP1 2A
A(n)
L VP4 VP2 VP3 VP1 2A2B 2C 3A 3C 3D3B
1–3T7
NheI ApaI HpaI
P1-2A
Fig. 1. Schematic structure of the plasmid containing the FMDV O1 Kaufbeuren (O1K)/A22 cDNA and derivatives. The NheI and ApaI
restriction enzyme sites (as indicated) were used as described in Methods to introduce cDNA fragments encoding the serotype A
FMDV capsid proteins VP2-VP3-VP1-2A (from A22 Iraq, white fill) into the plasmid pT7S3 [33], containing a full-length cDNA corres-
ponding to the O1K B64 strain of FMDV (coding sequences marked in grey). The plasmid-encoded amino acid sequences at the VP1/2A
junction are shown. The FMDV O1K/A22 wt, single mutants (VP1 K210E or 2A L2P) and double mutant (VP1 K210E and 2A L2P) were
produced as described in Methods. The full-length plasmids were linearized using HpaI prior to in vitro transcription and virus rescue.
The locations of restriction sites used are marked: NheI, ApaI and HpaI. Sequence changes in the capsid coding region of the rescued
viruses are indicated.
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introduced into a full-length FMDV cDNA, based on the
backbone of a chimeric O1 Kaufbeuren (O1K) virus con-
taining the coding sequence for the VP2-VP3-VP1-2A
region of the A22 capsid protein precursor (Fig. 1). Virus
was successfully rescued from this chimeric wt O1K/A22
plasmid and also from the O1K/A22 VP1 K210E mutant
(this had changed the codon encoding VP1 residue 210
from AAA to GAA). However, when the capsid protein
coding sequences within the rescued virus were determined,
it was found that the K210E substitution in VP1 had
reverted in the virus by passage 2 (Psg 2) to the wt sequence
(this only requires a single nt change) (see Fig. 1).
Two further modifications were, therefore, introduced into
the serotype A viruses: the 2A L2P modification was made
in isolation (using 3 nt changes, TTG to CCA) and a double
mutant containing both the K210E substitution (the single
nt change) and the 2A L2P substitution. Viruses were res-
cued successfully from both of these mutant plasmids. Con-
sensus sequencing indicated that the expected mutations
were still present within these rescued viruses and that no
other mutations were detected within the VP2-2A coding
region (see Fig. 1).
Analysis of the FMDV capsid proteins within cells infected
with the wt and mutant O1K/A22 viruses, as determined by
immunoblotting using anti-VP2 and anti-2A antibodies, is
shown in Fig. 2. As expected, the production of VP0 and
VP2 was very similar in each of the infected cell extracts
(Fig. 2a, lanes 2–7). However, the presence of the uncleaved
VP1-2A was only observed with the mutant viruses, either
containing the 2A L2P substitution alone (Fig. 2b, lanes 4
and 5) or with the double mutant (VP1 K210E and 2A L2P)
(Fig. 2b, lanes 6 and 7).
These results were confirmed using immunofluorescence (IF)
studies (Fig. 3). Consistent with the immunoblotting data, the
presence of FMDV 2A (still attached to VP1) was detected in
cells infected with the O1K/A22 2A L2P mutant virus
(Fig. 3g) and with the double mutant (O1K/A22 VP1 K210E
and 2A L2P) virus (Fig. 3h). In contrast, no signal for the 2A
peptide was observed in cells infected with the wt O1K/A22
virus (Fig. 3f) or in uninfected cells (Fig. 3e). The presence of
the FMDV capsid proteins could be detected in cells infected
with each of the viruses (Fig. 3b–d) but not in uninfected cells
(Fig. 3a). These results are consistent with those obtained
using the serotype O FMDVs previously [13]. It seems that
the free 2A peptide is not efficiently detected within cells using
the IF approach; it is assumed that either it breaks down very
quickly or the conditions of the IF assay are not suitable for
detection of this short peptide.
Use of next-generation sequencing to determine
sequence diversity within rescued FMDVs
As described previously [6, 13], consensus sequencing of the
capsid coding region (P1-2A) of the serotype O FMDVs res-
cued from the K210E and E83K mutant forms of the O1K/
O1M cDNAs identified the presence of additional amino acid
substitutions in the rescued viruses. We wished to analyse
these adaptations in more detail, in particular to examine the
appearance of sub-consensus level changes throughout the
near-complete genome sequence including the complete
polyprotein coding region. To achieve this, RNA was
extracted from the rescued O1K/O1M VP1 E83K and O1K/
O1M VP1 K210E viruses (as described by Gullberg et al. [6,
13]) at Psg 2 and/or Psg 3. Two separate, but overlapping,
cDNA fragments including the near-complete genome [ca. 8
kb, downstream of the poly(C) tract] were produced by
reverse transcription (RT)-PCR, mixed and then sequenced
using next-generation sequencing (NGS) at a coverage of
about 5000 reads per nt (except near the extreme 5¢- and 3¢-
termini).
This analysis showed that the rescued virus O1K/O1M VP1
E83K retained the expected substitution (encoding E83K) in
100% of the progeny at Psg 2, but there was some heteroge-
neity in the sequence near the VP1/2A junction (see Table 1).
As described earlier, the consensus sequencing indicated that
a substitution (L2P) within the 2A sequence occurred within
this rescued virus [13]. The analysis by NGS (see Table 1)
demonstrated that at Psg 2, some 83% of the reads
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Fig. 2. Detection of FMDV capsid proteins in BHK cells infected with
O1K/A22 wt and mutant viruses. Baby hamster kidney (BHK) cells
were infected with O1K/A22 wt or mutant viruses (single mutant 2A
L2P or double mutant VP1 K210E and 2A L2P) (m.o.i. of 0.1), and
whole-cell lysates were prepared at the indicated times post-
infection (p.i.). The presence of FMDV VP2 (and its precursor VP0) was
detected by immunoblotting using anti-VP2 antibodies (a) and FMDV
2A (attached to VP1 as VP1-2A) was detected using anti-2A antibodies
(b). Uninfected BHK cells were used as a negative control. Molecular
mass markers (kDa) are indicated on the left.
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corresponded to this L2P substitution in 2A, while two other
variants were also present (albeit at relatively low levels, 4
and 9%), which each encoded the K210N substitution in
VP1 (c.f. the K210E change described previously in O1M,
[13]). No other coding changes were present anywhere in
the genome at an abundance of more than 3%.
Consensus sequence analysis of the rescued O1K/O1M VP1
K210E virus has shown previously the generation of the
E83K substitution [6]. Using NGS, it was found that the
E83K substitution in VP1 was encoded in 78% of the reads
generated at Psg 2 and in 99% of the reads at Psg 3
(Table 1), consistent with the earlier consensus sequencing
Uninfected cells
(a) (b)
50 μm
(c) (d)
(e) (f) (g) (h)
O1K/A22
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Fig. 3. IF staining of FMDV proteins within serotype A FMDV-infected cells. FMDV proteins within uninfected or FMDV-infected cells
(using m.o.i. of 0.1) were detected (at 8 h p.i.) using an anti-FMDV A-Iraq polyclonal antibody (a–d) or an anti-2A antibody (e–h) and a
secondary antibody labelled with Alexa Fluor 568 (red). Uninfected cells are shown in (a) and (e). Cells were infected with the viruses
O1K/A22 (wt) (b and f), O1K/A22 2A L2P (c and g) or O1K/A22 VP1 K210E and 2A L2P (d and h) as indicated. The cellular nuclei were
visualized with DAPI (blue). Bar, 50 µm.
Table 1. Analysis of SNVs within rescued O1K/O1M viruses as determined by NGS
Nt
position
Wt Variant O1K/O1M VP1 E83K
(Psg 2) (%)*
O1K/O1M VP1 K210E
(Psg 2) (%)*
O1K/O1M VP1 K210E
(Psg 3) (%)*
SNV effect (whole
polyprotein)
SNV effect
(individual protein)
762 T C 6 – – (in 5¢ UTR) –
948 T G – 1 3 (in 5¢ UTR) –
1811 T C 6 – – – –
1875 A G 3 – – T253A VP4 (T52A)
2102 C T 3 – – – –
2357 A G – 3 3 – –
3537 G A 100 78 99 E807K VP1 (E83K)
3918 A G – 100 100 K934E VP1 (K210E)
3920 A C 4 – – K934N VP1 (K210N)
3920 A T 9 – – K934N VP1 (K210N)
3928 T C 83 – – L937P 2A (L2P)
5166 A G 3 – – S1350G 2C (S243G)
7392 T C – 5 7 F2092L 3D (F228L)
7765 A G 2 – – K2216R 3D (K353R)
SNV, single nucleotide variant.
*The percentage of each variant (1%) is given to the nearest integer.
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[6]. The K210E substitution was maintained in this rescued
virus in 100% of the reads at Psg 2 and Psg 3.
For the rescued serotype A viruses, consensus (Sanger)
sequencing of the rescued O1K/A22 2A L2P virus demon-
strated the maintenance of the introduced changes and did
not reveal any additional modifications, resulting in amino
acid substitutions within the P1-2A coding region. This was
confirmed by NGS, but an A-to-G nucleotide change, result-
ing in a single amino acid substitution (T44 to A within the
2C protein), was found in 13% of the reads from the rescued
virus (Table 2). Within the O1K/A22 VP1 K210E and 2A
L2P virus, only the expected changes in the P1-2A coding
region were observed, but an additional change, resulting in
the amino acid substitution A73V in the 2C protein, was
detected in 100% of the sequence reads (see Table 2). The
plasmid pO1K/A22 K210E L2P from which this virus was
rescued has been confirmed as having the expected sequence
in the 2C coding region (100% identity to O1K, data not
shown), and thus, this sequence change had occurred during
virus rescue. The significance of these changes in 2C is
unknown; neither residue is completely conserved among
FMDV strains [17]. The A73V change in 2C was not present
in the rescued O1K/A22 wt or the O1K/A22 2AL2P, and
there was no evidence for the T44A amino acid substitution
in either the O1K/A22 wt or the O1K/A22 VP1 K210E and
2A L2P virus that was encoded in a minority of the O1K/
A22 2A L2P virus reads.
Exploring potential sequence diversity at the
VP1/2A cleavage site
The results described previously [6, 13] indicated that modifi-
cation of the VP1/2A junction sequence from PxKQ/xLNF at
the P2 position (from K to E) or the P2¢ position (from L to P)
was sufficient to strongly inhibit cleavage by 3Cpro at this pro-
tein junction, but these changes did not affect virus viability.
Furthermore, the NGS data (Table 1) indicated that the K-to-
N substitution at residue 210 of VP1 was also probably viable
since some 13% of the virus population acquired this change.
To establish the range of amino acid substitutions that could
be tolerated at this junction, mutagenesis of the codon for resi-
due 210 within VP1 was undertaken within the context of the
O1K/A22 full-length cDNA. The mutagenesis generated nine
different codon sequences that encoded seven distinct amino
Table 2. Analysis of SNVs within rescued O1K/A22 viruses as determined by NGS
Nt position Wt Variant O1K/A22 (wt)
(Psg 2) (%)*
O1K/A22 2A L2P
(Psg 3) (%)*
O1K/A22 VP1
K210E 2A L2P
(Psg 3) (%)*
SNV effect (whole polyprotein) SNV effect (individual protein)
932 A C – 2 – (in 5¢-UTR) –
1060 T G 2 – – (in 5¢-UTR) –
1124 T A – 7 – N2K L (N2K)
1341 C T – – 4 P75S L (P75S)
1400 G T – – 2 – –
1865 C T – 2 – – –
2175 T C – 2 – F353L VP2 (F67L)
2342 A G – – 2 – –
2684 C T – 3 – – –
3154 T C – 1 – V679A VP3 (V174A)
3824 G C 2 – – – –
3884 T C – 8 – – –
3921 A G – – 100 K935E VP1 (K210E)
3930 T C – 90 100 † †
3931 T C – 98 100 L938P† 2A (L2P)†
3932 G A – 99 100 † †
4572 A G – 13 – T1152A 2C (T44A)
4660 C T – – 100 A1181V 2C (A73V)
4821 A C – 1 – I1235L 2C (I127L)
4843 G T – 1 – R1242I 2C (R134I)
5080 C T – 5 – T1321I 2C (T213I)
6924 C T – 11 – – –
7170 T C 3 – – Y2018H 3D (Y155H)
7358 C T – – 4 – –
SNV, single nucleotide variant.
*The percentage of each variant (1%) is given to the nearest integer.
†Change of the TTG to CCA codon was introduced by site-directed mutagenesis, and the three changes together result in the 2A (L2P) substitution.
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acid substitutions (see Table 3). RNA transcripts were pro-
duced from the mutant cDNAs and electroporated into baby
hamster kidney (BHK) cells, and infectious viruses were res-
cued in each case. From the virus harvests, RNA was extracted
and the sequence of VP1-2A coding region was determined,
and changes (if any) are shown in Table 3. Consistent with the
studies described above, the O1K/A22 VP1 K210E mutant
(with a single nt change, GAA) again reverted to the parental
sequence; however, when 2 nt changes were introduced
(GAG) to produce the K210E substitution, then viruses that
retained these 2 nt changes were obtained. Thus, the VP1 sub-
stitutions K210Q, K210R, K210A, K210V, K210M, K210N
and K210E (as the GAG double mutant) were all viable with-
out reversion or other adaptation within VP1 (Table 3). Using
consensus-level sequencing, no changes in the 2C coding
region were detected in any of these rescued viruses either
(data not shown).
The cleavage of the VP1/2A junction in cells infected with
the rescued mutant viruses was assessed using the IF assay,
as described above. The presence of the FMDV capsid pro-
teins (using anti-FMDV antisera) and of the VP1-2A (using
anti-2A antibodies) was determined in BHK cells infected
with the different viruses. FMDV infection, but with no
staining for VP1-2A, was observed in cells infected with the
viruses containing the VP1 residue K210 (wt) and R210
(Fig. 4). In contrast, cells infected with the rescued viruses
having the substitutions in VP1 K210Q, K210A, K210V,
K210M, K210N and K210E (double mutant) each showed
staining both for the FMDV capsid proteins and for 2A
(using the anti-2A antisera), indicative of blocked VP1/2A
cleavage (see Fig. 4, Table 3). No staining with either anti-
serum was observed in uninfected cells, as expected
(Fig. 4).
To confirm these results, immunoblotting was performed
using anti-2A antibodies to determine the presence of the
uncleaved VP1-2A within infected cells. The results are
shown in Fig. 5(a). Consistent with the IF results, no VP1-
2A product was detected in uninfected cells or in wt (K210)
or mutant K210R FMDV-infected cells. In contrast, the
presence of VP1-2A was readily apparent within cells
infected with mutant FMDVs having the K210Q, K210A,
K210V, K210M, K210N and K210E substitutions. The pres-
ence of FMDV capsid proteins in the lysates from cells
infected with each of the different FMDV variants was veri-
fied using anti-VP2 antibodies that recognize both VP0 and
VP2 (Fig. 5b). These results support the IF data and indicate
that the VP1/2A junction is only cleaved when residue 210
in VP1 is either K or R (these are both basic residues).
DISCUSSION
In our earlier studies, it was shown that the K210E substitu-
tion in VP1 within the FMDV O1M capsid inhibited cleav-
age of the VP1/2A junction and resulted in generation of a
second site substitution (E83K in VP1) in the mutant virus
[6]. Furthermore, introduction of the E83K substitution
alone in VP1 resulted in the production of another second
site change (with a substitution of L2P in 2A) that also
blocked VP1/2A junction processing in cells infected with
the rescued virus [13]. In contrast, this study has shown
that when the K210E substitution (GAA mutant) was intro-
duced into the VP1 of a serotype A virus (O1K/A22), the
virus reverted to wt (AAA) very rapidly (single nt change).
However, introduction of 2 nt changes (GAG codon)
enabled the K210E substitution to be maintained. Consis-
tent with the serotype O virus results [6, 13], this amino
acid substitution alone was sufficient to block VP1/2A
cleavage (see Figs 4 and 5). In addition, introduction of the
2A L2P change alone (employing 3 nt changes) or also with
the K210E substitution resulted in the generation of viruses
which maintained each of these changes. Furthermore, the
presence of the uncleaved VP1-2A protein was observed
within cells infected with these serotype A viruses
(Figs 2 and 3). Thus, consistent with results using the O1K/
O1M FMDV [6, 13], it is possible to obtain infectious
Table 3. Influence of residue K210 in VP1 on VP1/2A junction cleavage in FMDV-infected cells
Virus VP1 210 codon Viability Rescued virus sequence Rescued virus amino acid Comment VP1/2A cleavage*
pO1K/A22 K210 AAA + AAA K wt +
pO1K/A22 K210Q CAA‡ + CAA Q  
pO1K/A22 K210R AGA‡ + AGA R +
pO1K/A22 K210A(v1)† GCA‡ + GCA A  
pO1K/A22 K210A(v2)† GCG‡ + GCG A  
pO1K/A22 K210V GTT‡ + GTT V  
pO1K/A22 K210M ATG‡ + ATG M  
pO1K/A22 K210N AAC‡ + AAC N  
pO1K/A22 K210E(v1)† GAA‡ + AAA K Reversion +
pO1K/A22 K210E(v2)† GAG‡ + GAG E  
*VP1/2A cleavage was assessed from IF staining using anti-2A antibodies (as in Fig. 4) and by immunoblotting (Fig. 5a).
†v1 or v2 to distinguish different codons.
‡Nucleotide changes in this codon are indicated in bold font.
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Fig. 4. Determination of VP1/2A cleavage by IF staining for FMDV proteins within cells. FMDV proteins within uninfected or FMDV-
infected cells (using m.o.i. of 0.1) were detected (at 6 h p.i.) using an anti-FMDV A-Iraq polyclonal antibody or an anti-2A antibody (as
indicated) and a secondary antibody labelled with Alexa Fluor 568 (red) as in Fig. 3. The codon for residue 210 within VP1 (in paren-
theses) and the resulting individual amino acid residue within the different rescued viruses are indicated. Uninfected cells were used
as a negative control. The cellular nuclei were visualized with DAPI (blue). Bar, 200 µm.
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serotype A FMDVs, containing the uncleaved VP1-2A.
However, in contrast to the results using the serotype O
virus, there was no apparent selection for a substitution at
residue E83 in VP1 (or elsewhere within the VP1) within
the serotype A background. The basis for this difference is
not known, but it is noteworthy that the serotype A capsid
proteins assemble into FMDV empty capsids much more
efficiently than the serotype O proteins [18, 19]. It is also
apparent that some of the rescued serotype A viruses, with
the VP1/2A junction rendered non-cleavable, acquired sec-
ond site mutations within the non-structural protein 2C
(see Table 2). In particular, the A73V variant within 2C was
encoded by 100% of the sequence reads at Psg 3 of the res-
cued O1K/A22 VP1-K210E and 2A-L2P virus. This suggests
a strong selective pressure for this amino acid substitution.
The significance of this is currently unknown, but there is
some evidence for interactions between the capsid proteins
and the 2C protein of enteroviruses (e.g. poliovirus) during
virus morphogenesis [14–16].
Interestingly, it was also observed, using NGS, that during
the rescue of the O1K/O1M VP1 E83K virus, a minority of
the virus population encoded a K210N substitution in VP1
(c.f. the K210E substitution observed in a laboratory grown
O1M virus, [6]). It should be noted that the majority of the
serotype O VP1 E83K mutant virus RNA acquired the 2A
L2P substitution during the virus rescue procedure (see
Table 1). This encouraged analysis of the range of substitu-
tions that can be accommodated at residue 210 in VP1; this
is at position P2 relative to the VP1/2A cleavage site. Within
the serotype A background, there appears to be significant
selection pressure against the K210E substitution, since fol-
lowing independent transfections of a mutant RNA contain-
ing a single nt change (GAA) reversion to the wt (AAA)
sequence occurred. However, when 2 nt changes were used
(GAG) to make this amino acid substitution, then the
K210E substitution was maintained. The single nt substitu-
tion to make the K210E substitution was also maintained in
the O1K/A22 K210E and L2P double mutant; presumably
the presence of the two substitutions that blocked VP1/2A
cleavage overcame the selective pressure for reversion. In
addition, a range of other amino acid substitutions was tol-
erated. Most of these substitutions (e.g. K210A, K210V,
K210M and K210N) blocked cleavage of the VP1/2A junc-
tion; thus, the VP1-2A product was stable (see Figs 4 and
5). In contrast, the 2A peptide was released from the VP1 in
the K210R mutant. Therefore, it appears that the presence
of a positively charged residue (K or R) at residue 210 in
VP1 is essential for VP1/2A cleavage, and a negative charge
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Fig. 5. Assessment of FMDV VP1/2A cleavage in FMDV-infected BHK cells by immunoblotting. Uninfected or FMDV-infected BHK cell
lysates were analysed by SDS-PAGE and immunoblotting (as in Fig. 2). Where applicable, the cells were infected with the indicated
viruses (at an m.o.i. of 0.1) and the presence of FMDV 2A (attached to VP1 as VP1-2A) was detected using anti-2A antibodies (a), while
FMDV VP2 (and its precursor VP0) was detected by immunoblotting using anti-VP2 antibodies (b). Uninfected cells were used as a
negative control. Molecular mass markers (kDa) are indicated on the left.
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(as in K210E) is less well tolerated by itself and was selected
against. These results are consistent with the strong pre-
dominance of the K and R residues at this position in the
‘logos plot’ generated by Curry et al. [11] for 3Cpro cleavage
sites, with Q at the P1 position, based on the known sequen-
ces of over 100 strains of FMDV.
Using peptide cleavage assays, the VP1/2A peptide was the
most efficiently cleaved substrate for FMDV 3Cpro [10].
However, making the K210A substitution abrogated cleav-
age of this peptide, in accordance with the results presented
here. Zunszain et al. [12] have described additional modifi-
cations to the peptide substrate, which corresponds to the
VP1/2A junction. Changing the P2 residue in the cleavage
site (corresponding to K210 in VP1) from K to R or to orni-
thine (also positively charged) had relatively modest effects
on the cleavage rate. However, substitution to the neutral T
residue abrogated cleavage as observed here, with the K210
changed to Q, A, V, M or N (see Table 3, Figs 4 and 5).
It has been proposed that the FMDV 3Cpro may be a good
target for the development of an antiviral agent [20]. Fur-
thermore, it was shown that compounds that resemble the
peptide substrate can act as an efficient inhibitor of this pro-
tease. The presence of a positively charged residue at the P2
position generated the most effective inhibitors, while com-
pounds containing neutral residues (e.g. G and Q) or a nega-
tively charged residue (E) at this position were much less
effective, consistent with the poor cleavage of the VP1/2A
junction seen here in viruses containing equivalent
substitutions.
It is important to note that viable FMDVs with the VP1/2A
junction uncleaved can be obtained (as here, and as
described previously for serotype O viruses [6, 13]). Thus, it
may be wise to focus screens for such antiviral agents on
other 3Cpro cleavage sites so that the block on polyprotein
processing is most effective at inhibiting virus replication.
The results presented here demonstrate that the combina-
tion of reverse genetics and NGS provides powerful tools to
direct and identify virus adaptation, thus permitting novel
aspects of the virus biology to be identified.
METHODS
Plasmid construction
The structures of plasmids containing full-length FMDV
cDNAs used in this study are indicated in Fig. 1. The chime-
ric pO1K/A22 plasmids (containing the A22 Iraq capsid
coding sequences, as used in [19, 21]) in the FMDV O1K
backbone were generated using the same procedures as used
previously for the production of the pO1K/O1M VP1
K210E [6]. Briefly, the cDNAs corresponding to the A22
VP2-2A coding region were amplified from pGEM-3Z-A-
P1-2A-mIRES-3C [5] and pGEM-3Z-A-P1-2A-mIRES-3C
VP1K210E [6] with primers FMDVA_NheIVP4VP2_Fw
and FMDVA_ApaI2A2B_Re (see Table S1, available in the
online Supplementary Material) and used to generate the
full-length cDNAs termed pO1K/A22 wt and pO1K/A22
VP1 K210E, respectively (Fig. 1). In order to produce
pO1K/A22 2A L2P and the double mutant pO1K/A22 VP1
K210E and 2A L2P, intermediate plasmids (using pO1K/
A22 wt and pO1K/A22 VP1K210E, as described above, as
templates) were generated. This was achieved using the
QuikChange site-directed mutagenesis method (with Pfu-
Turbo DNA polymerase; Stratagene), according to the man-
ufacturer’s instructions, with primers containing the desired
modifications (see Table S1, namely FMDVA_2AL2P_Fw
together with FMDVA_2AL2P_Re or FMDVA_VP1-
K210E_2AL2P_Re). The subsequent steps to produce the
four pO1K/A22 variants were performed essentially as
described for the serotype O plasmid pO1K/O1M VP1
E83K [13]. Plasmids were amplified in Escherichia coli
Top10 cells (Invitrogen), purified (Midiprep kit; Thermo
Scientific) and verified by sequencing of the capsid coding
region (and for pO1K/A22 VP1 K210E the 2C coding region
as well) with a BigDye Terminator v. 3.1 Cycle Sequencing
kit and a 3500 Genetic Analyzer (Applied Biosystems).
Additional mutations, encoding changes at the VP1/2A
junction, were introduced into the pO1K/A22 full-length
FMDV cDNA (Fig. 1) by site-directed mutagenesis using a
megaprimer (146 bp) that was prepared by PCR using
primer O1PN20 and primer 13LPN21 (see Table S1) that
had NNN at the position corresponding to the codon for
the VP1 residue 210. This degenerate megaprimer was used,
with the pO1K/A22 full-length cDNA template and Pfu-
Turbo DNA polymerase (as above) to generate a collection
of nine plasmids encoding a variety of different amino acids,
with diverse properties, in place of VP1 residue K210; this is
at position P2 relative to the VP1/2A cleavage site. The
details of each modification made are indicated in Table 3.
Rescue of modified viruses from cDNA
Plasmids pO1K/A22 (wt), pO1K/A22 VP1 210E, pO1K/
A22 2A L2P and pO1K/A22 VP1 K210E 2A L2P (as shown
in Fig. 1) containing the full-length FMDV cDNA sequen-
ces were linearized by digestion with HpaI, purified (using a
QIAquick PCR purification kit; Qiagen) and transcribed in
vitro using T7 RNA polymerase (Megascript kit; Ambion).
The transcripts were analysed using agarose gel electrophor-
esis and then introduced into BHK cells by electroporation
as described previously [22, 23]. At 2 days post-electropora-
tion, the rescued viruses were harvested and amplified in
one, or two, subsequent passages (Psg 2 and Psg 3) in BHK
cells. After these passages, viral RNA was extracted
(QIAamp RNA Blood Mini kit; Qiagen) and reverse tran-
scribed using Ready-To-Go You-Prime First-Strand Beads
(GE Healthcare Life Sciences), and the FMDV cDNA
corresponding to the VP2-2A coding region was amplified
in a PCR (Expand High-Fidelity PCR System; Roche). Con-
trol reactions, lacking reverse transcriptase, were used to
show that the PCR products obtained were derived from the
viral RNA and not from residual DNA template. The ampli-
cons (~2000 bp) including the entire VP2-2A coding region
were visualized in agarose gels, purified (GeneJET Gel
Extraction kit, Thermo Scientific) and sequenced, on both
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strands, as above. Sequences were analysed using Vector
NTI software (Invitrogen).
For the library of VP1 K210 mutants, mutant viruses were
rescued essentially as described above. The sequencing cov-
ered the VP1-2A coding region (from a PCR product of ca
700 bp) both before and after virus rescue. The sequence of
the 2C coding region was also determined in selected cases.
The rescued viruses were titrated (and were in most cases ca
106 to 107 TCID50 ml
 1), and in some cases, a fourth pas-
sage in BHK cells was required to reach this titre.
The rescued serotype O viruses O1K/O1M VP1 E83K and
O1K/O1M VP1 K210E viruses have been described previ-
ously [6, 13].
RT-PCR and NGS
For the purpose of NGS, extracted RNA (isolated as
described above from virus harvests) was converted to
cDNA using SuperScript III (Invitrogen) with a T27 reverse
primer according to the manufacturer’s protocol. Two
cDNA amplicons were prepared by PCR using Phusion
DNA polymerase (Thermo Fisher) with the primers 13-N
PN 2+10-P PN 30 (Table S1) and separately 8-A PN 200
+13-N PN 3 (Table S1). These overlapping fragments (ca. 4
and 4.2 kb, respectively) correspond to most of the FMDV
genome [downstream of the poly(C) tract, see Belsham [1]],
including the complete polyprotein coding region (ca. 7 kb)
but excluding the S-fragment at the 5¢-terminus of the viral
genome. The fragments were gel purified, mixed and then
analysed by NGS essentially as described previously [24,
25]. The parental sequences of the FMDV chimeric O1K/
O1M cDNA (as described by Gullberg et al. [6]) were
assembled from the O1K sequence (accession no. X00871)
and the coding sequence for the O1M capsid proteins (from
accession no. AY593823) with known differences (see [6]),
while the chimeric O1K/A22 sequence was generated using
the O1K sequence and the A22 Iraq sequence ([17],
accession no. AY593764.1). The derived sequences were
used as the reference for mapping of sequence reads using
SAMtools [26], VarScan 2 [27] and VCFtools [28], in suc-
cession, in order to generate consensus sequences from the
mapped reads. Subsequently, consensus sequences were
aligned using MAFFT in Geneious (Biomatters). Finally, a
combination of SAMtools [26], Lo-Freq [29] and SnpEff
[30] was used for downstream single nucleotide variant
(SNV) analysis.
Virus infection of BHK cells
Virus titres were determined, as tissue culture infectious
doses (TCID50), by titration in BHK cells according to
standard procedures [31].
Monolayers of BHK cells, grown in 35 mm wells, were
inoculated with the rescued viruses at a m.o.i. of 0.1 TCID50
/cell. At the indicated times post-infection (p.i.), cell lysates
were prepared using 20 mM Tris/HCl (pH 8.0), 125 mM
NaCl and 0.5% NP-40, and clarified by centrifugation at
18 000 g for 10 min at 4

C.
Immunoblot analysis
Immunoblotting was performed, using cell lysates, accord-
ing to standard methods as described previously [21].
Briefly, aliquots of cell lysate were mixed with Laemmli
sample buffer (with 25 mM DTT), and the proteins were
separated by SDS-PAGE (12.5 or 4–15% polyacrylamide)
and transferred to PVDF membranes (Millipore). Specific
proteins were detected with primary antibodies recognizing
FMDV VP2 (monoclonal antibody 4B2, a gift from L. Yu,
as described by Yu et al. [32]) and FMDV 2A (ABS31; Milli-
pore). Bound proteins were visualized using appropriate
HRP-conjugated secondary antibodies (Dako) and a chemi-
luminescence detection kit (ECL Prime, Amersham) with a
Chemi-Doc XRS system (Bio-Rad).
IF assays
Monolayers of BHK cells, grown on glass coverslips in 35
mm well plates, were infected with the rescued O1K/A22
viruses (m.o.i. of 0.1). At 6–8 h p.i., the cells were fixed,
stained and mounted as previously described [6] using rab-
bit anti-FMDV A-Iraq serum and anti-FMDV 2A (ABS31,
as above) followed by a donkey Alexa Fluor 568-labelled
anti-rabbit IgG (A10042, Life Technologies). The slides
were mounted with Vectashield (Vector Laboratories) con-
taining DAPI, and images were captured using an epifluor-
escence microscope.
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Supplementary Table S1. Primers used for plasmid construction and cDNA synthesis  
 
Primer name Sequence (5´-3´) 
FMDVA_NheIVP4VP2_Fw CGCTCTGCTAGCCGATAAGAAGACCGAGGAGACCA 
FMDVA_ApaI2A2B_Re CTACTAGGGCCCGGGGTTGGACTCAACGTCTCCTG 
FMDVA_2AL2P_Fw CAACTTCCAAACTTCGATTTGCTCAAGTTGGCAGGAGAC 
FMDVA_2AL2P_Re GAAGTTTGGAAGTTGTTTTGCAGGTGCAATGATCTTCTG 
FMDVA_VP1K210E_2AL2P_Re GAAGTTTGGAAGTTGTTCTGCAGGTGCAATGATCTTCTG 
13-N PN2 AAGTTTTACCGTCGTTCCCGACGTAAAAGGGAGGTAACCAC
AAGCTTGAA 
  
10-P PN 30 TCTGGACAGCACCTTTGTCG 
8-A PN 200 
 
GAGACGTTGAGTCCAACCC 
13-N PN 3 CCGTAGGAGTGAAAATCCCGAAAGGGTTTTTCCCGCTTCCTT
AATCCAAA 
O1PN20 
 
GACATGTCCTCCTGCATCTG 
13LPN21 GCACCTGCANNNCAACTTTTGAAC 
a Underlined sequences represent restriction enzyme sites NheI and ApaI. Nucleotide changes 
producing amino acids substitutions are shown in boldface italics.     
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A B S T R A C T
The foot-and-mouth disease virus capsid precursor, P1–2A, is cleaved by the 3C protease (3Cpro) to VP0, VP3,
VP1 and 2A. The P1–2A precursor (wt or mutant) was expressed alone or with 3Cpro and processing of P1–2A
was determined. The VP2 K217R and VP3 I2P substitutions (near the VP0/VP3 junction) strongly reduced the
processing at this junction by 3Cpro while the substitution VP2 K217E blocked cleavage. At the VP3/VP1
junction, the substitutions VP3 Q2221P and VP1 T1P each severely inhibited processing at this site. Blocking
cleavage at either junction did not prevent processing elsewhere in P1–2A. These modiﬁcations were also in-
troduced into full-length FMDV RNA; only wt and the VP2 K217R mutant were viable. Uncleaved VP0-VP3 and
the processed products were observed within cells infected with the mutant virus. The VP0-VP3 was not in-
corporated into empty capsids or virus particles. The three junctions within P1–2A are processed by 3Cpro in-
dependently.
1. Introduction
Foot-and-mouth disease (FMD) is a highly contagious disease of
cloven-hoofed animals including cattle, pigs and sheep. The disease can
cause enormous economic losses during an outbreak because of severe
restrictions on international trade. FMD has been successfully eradi-
cated from Europe but it is still endemic in large areas of Africa and Asia
(Alexandersen et al., 2003). FMD sometimes causes epidemics in pre-
viously disease-free areas, as for instance the outbreak in the UK in
2001, which resulted in the loss of several million animals with total
costs estimated at about £ 8 billion (Alexandersen et al., 2003).
FMD is caused by infection with foot-and-mouth disease virus
(FMDV), which is a small, non-enveloped, RNA virus belonging to the
genus Aphthovirus within the large family of picornaviruses. Each FMDV
particle contains a single-stranded positive-sense RNA genome of
around 8400 nucleotides (nt) surrounded by a protein shell (capsid),
which is roughly spherical and about 25–30 nm in diameter. The capsid
is composed of 60 copies of 4 diﬀerent structural proteins, termed VP1,
VP2, VP3 and VP4. There are seven diﬀerent serotypes of FMDV,
namely O, A, C, SAT1, SAT2, SAT3 and Asia-1. There is no cross-pro-
tection between these serotypes and there is signiﬁcant nucleotide se-
quence diversity between them, especially in the capsid protein coding
regions.
The FMDV genome contains a single, long open reading frame
(ORF) of around 7000 nt. Translation initiation on the viral RNA to
produce the encoded polyprotein is achieved by the internal ribosomal
entry site (IRES), located within the 5′-untranslated region (UTR). The
polyprotein is processed largely by virus-encoded proteases. Processing
into the primary products, namely the Leader protease (Lpro), P1–2A, P2
and P3 occurs rapidly, during and after, synthesis. The Lpro is re-
sponsible for the cleavage at its own C-terminus, i.e. at the L/P1–2A
junction, while the 2A peptide (only 18 amino acids long) is required
for the “cleavage” at the 2A junction; this is a protease independent
break in the polypeptide chain and is termed “ribosomal skipping”
(Donnelly et al., 2001) or “StopGo” (Atkins et al., 2007). After this
initial processing, all other cleavages are catalyzed by the 3C protease
(3Cpro), except for the maturation of VP0 into VP2 and VP4. The P1–2A
precursor is subsequently processed to VP0, VP3 and VP1 and the 2A
peptide. The capsid proteins VP0, VP3 and VP1 remain associated with
each other (in a protomer) and assemble into pentamers. Twelve of
these pentamers can then assemble around a single RNA molecule to
form a virus particle, but they are also able to assemble into empty
capsid particles without any RNA (Abrams et al., 1995; Gullberg et al.,
2013a). During the assembly of the pentamers into a virus particle, the
VP0 is cleaved to generate VP2 and VP4 by a process that is currently
not understood. The VP4 is entirely internal within the virus particle,
whereas VP1, VP2 and VP3 are exposed on the capsid surface, con-
tributing to the antigenic properties of the virus. Moreover, these
https://doi.org/10.1016/j.virol.2018.07.010
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proteins are responsible for interacting with cell surface receptors to
promote virus entry into cells (Jackson et al., 2000). In FMDV empty
capsid particles, cleavage of VP0 into VP2 and VP4 can also occur,
however unprocessed VP0 is also present in the empty particles
(Gullberg et al., 2013a; Curry et al., 1997).
Attempts to express the 3Cpro at the same level as the P1–2A pre-
cursor have been problematic. The 3Cpro is not only able to cleave
diﬀerent junctions in the FMDV polyprotein, but can also cleave a
variety of cellular proteins that are important for normal cellular
functions, e.g. the translation initiation factors eIF4A and eIF4G
(Belsham et al., 2000), components of the cytoskeleton (Armer et al.,
2008) and histone H3 (Falk et al., 1990). Due to this, 3Cpro is probably
toxic to mammalian cells and high levels of the 3Cpro are known to
inhibit protein expression (Polacek et al., 2013). During an FMDV in-
fection, the P1–2A precursor and the 3Cpro will be expressed at about
the same level. However, in the FMDV polyprotein, the 3Cpro has to
cleave some ten diﬀerent junctions while, in contrast, only three
junctions (VP0/VP3, VP3/VP1 and VP1/2A are present in the P1–2A
precursor. An earlier study, has shown that reducing the expression
level of 3Cpro compared to that of P1–2A greatly increased the yield of
the structural FMDV proteins (Polacek et al., 2013).
The 3Cpro from diﬀerent picornaviruses cleave the protein junctions
with diﬀerent speciﬁcities, i.e. with diﬀerent amino acids upstream and
downstream of the cleavage site. The amino acid residues ﬂanking the
cleavage sites are designated as P4 P3 P2 P1 / P1′ P2′ P3′ P4′ respec-
tively. In many picornaviruses (e.g. the enteroviruses, like poliovirus),
the 3Cpro cleavage sites always contain a glutamine residue (Q) at the
P1 position, however FMDV 3Cpro shows greater diversity in its re-
cognition sequence and is able to process junctions containing either a
glutamate (E) or a glutamine (Q) at the P1 position. The VP0/VP3
junction, in most FMDVs, belongs to the E/x (where x can be a variety
of residues) group of sites (with the exception of most of the SAT ser-
otypes, which have a Q). The amino acid sequence for this junction in
A22 Iraq FMDV is PSKE/GIVP, whereas the consensus sequence for the
VP0/VP3 junction for both serotype O and A FMDVs is PSKE/GIFP.
However, comparison of the diﬀerent FMDV junctions from diﬀerent
serotypes indicates that 3Cpro is able to process the E/x junction without
being very constrained by the nature of the P2 residue, as it can be
lysine (K), arginine (R), threonine (T), histidine (H) or glutamine (Q)
(Curry et al., 2007). The P1′ residue seems to have a strong inﬂuence on
the junction since it is generally a glycine (G) but sometimes serine (S).
At residue P2′, the VP0/VP3 junction in A22 Iraq FMDV has an iso-
leucine (I) residue, interestingly in the E/x group of sites this residue is
most often a proline (P), but can also be a G, leucine (L), valine (V) or I
(as in the A22 Iraq strain) (Curry et al., 2007). However, for the VP0/
VP3 junction it is commonly an isoleucine and only 10 out of 133 se-
quences have a valine (Carrillo et al., 2005). The VP3/VP1 junction
generally belongs to the Q/x group of sites and thus usually has a Q at
the P1 residue (Q/x) (with the exception of some serotype O viruses,
which have an E at the P1 position). The amino acid sequence at the
VP3/VP1 junction for the A22 Iraq FMDV sequence, as used here, is
PRSQ/TTTT, and the consensus sequence for both serotype O and A
FMDVs is xRxQ/TTxx.
We have earlier investigated the characteristics of the cleavage at
the VP1/2A junction (Gullberg et al., 2013b; Gullberg et al., 2014),
which belongs to the Q/x group of sites, and determined important
properties of the amino acid residues at the P2 and P2′ positions at this
junction (Gullberg et al., 2014; Kristensen et al., 2016). Surprisingly it
was demonstrated that cleavage at the VP1/2A junction is not required
for virus viability (Gullberg et al., 2013b; Kristensen et al., 2016). We
have now expanded the analysis of FMDV capsid protein processing to
investigate the junctions between VP0/VP3 and VP3/VP1 that belong
to the E/x and Q/x groups respectively. These junction cleavages were
investigated by expressing the P1–2A precursor alone or together with
the 3Cpro in a transient expression assay and also using full-length
FMDV RNA transcripts.
2. Results
2.1. Optimisation of the transient expression assay
The FMDV A22 Iraq P1–2A capsid precursor has been expressed,
within BHK cells, both alone and in the presence of the FMDV 3Cpro
using a transient expression system. The plasmid expressing the P1–2A
product is a derivative of the full-length plasmids used for virus rescue
and thus contains the IRES and the coding regions for the Leader pro-
tease (Lpro) as well as the P1–2A capsid precursor but has had the
coding regions for the non-structural proteins (including 3Cpro) re-
moved, see Fig. 1. The Lpro can have an adverse eﬀect on the level of
product generated from the expression system (Polacek et al., 2013;
Guan and Belsham, 2017). Therefore, a mutation which results in an
amino acid substitution (W52A) within Lpro (Guan and Belsham, 2017)
was introduced into the cDNA. The modiﬁed Lpro retains the L/P1
cleavage activity but does not eﬃciently induce cleavage of the trans-
lation initiation factor eIF4G; this factor is required for the initiation of
cap-dependent protein synthesis. The presence of this modiﬁcation
greatly enhanced the expression of the P1–2A capsid precursor from
such plasmids in the transient expression assay and, as expected, no loss
of the intact eIF4G was detected within transfected cells (c.f. the con-
structs with the wt Lpro, see Supplementary material Fig. S1). Thus, for
all the subsequent analyses in the transient expression system the W52A
derivatives of the plasmids expressing the L-P1–2A region of the
genome were employed. Furthermore, to get the highest levels of pro-
cessed capsid protein expression, the amounts of the plasmids encoding
the P1–2A precursor and the 3Cpro were optimized (see Methods).
Fig. 1. Schematic representation of the FMDV
genome and the plasmids used in the transient
expression assays. The cDNA sequence en-
coding VP2-VP3-VP1–2A is derived from
FMDV A22 Iraq. The viral cDNA backbone is
derived from FMDV O1 Kaufbeuren (O1K),
shown in the upper part of the ﬁgure. The ApaI
sites were used to remove the coding sequence
for the non-structural proteins. The Leader
protease cleaves at its own C-terminus (as in-
dicated by the arrow), and the 3Cpro is re-
sponsible for cleavage of the other junctions
(except for VP4/VP2) within the expressed
protein. In the lower part of the ﬁgure, the
diﬀerent amino acid substitutions encoded by
the diﬀerent plasmids are indicated.
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2.2. Processing of the P1–2A precursor at the VP0/VP3 junction
To investigate the eﬀect of the P2 residue in the E/x junction (VP2/
VP3) we introduced two diﬀerent mutations individually into the cDNA
that result in the VP2 K217R substitution and the VP2 K217E sub-
stitution, these were designed as fairly conservative (retaining the po-
sitive charge) or fairly drastic (positive to negative charge) changes,
respectively. In addition, the VP3 I2P substitution was introduced to see
whether this would have a similar eﬀect on the E/x junction, as ob-
served previously at the Q/x site (at the VP1/2A junction (Gullberg
et al., 2014)). The diﬀerent substitutions that were analysed are shown
in Fig. 1.
Expression of the P1–2A coding region for the wt and the three
diﬀerent mutants (VP2 K217R, VP2 K217E and VP3 I2P), in the absence
of 3Cpro, led to the synthesis of products corresponding to the P1–2A
precursor (approximately 85 kDa) (Fig. 2a, b and c, lanes 1, 3, 5 and 7),
as expected. In the presence of 3Cpro, the wt P1–2A was eﬃciently
processed to generate VP0 (ca. 37 kDa) and VP1 (ca. 28 kDa) (note that
the speciﬁc antibodies used do not detect VP3 (Gullberg et al., 2013a)
but presumably this was also made) (Fig. 2a, b and c, lane 2). The
processing of the VP3/VP1 junction in the wt P1–2A seems to happen a
little more slowly than the processing of the VP0/VP3 junction, since
the VP3-VP1 product (ca. 49 kDa) was readily detected but only very
little of the VP0-VP3 product (ca. 58 kDa) was observed (Fig. 2a, lane
2).
When the VP0/VP3 junction was modiﬁed (as in the VP2 K217R,
VP2 K217E and VP3 I2P mutants), products corresponding to the un-
processed VP0-VP3 were readily detected (see Fig. 2a and Fig. 2b, lanes
4, 6 and 8). Some cleavage of the modiﬁed junction still occurred with
the VP2 K217R and VP3 I2P mutants since VP0 was also produced
(Fig. 2a and b, lanes 4 and 8) but this was not the case with the VP2
K217E mutant (Fig. 2a and b, lane 6) suggesting a severe block on
processing at this site as a result of this substitution. The production of
VP1 (following cleavage of the unmodiﬁed VP3/VP1 junction) was
detected from the wt precursor and also from each of the mutant pre-
cursors (Fig. 2c, lanes 2, 4, 6, 8). It is concluded that amino acid sub-
stitutions at the P2 and P2′ positions adversely aﬀect the processing at
the VP0/VP3 junction (an E/x site) but this change does not block
processing at the VP3/VP1 junction.
2.3. Processing of P1–2A capsid precursor at the VP3/VP1 junction
Using similar analyses, the production and processing of the P1–2A
precursor from the wt plasmid or one of the mutants encoding an amino
acid substitution close to the VP3/VP1 junction, were analysed in
transient expression assays by immunoblotting and the results are
shown in Fig. 3.
The VP3/VP1 junction belongs to the Q/x group of sites, like the
VP1/2A junction. To investigate the eﬀect of changes near this junction
we introduced substitutions at the P1 and the P1′ residues, namely VP3
Q221P and VP1 T1P, these were both expected to be highly deleterious
to cleavage. The two diﬀerent substitutions are indicated in Fig. 1.
As expected, expression of the plasmids encoding P1–2A (wt) and
the mutants VP3 Q221P and VP1 T1P in the absence of 3Cpro led to the
synthesis of products corresponding to the P1–2A precursor (Fig. 3a,
lanes 1, 3 and 5). In the presence of 3Cpro, the P1–2A wt was again
eﬃciently processed to generate VP0 and VP1 (Fig. 3a, b and c, lane 2)
as in Fig. 2. Processing of the VP3 Q221P and VP1 T1P P1–2A mutants
also produced VP0 (Fig. 3a, b, lanes 4 and 6). However, in contrast to
the P1–2A (wt) (lane 2), no VP1 was detected (Fig. 3c, lanes 4 and 6)
but a major product corresponding to the uncleaved VP3-VP1 (ca.
49 kDa) was observed (Fig. 3c, lanes 4 and 6). This indicates that pro-
cessing of the VP3/VP1 junction in the P1–2A precursor by 3Cpro was
severely inhibited by these single amino acid substitutions. However,
abrogating cleavage of this junction did not block processing of the
VP0/VP3 junction within the P1–2A.
2.4. Processing of P1–2A capsid precursor at the VP1/2A junction
The VP1/2A junction also belongs to the Q/x group and was not
modiﬁed in any of the mutants described above. However, the pro-
cessing of the VP1/2A junction is known to be the slowest within the
context of the P1–2A precursor (Gullberg et al., 2013a, 2013b; Ryan
et al., 1989), and thus we investigated whether modifying the proces-
sing of one of the other junctions between the structural proteins af-
fected the VP1/2A cleavage site.
Processing of the VP1/2A junction from the P1–2A precursor from
the plasmids encoding the wt P1–2A or mutant P1–2As with single
Fig. 2. Eﬀect of substitutions at the VP0/VP3 junction on capsid precursor
processing. BHK cells (infected with vTF7-3 (Fuerst et al., 1986) were trans-
fected with plasmids that express the P1–2A (wt or mutant having a substitution
at the VP0-VP3 junction) alone (odd numbered lanes) or with the plasmid
pSKRH3C (Belsham et al., 2000) encoding the 3Cpro (even numbered lanes). A
negative control (No DNA) was included (lane 9). Cell lysates were prepared
and analysed by immunoblotting. Molecular mass markers (kDa) are indicated
on the left. The structural proteins corresponding to the diﬀerent bands are
indicated on the right of the ﬁgure and were detected using the following: (a)
guinea pig anti-FMDV O-Man antisera, (b) murine monoclonal anti-VP2 anti-
bodies (4B2) and (c) guinea pig anti-FMDV A-Iraq antisera. Bound antibodies
were visualized using the appropriate HRP-conjugated secondary antibodies
(Dako) and a chemiluminescence detection kit (Pierce ® ECL Western Blotting
Substrate, Thermo Fisher Scientiﬁc). The results are representative of at least 3
separate transfections that yielded similar results.
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amino acid substitutions at either the VP0/VP3 or the VP3/VP1 junc-
tion, was determined in transient expression assays by immunoblotting
using an anti-2A antibody and the results are shown in Fig. 4. A P1–2A
mutant with the VP1 K210E substitution (Gullberg et al., 2013b;
Kristensen et al., 2016), which inhibits cleavage at the VP1/2A junc-
tion, served as positive control (Fig. 4, lanes 8 and 9). Expression of the
plasmids encoding the wt and mutant P1–2A products in the absence of
3Cpro led to the expected synthesis of the P1–2A precursor in each case
(Fig. 4, lanes 1, 3, 5 and 8). When co-expressed with 3Cpro, processing
of the P1–2A occurred. The VP1 K210E mutant (positive control)
yielded a clear product that is detected by the anti-2A antibody at
around 28 kDa that is VP1–2A (Fig. 4, lane 9) as expected. In contrast,
no VP1–2A could be detected from the wt or from the other mutants
indicating that cleavage at the VP1/2A junction had occurred in each
case (Fig. 4, lane 2, 4 and 6). Similarly, no product was detected in the
negative control (No DNA, Fig. 4, lane 7). Taken together, these results
indicate that blocking the cleavage at either the VP0/VP3 junction or
the VP3/VP1 junction had no adverse eﬀect on processing at the VP1/
2A junction.
2.5. Substitutions at the VP0/VP3 or VP3/VP1 junctions in the full-length
virus
The eﬀect of modifying the VP0/VP3 and VP3/VP1 junctions on
virus infectivity was also examined. The modiﬁcations resulting in the
diﬀerent amino acid substitutions were tested in conjunction with
speciﬁc silent (synonymous) mutations (see Methods) within a full-
length FMDV cDNA based on the backbone of a chimeric O1
Kaufbeuren (O1K) virus containing the coding region for the VP2-VP3-
VP1–2A of the A22 Iraq strain of FMDV (as described previously,
(Polacek et al., 2013; Kristensen et al., 2016; Porta et al., 2013)). The
amino acid substitutions are indicated in Fig. 1. Full-length RNA tran-
scripts were produced in vitro from the linearized plasmids and were
introduced into BHK cells by electroporation. After 2 passages in cells,
high titre virus stocks were obtained from the parental chimeric FMDV
(wt) and from the FMDV (VP2 K217R) mutant. Three passages were
performed for the other mutants, but none of them produced CPE and
no virus could be rescued (Table 1). To determine whether the in-
troduced mutations were retained in the FMDV (VP2 K217R) mutant,
RNA was extracted from the virus harvests and following RT-PCRs, the
region encoding the P1–2A precursor was sequenced at passage two,
three and four. It was found that the rescued virus from the FMDV (VP2
K217R) mutant had retained both the encoded amino acid substitution
and the silent mutation (tag). Moreover, no second site mutations were
Fig. 3. Eﬀect of substitutions at the VP3/VP1 junction on capsid precursor
processing. The P1–2A precursor (wt or mutant having a substitution at the
VP3-VP1 junction) was expressed alone or with 3Cpro in transient expression
assays in BHK cells as in Fig. 2. Cell lysates were prepared and analysed by
immunoblotting. The odd numbered lanes shows the P1–2A precursors ex-
pressed alone and the even numbered lanes shows the precursor co-expressed
with the 3Cpro. A negative control (No DNA) is included in lane 9. Molecular
mass markers (kDa) are indicated on the left. The structural proteins corre-
sponding to the diﬀerent bands are indicated on the right of the ﬁgure and were
detected using the following antibodies: (a) guinea pig anti-FMDV O-Man an-
tisera, (b) murine anti-VP2 antibody and (c) guinea pig anti-FMDV A-Iraq an-
tisera. Bound antibodies were visualized using the appropriate HRP-linked
secondary antibodies (Dako) and a chemiluminescence detection kit (Pierce ®
ECL Western Blotting Substrate, Thermo Fisher Scientiﬁc). The results are re-
presentative of 3 separate transfections that yielded similar results.
Fig. 4. Cleavage of the VP1/2A junction is unaﬀected by blocking cleavages
elsewhere in P1–2A. BHK cells were transfected with the P1–2A (wt), P1–2A
(VP2 K217E), P1–2A (VP1 T1P) and a positive control P1–2A (VP1 K210E)
either alone or together with the plasmid encoding the 3Cpro as described for
Fig. 2. Cell lysates were prepared and analysed by immunoblotting using a
rabbit anti-2A antibody (ABS31 Merck Millipore). Bound antibodies were vi-
sualized using HRP–linked anti-rabbit secondary antibodies (Dako) and a che-
miluminescence detection kit (Pierce ® ECL Western Blotting Substrate, Thermo
Fisher Scientiﬁc). Molecular mass markers (kDa) are indicated on the left. The
structural proteins containing 2A corresponding to the diﬀerent bands are in-
dicated on the right. A negative control (No DNA) (lane 7), and positive controls
(where VP1–2A processing is blocked) (lanes 8 and 9) are shown. These ana-
lyses were performed following each of the transfections used to generate the
results in Fig. 2 and Fig. 3 with very similar results.
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observed within the sequence encoding the P1–2A precursor (data not
shown).
2.6. Growth curve of the FMDV (wt) and FMDV (VP2 K217R)
The growth of the FMDV (wt) and the FMDV (VP2 K217R) mutant
was determined by infecting BHK cells, using a MOI of 0.05 TCID50/
cell, and harvesting the cells at diﬀerent time points post infection.
From each time point, samples were titrated to determine the virus
yield (TCID50/ml). The results showed that there was no major diﬀer-
ence between the growth rates of the two viruses (see Supplementary
material Fig. S2).
2.7. Delayed processing of the VP0-VP3 junction within cells infected by the
FMDV (VP2 K217R) mutant
The production of the viral capsid proteins within cells infected with
the rescued viruses, FMDV (wt) and the FMDV (VP2 K217R mutant)
was visualized from cell extracts by immunoblotting using antibodies
directed against the diﬀerent FMDV capsid proteins. BHK cells were
infected with the FMDV (wt) and the FMDV (VP2 K217R), and cell
lysates were prepared at diﬀerent time points (as indicated in Fig. 5).
The FMDV (wt) P1–2A precursor was eﬃciently processed to generate
the structural proteins (VP0, VP2, VP1, see Fig. 5, lanes 3, 5 and 7) and,
also presumably VP3 and VP4 (not detected by these antibodies). From
the FMDV (VP2 K217R) P1–2A, each of the mature structural proteins
was also detected, however the processing intermediate, VP0-VP3
(around 58 kDa) could also be detected at all time points (Fig. 5a and b,
lanes 4, 6 and 8) indicating a signiﬁcant delay in the processing of the
modiﬁed VP0/VP3 junction (as observed in the transient expression
assays, see Fig. 2a and b). This was particularly pronounced at the early
stages of infection, when the level of the 3Cpro is relatively low.
2.8. The VP0-VP3 intermediate is not incorporated into either mature
FMDV particles or empty capsids
To determine whether the uncleaved VP0-VP3 intermediate was
incorporated into either empty capsids or virus particles, clariﬁed ly-
sates from cells infected with either FMDV (wt) or the FMDV (VP2
K217R) mutant were analysed by sucrose gradient ultra-centrifugation.
The fractions were analysed by ELISA to determine the fractions con-
taining either protomers/pentamers (fraction 2), empty capsids (frac-
tion 9) or complete virus particles (fraction 20), see Fig. 6a. These three
fractions were analysed by immunoblotting. Fraction 2 comprised un-
assembled material (Fig. 6b lanes 1 and 2) and included VP0 and also,
for the mutant, VP0-VP3. Fraction 9 contained empty capsids and both
VP0 and VP2 were present (Fig. 6b, lanes 3 and 4). Fraction 20 included
intact virus particles; almost no VP0 was detected, but a high level of
VP2 was observed (Fig. 6b, lanes 5 and 6). The VP0-VP3 intermediate
could only be detected in fraction 2 for the FMDV (VP2 K217R) mutant,
indicating that this intermediate was not incorporated into either the
assembled empty capsids or the complete virus particles. Interestingly,
the intact P1–2A precursor could also be detected in fraction 2 for the
FMDV (VP2 K217R) mutant, see Fig. 6b lane 2. The three diﬀerent
fractions were also analysed with the anti-FMDV O-Man antibody; this
conﬁrmed the presence of the unprocessed VP0-VP3 intermediate only
being present in FMDV (VP2 K217R) fraction 2 (data not shown).
3. Discussion
The FMDV P1–2A precursor is processed by 3Cpro into VP0, VP3,
VP1 and 2A The cleavage occurs either at Q/x or E/x junctions, and for
both of these types of junction the nature of the residues ﬂanking the
junctions is of high importance for optimal cleavage. In the present
study we have examined the consequences of either blocking or
Table 1
Rescued viruses.
Name VP0/VP3
junction
VP3/VP1
junction
Rescued virus
pO1K/A22 wild-type (wt) ELPSKE/GIVPVA IDPRSQ/TTTTGE +
pO1K/A22 (VP2 K217R) ELPSRE/GIVPVA +
pO1K/A22 (VP2 K217E) ELPSEE/GIVPVA –
pO1K/A22 (VP3 I2P) ELPSKE/GPVPVA –
pO1K/A22 (VP3 Q221P) IDPRSP/TTTTGE –
pO1K/A22 (VP1 T1P) IDPRSQ/PTTTGE –
Fig. 5. Production of uncleaved VP0-VP3 within FMDV-infected cells. BHK cells
were infected with FMDV (wt) and FMDV (VP2 K217R). Cell lysates were
prepared at 3 h p.i. (lane 3 and 4), 6 h p.i. (lane 5 and 6) and 22 h p.i. (lane 7
and 8) and analysed by immunoblotting. Molecular mass makers (kDa) are
indicated on the left. Cell extracts containing the wt P1–2A expressed alone and
together with 3Cpro from a transient expression assay were included to act as
markers for the structural proteins. Uninfected cells (negative control) were
also included (lane 9). The structural proteins are indicated on the right of the
ﬁgure. The antibodies used to detect the structural proteins were: (a) guinea pig
anti-FMDV O-Man antisera, (b) murine anti-VP2 antibody and (c) guinea pig
anti-FMDV A-Iraq antisera. Bound antibodies were visualized using appropriate
HRP–linked secondary antibodies (Dako) and a chemiluminescence detection
kit (Pierce ® ECL Western Blotting Substrate, Thermo Fisher Scientiﬁc). Similar
results were obtained in 4 independent virus-infection experiments.
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delaying the processing of individual junctions within the FMDV P1–2A
precursor by the 3Cpro by substituting speciﬁc amino acids ﬂanking the
junctions.
The structure of FMDV 3Cpro closely resembles the conformation of
chymotrypsin (Allaire et al., 1994), and indeed, it belongs to the family
of chymotrypsin-like serine proteases. The active site is responsible for
the substrate binding and is located between two six-stranded β-barrels
(Matthews et al., 1999). Normally, the serine proteases contain a cat-
alytic triad composed of the amino acids Ser-His-Asp at the active site,
but the FMDV 3Cpro has Cys-His-Asp/Glu at the active site (Sweeney
et al., 2007; Gosert et al., 1997).
The active site of the enzyme typically recognizes the diﬀerent side
chains of the amino acids ﬂanking the cleavage site. The side chains
serve as features for binding and directing the peptide/polyprotein
backbone into the correct orientation in the active site. Hydrogen bonds
are formed between the substrate and the protease and these contacts
are further strengthened by non-polar contacts between the peptide
side chains and the protease. The S1 pocket of the FMDV 3Cpro is re-
sponsible for binding to the side chain of the P1 residue of the substrate
(Birtley et al., 2005). The P1-E side chain binds in almost the same
manner as the alternative P1-Q side chain, thus making the FMDV 3Cpro
able to process junctions containing either of these amino acids at this
position. The hydrogen bonds from the P1 residue to the side chains of
His181 and Thr158 in the 3Cpro are important, as an earlier study showed
that substitutions to other amino acids, within synthetic peptide sub-
strates, that contained either uncharged (norleucine), longer (adipic
acid) or shorter (aspartate) side chains, blocked the processing of these
substrates (Zunszain et al., 2010).
3.1. Processing of the P1–2A precursor in the transient expression assay
At the VP0/VP3 junction (see Fig. 1), which has a glutamate (E) at
the P1 position and a lysine (K) at the P2 position, we introduced dif-
ferent substitutions both upstream and downstream of the junction.
Interestingly, the fairly conservative VP2 K217R substitution (each has
a positively charged side chain) at residue 2 strongly aﬀected the pro-
cessing of this VP0/VP3 junction (E/x group). VP0 could be detected,
but the elevated level of the processing intermediate VP0-VP3 indicated
that the processing rate at the VP0/VP3 junction had been reduced. We
previously reported that the VP1 K210R substitution at the VP1/2A
junction (the P2 position in a Q/x group site) did not aﬀect cleavage at
this junction (Kristensen et al., 2016). However, it should be noted that
the P2 position in the Q/x group is, in some FMDVs, an R whereas R is
never present at the P2 position in the E/x sites (Curry et al., 2007).
Substituting the positively charged lysine (K) residue for the nega-
tively charged glutamate (E) at the P2 residue in the VP0/VP3 junction
(VP2 K217E) severely impeded the cleavage. This is consistent with
earlier ﬁndings on the VP1/2A junction where the VP1 K210E sub-
stitution greatly reduced the processing of the VP1/2A junction
(Gullberg et al., 2013b; Kristensen et al., 2016). These results revealed
that the P2 residue is of high importance in the E/x group and that
processing can be reduced to diﬀerent degrees according to how con-
servative the substitution is.
The VP0/VP3 junction was also modiﬁed by changing one amino
acid downstream of the cleavage site, at the P2′ position, in the VP3 I2P
mutant. This substitution adversely aﬀected the processing of the
junction as seen with the VP2 K217R substitution. This is interesting as
the introduction of a proline residue at P2′ may be expected to induce a
more drastic change in structure compared to the arginine substitution
Fig. 6. Analysis of VP0-VP3 within assembled and un-
assembled virus components within FMDV-infected cells.
(a) BHK cells were infected with FMDV wt (solid line) and
FMDV VP2 K217R (dotted line), using an MOI of 1, and
harvested at 18 h p.i. The clariﬁed lysates were loaded on
15–30% sucrose gradients and separated into separate
fractions following centrifugation. FMDV proteins in the
diﬀerent fractions were detected using a serotype speciﬁc
antigen ELISA. The absorbances were plotted for each
fraction. The background (mock infected BHK cells) OD
was subtracted. The locations of protomers/pentamers,
empty capsids and virus particles are indicated. Fraction 1
is the top of the gradient. (b) Proteins from fractions cor-
responding to the protomers/pentamers (fraction 2), the
empty capsids (fraction 9) and the virus particles (fraction
20) were analysed by immunoblotting as in Figs. 2–4,
using the monoclonal anti-VP2 antibody. Molecular mass
makers (kDa) are indicated on the left and identiﬁcation of
the structural proteins are shown on the right. The results
presented were generated from a single, optimized, ex-
periment with the presence of the VP0-VP3 precursor
being consistent with the analyses presented in Fig. 5.
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at the P2 position. It is clear that 3Cpro was able to process the modiﬁed
junction since VP0 still could be detected (Fig. 2), but a product cor-
responding to VP0-VP3 was also detected at a similar level as with the
K217R, indicating that the 3Cpro cleavage at this site was slowed. An
earlier study has reported that a substitution from leucine to alanine at
the P2′ residue in a synthetic peptide corresponding to a Q/x group site
only caused a minor eﬀect on the processing (Birtley et al., 2005). In-
terestingly, we have shown earlier that substituting the leucine for a
proline at the P2′ residue in the VP1/2A junction in full length FMDV,
completely blocked the processing of this junction (Gullberg et al.,
2014). However proline is actually one of the most abundant amino
acids at the P2′ position in the E/x group of sites within FMDVs,
whereas it is never seen at the P2′ position in the Q/x group (Curry
et al., 2007). This result indicates that even though changing an iso-
leucine to a proline is a fairly drastic change and the cleavage of this
junction is clearly reduced, the 3Cpro has a broad tolerance for diﬀerent
amino acids at this position and a variety of residues are found in other
FMDV junctions at this speciﬁc position in the E/x sites.
The VP3/VP1 junction has a glutamine (Q) at the P1 position. As
mentioned above, 3Cpro is able to cleave junctions containing either a
glutamate or a glutamine residue at the P1 position as the side chains of
these amino acids are able to interact with the S1 pocket of the 3Cpro. It
was therefore not surprising that cleavage by 3Cpro was completely
prevented when the P1 residue was changed to a proline (VP3 Q221P).
At the P1′ position, large hydrophobic side chains are required for
optimal cleavage of the Q/x-group. The P1′ residue is very often either
leucine, isoleucine or threonine (Curry et al., 2007). Leucine and iso-
leucine are very similar, but threonine seems to stand out from the
group since it has an -OH side chain. An earlier study showed that
substituting a leucine to a glycine at the P1′ position in a synthetic
peptide representing the VP1/2A sequence caused a ten-fold reduction
in cleavage rate. In contrast, substitutions to valine or cysteine, which
both have non-polar side chains only reduced the cleavage rate by two-
fold (Zunszain et al., 2010). In the VP3/VP1 junction a threonine is
present at the P1′ position in all FMDVs (Carrillo et al., 2005). Threo-
nine, does not have a large hydrophobic side chain, as leucine and
isoleucine do, indicating that other properties of these amino acids must
also aﬀect the processing. Substituting the P1′ residue in the Q/x group
(VP1 T1P) at the VP3/VP1 junction severely inhibited the processing of
this junction. Introducing a proline is known to be very disruptive in the
polypeptide chain and therefore was expected to have a negative eﬀect.
However, it is interesting that although for the Q/x group substitution
to a proline at either P1′ in the VP3/VP1 junction (as shown here) or
substitution to a proline at P2′ in the VP1/2A junction (Gullberg et al.,
2014) almost completely blocked cleavage, in contrast changing the P2′
residue to a proline in the VP0/VP3 junction (E/x group) only caused a
moderate reduction in processing by 3Cpro.
For all of the mutants having a substitution near the VP0/VP3
junction, the production of VP1 from the modiﬁed P1–2A could be
detected in the presence of 3Cpro, and for all of the mutants having a
substitution in the VP3/VP1 junction, VP0 could be detected following
processing. Furthermore, the VP1/2A junction was also fully processed
in all of these mutants. These results indicate that 3Cpro is able to
process these 3 junctions independently and that processing of these
junctions does not need to occur in a ﬁxed order. However, it is note-
worthy that in the wt protein, processing of the VP3/VP1 junction
seems to occur more slowly than processing of the VP0/VP3 junction.
This contrasts with earlier studies that indicated that initial processing
of the P1–2A precursor happens at the VP3/VP1 junction, followed by
processing of the VP0/VP3 junction with the ﬁnal processing at the
VP1/2 A junction (Bablanian and Grubman, 1993). For this earlier
study, the rabbit reticulocyte lysate in vitro translation system was used
to produce the P1–2A precursor. The use of this cell-free analysis versus
the cell-based analysis used here might explain the diﬀerences ob-
served. Blocking processing at either the VP0/VP3 or the VP3/VP1
junctions did not aﬀect the processing of the VP1/2A junction, as
shown in Fig. 4 (and indeed, we have shown earlier that blocking
cleavage of the VP1/2A junction does not impede any of the other
cleavages as viable virus can still be obtained with the 2A L2P mutant
(Gullberg et al., 2014)).
3.2. Processing of the P1–2A precursor in infectious virus
Using the transient expression assay, we showed that the VP2
K217R and the VP3 I2P substitutions markedly reduced cleavage of the
junction by the 3Cpro, whereas the other substitutions tested essentially
blocked the cleavage. Interestingly, the full-length FMDV RNA en-
coding the VP2 K217R substitution was the only one of the mutants that
was able to form infectious virus particles and replicate. It is surprising
that the mutant containing the VP3 I2P substitution did not replicate,
since cleavage seemed to be reduced to about the same level as for the
VP2 K217R substitution in the transient expression assay. Comparing
the proteins expressed by the wt virus with the mutant virus containing
the VP2 K217R substitution within infected cells clearly showed re-
duced processing of the VP0/VP3 junction, however this modiﬁcation
does not seem to aﬀect the level of the mature structural proteins to a
high degree, as similar amounts of the fully processed proteins were
detected in cells infected with the wt and mutant virus containing the
VP2 K217R substitution (Fig. 5). These results are consistent with our
earlier ﬁndings for the Q/x group sites, showing that processing of the
VP1/2A junction was not completely blocked by the substitution VP1
K210R (Kristensen et al., 2016).
Separation of protomers/pentamers, empty capsids and virus par-
ticles was achieved using sucrose gradient centrifugation (Fig. 6a). By
immunoblotting, it was apparent that the VP0-VP3 intermediate was
only present in unassembled material (Fig. 6b). This contrasts with the
fact that FMDV is able to incorporate uncleaved VP1–2A into the virus
particle (Gullberg et al., 2013b). However, based on the structure of the
pentamer from an assembled A22 Iraq virus particle it is clear that the
C-terminus of VP2 and the N-terminus of VP3 are located very far apart
(Fig. 7) (Curry et al., 1996), (although adjacent in the uncleaved
P1–2A) and this presumably explains why the assembled virus particles
are not able to incorporate the VP0-VP3 intermediate. There was little
diﬀerence in the growth rate of the FMDV (wt) and the FMDV (VP2
K217R) viruses (Fig. S2). High amounts of empty capsids are produced
in both the wt and the mutant, thus suggesting that the structural
proteins are produced in excess. Moreover, it seems that the majority of
the VP0-VP3 intermediate gets cleaved, especially later in infection
(Fig. 5). Both of these features may explain why a small amount of non-
functional VP0-VP3 intermediate can be tolerated and not cause a se-
lective disadvantage to the mutant FMDV.
Overall, the results presented here provide important information
about the two diﬀerent groups of junctions within the capsid precursor
that are cleaved by the FMDV 3Cpro. The results show that there is no
strict order of cleavage of the structural proteins, as blocking of one
junction did not prevent cleavage of the other junctions.
The 3Cpro is responsible for cleaving 10 out of the 13 cleavage sites
in the polyprotein, thus making the enzyme an attractive drug target to
interfere with the lifecycle of the virus (Curry et al., 2007). Moreover,
3Cpro is functionally conserved among diﬀerent serotypes of FMDV,
which provides a possibility of targeting multiple serotypes instead of
just one serotype, as is the case with current vaccines.
4. Methods
4.1. Plasmid construction
The plasmid pO1K/A22 contains a full-length cDNA corresponding
to a chimeric FMDV genome as previously described (Polacek et al.,
2013; Kristensen et al., 2016). It includes the capsid coding sequence
from FMDV A22 Iraq and the rest of the genome from FMDV O1K.
Variants of this plasmid encoding amino acid substitutions at either the
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VP0/VP3 or VP3/VP1 cleavage sites were produced using site-directed
mutagenesis (Chen et al., 2000). Phusion® High-Fidelity DNA Poly-
merase (Thermo Fisher Scientiﬁc) was used in all of the PCR ampliﬁ-
cations according to the manufacturer's instructions unless otherwise
noted. Brieﬂy, fragments were ampliﬁed in PCRs, using the pO1K/A22
plasmid as template, together with primers specifying the desired mu-
tations, see Table 2. The PCR products (580 bp for the VP0/VP3 junc-
tion and 160 bp for the VP3/VP1 junction) were gel puriﬁed using the
GeneJET Gel puriﬁcation kit (Thermo Fisher Scientiﬁc) and used as
megaprimers for a second round of PCR, again using the wt pO1K/A22
as template to make full length plasmids of approximately 11,000 bp.
After the PCR and subsequent DpnI digestion of the template DNA, the
products were puriﬁed using the GeneJET PCR puriﬁcation kit (Thermo
Fisher Scientiﬁc) and transformed into chemically competent Escher-
ichia coli (E. coli) cells. Plasmids were ampliﬁed from individual
colonies, puriﬁed using the GeneJet Plasmid Miniprep Kit (Thermo
Fisher Scientiﬁc) and sequenced by Sanger Sequencing using the
BigDye Terminator v.3.1 Cycle Sequencing kit and a 3500 Genetic
Analyzer (Applied Biosystems).
To prepare constructs (lacking the 3Cpro coding region) suitable for
the transient expression assays, plasmids were digested with ApaI to
remove most of the cDNA encoding the non-structural proteins down-
stream of the 2 A peptide (Fig. 1). The digested plasmids were analysed
using agarose gel electrophoresis and the largest fragments puriﬁed
using the GeneJET Gel Extraction Kit (Thermo Fisher Scientiﬁc). The
fragments were self-ligated using Ready To Go T4 DNA ligase (Amer-
sham Biosciences) and transformed into E. coli. From the resulting co-
lonies, plasmids were puriﬁed using a Plasmid Midi Kit (Qiagen) and
sequenced to conﬁrm the absence of the FMDV sequence downstream
of the 2 A. These constructs contained the cDNA region encoding the wt
Fig. 7. Separation of the C-terminus of VP2 and the N-
terminus of VP3 during capsid assembly. The structure of
the FMDV A22 Iraq capsid pentamer (PDB 4GH4) (Curry
et al., 1996) was visualized using pdb-viewer. An en-
largement of the 5-fold axis of the pentamer is shown in
the red box where the N-termini of the VP3s are marked
with red symbols. The C-termini of the VP2s are marked
with blue circles. The cleavage site in the uncleaved P1–2A
precursor is also indicated.
Table 2
Primers used for site-directed mutagenesis.
Primers for megaprimers Changes Name
Plasmids for the Transient expression assay, introducing Leader (W52A) substitution
SG31_Fw: CCACGACAACTGCGCGTTGAACGCC Leader (W52A) TGG->GCG P1–2A (wt)
14TPN6_Rev: CAAACAGGTGCTTCTTGAAAAATCTTTC
Plasmids for the Transient expression assay, introducing substitutions in the VP2/VP3 and VP3/VP1 junctions, note that all constructs contains the Leader (W52A)
substitution
14TPN5_Fw: GAGTGTGGGAGTCACGTACG VP2 K217R (AAA-> CGT) P1–2A (VP2 K217R)
1PTK18_Rev: GACCGGAACAATCCCCTCACGCGAGGGGAG VP3 V3V (GTA->GTT)
13LPN48_Fw: CCCCTCGGAGGAGGGGATTGTACCG VP2 K217E (AAA-> GAG) P1–2A (VP2 K217E)
13LPN50_Rev: GCACGCCTCAGCCACATCCAAC
13LPN49_Fw: CCCCTCGAAGGAGGGGCCTGTACCG VP3 I2P (ATT-> CCT) P1–2A (VP3 I2P)
13LPN50_Rev: GCACGCCTCAGCCACATCCAAC
13LPN22_Fw: GCTCACCCACCACTACCACCGGG VP3 Q221P (CAA-> CCC) P1–2A (VP3 Q221P)
13LPN30_Rev: GAGGTCAATGACATGTGTGG
13LPN23_Fw: GCTCACAACCCACTACCACCGGG VP1 T1P (ACC-> CCC) P1–2A (VP1 T1P)
13LPN30_Rev: GAGGTCAATGACATGTGTGG
Plasmids for production of full-length FMDV RNAs
14TPN5_Fw: GAGTGTGGGAGTCACGTACG VP2 K217R (AAA-> CGT) pO1K/A22 (VP2 K217R)
1PTK18_Rev: GACCGGAACAATCCCCTCACGCGAGGGGAG VP3 V3V (GTA->GTT)
14TPN5_Fw: GAGTGTGGGAGTCACGTACG VP2 K217E (AAA->GAG) pO1K/A22 (VP2 K217E)
1PTK22_Rev: AGCGACCGGTACGATCCCCTCCTCCGAGGG VP3 I2I (ATT-> ATC)
14TPN5_Fw: GAGTGTGGGAGTCACGTACG VP3 I2P (ATT-> CCT) pO1K/A22 (VP3 I2P)
1PTK20_Rev: GTACAGGCCCCTCCTTCGAGGGGAGCTCAC VP2 K217K (AAA->AAG)
14TPN7_Fw: GACAAATCAAGGTTTATGCCAACATTGC VP3 Q221P (CAA->CCC) pO1K/A22 (VP3 Q221P)
1PTK24_Rev: CGGTGGTAGTAGTGGGTGAGCGGGGGTCAA VP1 T1T (ACC->ACT)
14TPN7_Fw: GACAAATCAAGGTTTATGCCAACATTGC VP1 T1P (ACC-> CCC) pO1K/A22 (VP1 T1P)
1PTK26_Rev: CCGGTGGTAGTGGGCTGTGAGCGGGGGTCA VP3 Q221Q (CAA-> CAG)
Bold =Nucleotide changes generating amino acid changes. Underlined = silent mutations.
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Leader (L) protease, which adversely aﬀects the expression level of the
P1–2A precursor in the transient expression assay (see Supplementary
material Fig. S1). The W52A mutant form of the Lpro retains the L/P1
cleavage activity but is unable to induce cleavage of the translation
initiation factor eIF4G (Guan and Belsham, 2017). This modiﬁcation
was introduced into each of the constructs by site-directed mutagenesis,
as described above, see Table 2 for primers. The PCR products were
DpnI digested, transformed into E. coli, puriﬁed using a Plasmid Midi Kit
(Qiagen) and sequenced to conﬁrm the presence of expected mutations
and the absence of other changes in the P1–2A region. All of these
constructs contained the Leader (W52A) substitution and lacked the
coding region for the non-structural proteins. These constructs were
called: P1–2A (wt), P1–2A (VP2 K217R), P1–2A (VP2 K217E), P1–2A
(VP3 I2P), P1–2A (VP3 Q221P) and P1–2A (VP1 T1P).
The ﬁve mutant plasmids (derived from pO1K/A22) containing the
chimeric full-length FMDV coding sequence with diﬀerent substitutions
(VP2 K217R, VP2 K217E, VP3 I2P, VP3 Q221P or VP1 T1P) were fur-
ther modiﬁed to introduce diﬀerent silent mutations near the modiﬁed
junctions enabling tracking of each mutant in case of potential sequence
reversions. The silent changes introduced and primers used to make
them are listed in Table 2. Brieﬂy, forward and reverse primers were
used in PCRs with each of the ﬁve plasmids to create megaprimers
(580 bp for the VP0/VP3 junction and 160 bp for the VP3/VP1 junc-
tion), which were subsequently used in a long PCR with the same
template to introduce the silent mutations. The PCR products were DpnI
digested, transformed into E. coli and the presence of the desired silent
mutation in each plasmid was veriﬁed by sequencing. These constructs
were termed: pO1K/A22 (VP2 K217R), pO1K/A22 (VP2 K217E),
pO1K/A22 (VP3 I2P), pO1K/A22 (VP3 Q221P) and pO1K/A22 (VP1
T1P). See Fig. 1 for an overview of the diﬀerent substitutions (note that
the silent mutations are not shown in Fig. 1, but can be seen in Table 2).
4.2. Transient expression assays
For the transient expression assays, baby hamster kidney (BHK) cells
were seeded into 35-mm wells approximately 24 h before starting the
assay. The BHK cells (around 90% conﬂuent) were infected with a re-
combinant vaccinia virus, termed vTF7-3 (Fuerst et al., 1986), that
expresses the T7 RNA polymerase. After one hour, this virus was re-
moved and the infected cells were transfected with the indicated
plasmid DNA using FuGENE 6 (Promega) essentially as described pre-
viously (Belsham et al., 2008). For the co-transfections, 1 µg of the
plasmid containing the FMDV P1–2A coding region and 10 ng of the
plasmid (pSKRH3C) (Belsham et al., 2000) encoding the FMDV 3Cpro
were mixed prior to transfection. The cells were incubated in 5% CO2 at
37 °C overnight. The cells were lysed with 500 µL Buﬀer C (20mM Tris-
HCl (pH 8.0), 125mM NaCl and 0.5% NP-40) and the cell extracts were
clariﬁed by centrifugation at 18,000×g for 10min at 4 °C.
4.3. Immunoblot analysis of samples from transient expression assay
Immunoblotting was performed using cell lysates mixed with either
2× Laemmli sample buﬀer (Bio-Rad) or red loading buﬀer Pack (New
England BioLabs) (containing 25mM DTT). The proteins were sepa-
rated by SDS-PAGE (4–20%, 12% or a 7.5% Bis-Tris gels (Bio-Rad)) and
transferred to either PVDF membranes (Milipore) or nitrocellulose
membranes (Bio-Rad). PBS containing bovine serum albumin (BSA)
(5%), (for the anti-VP2 antibody and the anti-FMDV O-Man antibody)
or skimmed milk powder (5%) (for the anti-2A antibody, the anti-eIF4G
antibody and the anti-FMDV A-Iraq antibody) and Tween (0.1%) was
used as blocking buﬀer and dilution buﬀer for the primary and sec-
ondary antibodies. The proteins were detected using guinea pig anti-
FMDV O-Manisa antisera (1:1000), or anti-VP2 antibodies (1:2000)
(mouse monoclonal antibody 4B2 (Yu et al., 2011), kindly provided by
L. Yu, Harbin, P. R. China), guinea pig anti-FMDV A-Iraq antisera
(1:1000), FMDV anti-2A-peptide antibody (1:1000) (Rabbit, ABS31
Merck Millipore) or anti-eIF4G antibody (1:1000) (Goat, SC-9602 Santa
Cruz Biotechnology) as primary antibodies. The bound proteins were
visualized using appropriate HRP-conjugated secondary antibodies
(Dako) and a chemiluminescence detection kit (Pierce ® ECL Western
Blotting Substrate, Thermo Fisher Scientiﬁc). Images were captured
using either a Chem-Doc XRS system (Bio-Rad) or a G:BOX Chemi XX6
(Syngene).
4.4. Rescue of infectious virus from modiﬁed FMDV cDNA
The plasmids, containing the full-length wt or mutant FMDV cDNAs,
i.e. pO1K/A22 (VP2 K217R), pO1K/A22 (VP2 K217E), pO1K/A22 (VP3
I2P), pO1K/A22 (VP3 Q221P) and pO1K/A22 (VP1 T1P) were linear-
ized by digestion with HpaI and puriﬁed using the GeneJET PCR pur-
iﬁcation kit (Thermo Fisher Scientiﬁc). The linearized plasmids were
transcribed in vitro using the MEGAscript® T7 Transcription Kit
(Thermo Fisher Scientiﬁc). An aliquot (1 µL) of each RNA sample was
visualized following agarose gel electrophoresis to check yield and in-
tegrity and the rest (19 µL) was introduced into BHK cells by electro-
poration as described previously (Nayak et al., 2006).
The cells were transferred to Falcon ﬂasks and Eagle's medium
containing 5% calf serum was added. The cells were incubated over-
night at 37 °C. The rescued viruses were ampliﬁed using three passages
in BHK cells. Cytopathic eﬀect (CPE) was only detected with the FMDV
(wt) and the mutant virus containing the VP2 K217R substitution,
termed FMDV (VP2 K217R). After each passage, viral RNA, from the wt
and the mutant virus was isolated using the RNeasy Mini Kit (Qiagen)
and reverse transcribed using Ready-To-Go You-Prime First-Strand
Beads (GE Healthcare Life Sciences) together with random primers. The
cDNA corresponding to the P1–2A region was ampliﬁed as four over-
lapping fragments of around 1000 bp by AmpliTaq Gold DNA
Polymerase (Thermo Fisher Scientiﬁc), visualized on agarose gels and
puriﬁed using the GeneJET PCR puriﬁcation kit (Thermo Fisher
Scientiﬁc) (primers listed in Table S1, see Supplementary material). For
each RNA, a negative control, lacking the reverse transcriptase, was
included in the RT-PCRs to verify that the PCR products were obtained
from viral RNA and not from residual plasmid template. The PCR
products were sequenced (primers are listed in Table S1, see
Supplementary material) using the BigDye Terminator v.3.1 Cycle Se-
quencing kit and a 3500 Genetic Analyzer (Applied Biosystems). Se-
quences were analysed using Geneious 9.0.2 (Biomatters).
4.5. Titration of FMDV (wt) and FMDV (VP2 K217R)
After the three passages in BHK cells, both the rescued FMDV (wt)
and the FMDV (VP2 K217R) stocks were titrated. Brieﬂy, 50 µL BHK
suspension (400,000 cells/ml in Eagles medium with 20% fetal bovine
serum (FBS)) were loaded in each well of a 96-well plate and 50 µL
Eagles medium was added. Lastly, 50 µL of virus dilutions from 10−2 to
10−9 were added to the wells. Each dilution was tested in quintuplicate
together with two negative controls. The plates were incubated at 37 °C
in 5% CO2 and read each day for three days after infection, and the
titres (TCID50 /ml) were calculated.
4.6. Immunoblot analysis of FMDV-infected cells
Monolayers of BHK cells, grown in 35mm wells (approximately
200,000 cells per well), were infected with either the FMDV (wt) or the
FMDV (VP2 K217R) at a MOI of 1 TCID50/cell. Cells were lysed using
Buﬀer C (as described above) at 3, 6 and 22 h post-infection. The
samples were analysed by immunoblotting as described above.
4.7. Growth curve of FMDV (wt) and FMDV (VP2 K217R)
BHK cells were infected with the FMDV (wt) and the FMDV (VP2
K217R) using a MOI =0.05. Samples were harvested at 0, 2, 5, 10, 15,
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24 and 30 h p.i. and then titrated as described above.
4.8. Sucrose gradient analysis
BHK cells (1 well in a 6-well plate) were infected with O1K/A22
FMDV (wt) or O1K/A22 FMDV (VP2 K217R) (MOI of 1 TCID50 per cell).
At 18 h p.i., the medium was removed and the cells were lysed with
250 µL buﬀer C containing protease inhibitor (cOmplete Mini, EDTA-
free protease inhibitor (Roche)). Samples were clariﬁed by centrifuga-
tion for 18,000 g for 10min and 200 µL of the supernatant was loaded
directly onto each 15–30% sucrose gradient. For making the gradients,
sucrose was dissolved in PBS and the 15% sucrose solution was added
to the tube. The 30% sucrose solution was applied afterwards in the
bottom by putting a needle through the 15% sucrose solution. Lastly the
gradients were ﬁnished using a gradient maker (Gradient Master 108
(BIOCOMP)). The samples were centrifuged at 245,000×g in a SW 55
Ti rotor (Beckman Coulter) for 1 h at 10 °C. Fractions of 240 µL were
collected from the top of the gradient by using a Piston Gradient
Fractionator™ (BIOCOMP) and analysed by antigen ELISA (see below)
and immunoblotting (as above).
4.9. ELISA
An antigen detection enzyme-linked immunosorbent assay (ELISA)
against FMDV serotype A, was performed as described previously
(Gullberg et al., 2013b; Roeder et al., 1987). Brieﬂy plates were coated
with FMDV A22 Iraq rabbit antisera overnight, the plate was washed
and blocked with dilution buﬀer (2% BSA diluted in PBS buﬀer with 1%
Tween) and the gradient fractions were added. Detection of the bound
FMDV proteins was achieved using polyclonal guinea pig anti-FMDV
A22 Iraq sera plus rabbit anti-guinea pig Ig conjugated to horseradish
peroxidase (Dako). A dissolved SIGMAFAST™ OPD tablet (Sigma-Al-
drich) was added, and after seeing colour develop, Stop-solution (1mM
H2SO4) was added. The plates were read in a SpectraMax® i3 plate
reader (Molecular Devices).
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Figure S1 
Influence of wt and mutant Leader proteases on the expression level of the P1-2A within transient 
expression assays. Two versions of three different plasmids expressing either the mutant (W52A) 
Leader protease (lanes 1, 3 and 5) or the wt Leader  (lanes 2, 4, and 6) were transfected into cells 
infected with vTF7-3 (29). Cell extracts were prepared after 20h and analysed by immunoblotting 
with an anti-FMDV O-Man antibody (a).  The status of the cellular translation factor eIF4G was 
determined in these extracts using anti-eIF4G antibodies (b).  
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Figure S2 
Growth curve of FMDV (wt) and FMDV (VP2 K217R) mutant in BHK cells. The wt and mutant viruses 
were used to infect BHK cells at a MOI of 0.05 TCID50/cell, and harvested by freezing at the indicated 
time points post infection. The samples from the different time point were titrated and the virus 
yield (as TCID50/ml) was calculated and plotted against time. 
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Table S1: Primers for generating PCR products from cDNA and their sequencing 
Primers for PCR product Primers for sequencing the PCR product 
11FPN40_Fw: ACCTCYRAHGGGTGGTACGC 
14TPN8_Rev: CGTCCGAACAAGCGACCGGTA 
14TPN5_Fw: GAGTGTGGGAGTCACGTACG 
14TPN6_Rev: CAAACAGGTGCTTCTTGAAAATCTTTC 
14TPN5_Fw: GAGTGTGGGAGTCACGTACG 
14TPN10_Rev: CTGCCACATCAGACGCAGTGT 
14TPN7_Fw: GACAAATCAAGGTTTATGCCAACATTGC 
14TPN8_Rev: CGTCCGAACAAGCGACCGGTA 
14TPN7_Fw: GACAAATCAAGGTTTATGCCAACATTGC 
14TPN12_Rev: GGAGCGCGAGCCTCGTAAAT 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
14TPN10_Rev: CTGCCACATCAGACGCAGTGT 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
14TPN14_Rev: GTCGAGACCGGTTCTGATGGC 
14TPN11_F: AACCTAACCTGGGTACCCAATGG 
14TPN12_Rev: GGAGCGCGAGCCTCGTAAAT 
Y = C or T; R = A or G; H = A or C or G. 
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Abstract 
Many picornaviruses cause important diseases in humans and other animals including poliovirus, 
rhinoviruses (causing the common cold) and foot-and-mouth disease virus (FMDV). These small, 
non-enveloped viruses consist of a positive-stranded RNA genome (ca. 7-9 kb) enclosed within a 
protein shell composed of 60 copies of three or four different capsid proteins. For the aphthoviruses 
(e.g. FMDV) and cardioviruses, the capsid precursor, P1-2A, is cleaved by the 3C protease (3Cpro) to 
generate the capsid proteins, VP0, VP3 and VP1 plus 2A. For enteroviruses, e.g. poliovirus, the capsid 
precursor is P1 alone, which is cleaved by the 3CD protease (3CDpro) to generate just VP0, VP3 and 
VP1. The sequences required for correct processing of the FMDV capsid protein precursor in 
mammalian cells were analyzed. Truncation of the P1-2A precursor from its C-terminus showed that 
loss of the 2A peptide (18 residues long) and 27 residues from the C-terminus of VP1 (211 residues 
long) resulted in a precursor that cannot be processed by 3Cpro although it still contained two 
unmodified internal cleavage sites (VP0/VP3 and VP3/VP1 junctions). Furthermore, introduction of 
small deletions within P1-2A identified residues 185-190 within VP1 as being required for 3Cpro-
mediated processing and for optimal accumulation of the precursor. Within this C-terminal region 
of VP1, five of these residues (YCPRP), are very highly conserved in all FMDVs and are also conserved 
amongst other picornaviruses. Mutant FMDV P1-2A precursors with single amino acid substitutions 
within this motif were highly resistant to cleavage at internal junctions. Furthermore, these results 
can explain earlier observations that loss of the C-terminus (including the conserved motif) from the 
poliovirus capsid precursor conferred resistance to processing. Thus, this motif seems essential for 
maintaining the correct structure of picornavirus capsid precursors prior to processing and 
subsequent capsid assembly; it may represent a site that interacts with cellular chaperones. 
Author Summary 
The picornavirus family includes clinically important human and animal pathogens, for example: 
poliovirus, rhinovirus (causing the common cold) and foot-and-mouth disease virus (FMDV) that 
infects cloven-hoofed animals. Picornaviruses contain a positive-sense RNA genome surrounded by 
a protein shell, also called a capsid. The capsid proteins are made from a precursor and correct 
processing and assembly of these capsid proteins is necessary in the virus life cycle to create new 
infectious virus particles. In this study, we have identified a short motif (just 5 amino acids long) 
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within the capsid precursor, which is highly conserved among picornaviruses. Deletion of this motif 
inhibited processing of the junctions between the mature structural proteins within this precursor, 
with one junction being more than 400 amino acids away from this region. This motif also seems to 
be required for the optimal accumulation of the capsid precursor in cells. We hypothesize that the 
motif may be involved in binding to a cellular protein, such as a chaperone, to stabilize the capsid 
precursor and promote its correct folding to allow it to be processed by the viral protease prior to 
capsid assembly.   
Introduction 
Picornaviruses comprise a large family of non-enveloped RNA viruses that includes important 
human and animal pathogens. Examples include poliovirus (PV) (genus: Enterovirus), hepatitis A 
virus (Hepatovirus), encephalomyocarditis virus (Cardiovirus) and foot-and-mouth disease virus 
(FMDV) (Aphthovirus).  
 
In picornavirus particles, the RNA genome (ca. 7,100-8,900 nt) is surrounded by a protein shell 
(capsid) consisting of the four structural proteins VP1, VP2, VP3 and VP4 [1], with the exception of 
parechoviruses and kobuviruses in which the VP0 (the precursor of VP2 and VP4) remains uncleaved 
(reviewed by [2]). The capsid is composed of 60 copies of each of these structural proteins; VP1, VP2 
and VP3 are exposed on the surface of the particle while VP4 is entirely internal [3–5]. 
 
Translation of the positive-sense RNA genome is dependent on the internal ribosomal entry site 
(IRES) within the 5′ untranslated region (UTR) that directs cap-independent translation initiation [6]. 
During and after translation of the single open reading frame, processing of the newly synthesized 
polyprotein occurs (reviewed in [2]). Usually three or four primary products are formed, namely the 
Leader (in many picornaviruses), the capsid precursor P1 or P1-2A (depending on the genus) and 
the precursors of the non-structural proteins, namely P2 and P3. Many of these viruses, e.g. 
members of the Cardiovirus, Hepatovirus and Aphthovirus genera, have a Leader protein at the N-
terminus of the polyprotein, i.e. upstream of the capsid precursor. In the Aphthoviruses, the Leader 
protein is a protease (Lpro), which cleaves itself from the N-terminus of the P1-2A precursor, see Fig. 
1. Cleavage of the junction between the structural and non-structural proteins, at either the VP1/2A 
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or the 2A/2B junction, is usually mediated by the 2A protein, but the function of the 2A protein 
varies between the genera [7], see Fig. 1. In the cardio- and aphthoviruses cleavage at the 2A/2B 
junction (at the C-terminus of 2A) is protease independent and happens during translation by a 
process termed “ribosomal skipping” [8] or “StopGo” [9]. In this case, the 2A protein remains 
attached to the precursor of the structural proteins (as P1-2A) until it is removed by the 3C protease 
(3Cpro). In the enteroviruses, the cleavage at the VP1/2A junction (i.e. at the N-terminus of 2A), to 
release P1, is mediated by the 2A protein that is a chymotrypsin-like protease [10,11]. 
 
The P2-P3 junction and the other protein junctions within these precursors are cleaved by 3Cpro to 
produce the mature non-structural proteins. However, the P1 capsid precursor of enteroviruses 
requires the 3CD protease (3CDpro) for its processing [12,13] whereas for the cardio- and 
aphthoviruses the 3Cpro is sufficient to cleave the P1-2A precursor into three structural proteins 
(VP0, VP3 and VP1) plus 2A [1,14], see Fig. 1. During capsid assembly, VP0 is cleaved (in most 
picornaviruses) to generate VP2 and VP4 by a process that is currently not understood.  
 
There are seven different serotypes of FMDV: O, A, C, SAT 1, SAT 2, SAT 3 and Asia 1. There is a high 
level of sequence variation between the surface exposed structural proteins of these different 
serotypes. The internal VP4 protein is the most conserved of the capsid proteins with 81% of the 
residues being invariant [15]. In contrast, only 26% of the VP1 protein residues are invariant and 
furthermore it ranges in size (209-213 aa) between serotypes [16]. VP1 is the most surface exposed 
capsid protein [3] and has been one of the most studied FMDV proteins due to its antigenic 
importance and role in virus attachment [17].      
 
One of the antigenic sites in VP1 is located on the G-H loop (including residues 141-160), which 
contains an arginine-glycine-aspartate (RGD) motif that is involved in the attachment of the virus to 
cellular integrin receptors [18,19]. Surprisingly, previous work has demonstrated that a cell-culture 
adapted FMDV, lacking part of this G-H loop (aa 142-154), is still able to replicate and grow normally 
in cell culture through the use of heparan sulfate proteoglycans (HSPG) as receptor [20]. 
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Viruses have only a very limited coding capacity within their genomes and thus they rely on cellular 
factors and pathways to complete their life cycle. Several studies have suggested that cellular 
chaperones, including various different heat shock proteins (Hsps), are required to facilitate virus 
entry, genome replication, protein expression and protein assembly for a variety of viruses, 
including picornaviruses. Viral proteins, like cellular proteins, are dependent on such chaperones for 
their correct folding and assembly [21–24]. Studies on the role of Hsp90, using specific inhibitors, 
have shown that these agents reduce the replication of diverse viruses in vitro. The Hsp90 appears 
to be involved in the regulation of viral polymerase function in the case of herpesvirus [25] and 
hepatitis B virus [21], whereas this chaperone seems to be required for capsid processing and 
assembly in different picornaviruses [23,26]. Hsp90 and Hsp70 have been reported to interact with 
the PV capsid precursor, P1 [23,27]. The interaction between PV P1 and Hsp90 (possibly together 
with Hsp70), and likely in conjunction with its co-chaperone p23, is believed to protect the P1 from 
degradation by proteasomes (which remove misfolded proteins) and is also involved in the folding 
of P1 allowing it to be correctly processed by the 3CDpro [23].       
 
Recently, we have shown that impeding the processing of one of the cleavage sites within the FMDV 
P1-2A, at either the VP0-VP3 or the VP3-VP1 junctions, did not block processing of the other 
cleavage sites, indicating that processing of these junctions is mutually independent [28]. However, 
in an earlier study, it was shown that truncation of VP1 (removing the C-terminal 42 amino acids of 
VP1) completely blocked processing of the residual capsid precursor at both the VP0-VP3 and the 
VP3-VP1 junctions by 3Cpro in a cell-free system [29]. Similarly, truncating the PV P1 precursor, by 
removing 50 aa from the C-terminus of VP1 (302 residues in length), blocked cleavage of the 2 
junctions within the P1 precursor in vitro [30]. The basis for these effects has not been explained. 
However, taken together, these results suggest that the C-terminus of VP1 is important in relation 
to the processing of the entire capsid precursor of picornaviruses.     
 
In this study, we have now identified a short region within the C-terminus of VP1 that is critical for 
the processing of the FMDV capsid precursor. This region contains a stretch of five amino acids that 
are very highly conserved amongst all FMDVs. Furthermore, this region is also strongly conserved 
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between most other picornaviruses, including PV, suggesting a shared role for this motif for capsid 
processing and assembly within the picornavirus family. 
 
 
Results  
Truncation of the capsid precursor prevents its processing by 3Cpro in cells 
Previous studies have shown that truncation of the FMDV P1-2A, by removal of the 2A peptide and 
the C-terminal 42 residues of VP1, completely abrogated processing by 3Cpro in vitro [29] even 
though the cleavage sites between VP0 and VP3 and between VP3 and VP1 were unmodified. To 
confirm these observations, within cells, stop codons were introduced at different positions within 
the P1-2A coding sequence. Transient expression assays were used to express the FMDV A22 Iraq 
P1-2A capsid precursor and its derivatives, within BHK cells, both in the absence and presence of 
the FMDV 3Cpro. The plasmids encoding both the P1-2A (wt) and the P1 alone (truncated at the first 
amino acid of the 2A peptide) served as positive controls. Both of these controls yielded the 
expected products corresponding to the P1-2A precursor and the P1 precursor (approximately 85 
kDa), respectively in the absence of 3Cpro (Fig. 2, lanes 1 and 3). When these plasmids were co-
transfected with a plasmid that expresses the 3Cpro, both of these products were efficiently 
processed as indicated by the production of  VP0 (approximately 37 kDa) (Fig. 2, lanes 2 and 4) and 
VP1 (approximately 28 kDa, data not shown), note that the antibodies do not recognize VP3 [31], 
but presumably this was also made. Thus, the absence of the 2A peptide did not affect processing 
of the capsid precursor by 3Cpro (as observed previously [14,26]). 
 
Plasmids encoding mutant precursors, truncated to residue 205 in VP1 and 199 in VP1 (VP1 being 
211 aa in length in FMDV A22 Iraq (wt)), generated products of approximately 85 kDa in the absence 
of 3Cpro (Fig. 2, lanes 5 and 7), and these were efficiently processed in the presence of 3Cpro (Fig. 2, 
lanes 6 and 8). The four additional mutants, P1 (VP1 Y185Stop), P1 (VP1 L158Stop), P1 (VP1 
A107Stop) and P1 (VP1 L53Stop) all yielded products corresponding to their expected size in the 
absence of 3Cpro (Fig. 2, lanes 9, 11, 13 and 15), however it is noteworthy that these truncated 
products accumulated to a lower level in the cell lysates. Strikingly, no processing of these truncated 
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precursors was detected for any of these four mutants in the presence of 3Cpro (Fig. 2, lanes 10, 12, 
14 and 16) although each of these products contained the unmodified VP0/VP3 and VP3/VP1 
junctions. As expected, no products were detected in the negative control (no DNA) (Fig. 2, lane 17). 
 
Mapping of the determinants of 3Cpro mediated processing of the capsid-precursor  
In order to map the determinants of capsid processing more precisely, plasmids were constructed 
to express mutant forms of the P1-2A precursor with fairly small internal deletions within the C-
terminal portion of VP1. To serve as positive controls, both the P1-2A (wt) and a mutant form with 
a deletion within VP1, designated P1-2A (VP1 Δ142-154), were included. The latter deletion is 
tolerated by the infectious virus [20] and thus it was expected that 3Cpro should be able to fully 
process all of the junctions in this deletion mutant. As expected, expression of both the P1-2A (wt) 
and the P1-2A (VP1 Δ142-154) led to the synthesis of products corresponding to the P1-2A precursor 
(approximately 85 kDa) (Fig. 3, lanes 1 and 13). Furthermore, both the P1-2A (wt) and the P1-2A 
(VP1 Δ142-154) products were efficiently processed in the presence of 3Cpro (Fig. 3, lanes 2 and 14). 
Notice that the VP1 product derived from the P1-2A (VP1 Δ142- 154) mutant migrated faster than 
the VP1 produced from the P1-2A (wt) due to the internal deletion.   
 
Five different short deletions were introduced into the region of VP1 spanning residues 185-199 
(the region found to be critical by the truncation analysis), namely P1-2A (VP1 Δ185-199), P1-2A 
(VP1 Δ185-189), P1-2A (VP1 Δ188-192), P1-2A (VP1 Δ191-195) and P1-2A (VP1 Δ194-199). Each of 
these constructs generated products that were very similar in size as the wt P1-2A in the absence 
of 3Cpro (Fig. 3, lanes 3, 5, 7, 9 and 11). However, in the presence of 3Cpro the mutant having the 
largest deletion, P1-2A (VP1 Δ185-199) could not be processed (Fig. 3, lane 4). The same product, 
corresponding to the P1-2A precursor, was observed both in the absence and presence of 3Cpro. 
Similarly, the mutants P1-2A (VP1 Δ185-189) and P1-2A (VP1 Δ188-192) were also not processed in 
the presence of 3Cpro (Fig. 3, lanes 6 and 8). It is again noteworthy that the mutant P1-2A products 
that could not be processed accumulated to a lower level in the cell lysates than the P1-2A 
precursors that could be processed (c.f. lanes 3, 5, 7 and 1, 9, 11, 13). In contrast, co-expression of 
3Cpro with the P1-2A (VP1 Δ191-195) and P1-2A (VP1 Δ194-199) led to production of VP0 indicating 
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that processing of these mutant precursors had occurred (Fig. 3, lanes 10 and 12). However, it is 
noteworthy that no product corresponding to VP1 was detected, when P1-2A (VP1 Δ191-195) was 
co-expressed with 3Cpro (Fig. 4a, lane 4). Furthermore, unexpectedly, when the P1-2A (VP1 Δ194-
199) was co-expressed with 3Cpro a major product corresponding to the intermediate VP3-VP1 
(approximately 49 kDa) was detected (Fig 4a, lane 6). Only a weak signal corresponding to the 
mature VP1 was detected indicating severe inhibition of processing at the VP3/VP1 junction in this 
mutant (Fig 4a, lane 6), n.b. this cleavage site is located over 190 residues away in the linear 
sequence. No products were detected in the negative control lane. (Fig. 4a, lane 9). 
 
Due to inefficient detection of VP1 from some of the mutant precursors, an extra modification that 
blocks processing of the VP1/2A junction (2A L2P) [32] was introduced into the plasmids that express 
P1-2A (VP1 Δ191-195), P1-2A (VP1 Δ194-199) and the positive controls; P1-2A (wt) and P1-2A (VP1 
Δ142-154). The additional modification (2A L2P) ensured that the 2A peptide remained fused to the 
VP1 (as VP1-2A). Each of these constructs generated products corresponding to the P1-2A precursor 
in the absence of 3Cpro (Fig. 4b, lanes 1, 3, 5 and 7). The 2A L2P substitution increased the sensitivity 
of VP1 detection when using the anti-FMDV A-Iraq antibody. This showed that the P1-2A (wt + 2A 
L2P) and the P1-2A (VP1 Δ142-154 + 2A L2P, positive control) precursors were fully processed to 
yield VP0 and VP1-2A in the presence of 3Cpro as expected (Fig. 4b, lanes 2 and 8). It also verified 
that cleavage at the VP3-VP1 junction in the P1-2A (VP1 Δ194-199 +2A L2P) occurred at a slower 
rate compared to wt, since the VP3-VP1-2A intermediate was far more abundant for the P1-2A (VP1 
Δ194-199 + 2A L2P) than for the P1-2A (wt +2A L2P) in the presence of 3Cpro (compare lanes 6 and 
2 in Fig. 4b). It should be noted that some mature VP1-2A could be detected from the P1-2A (VP1 
Δ194-199 + 2A L2P) and thus cleavage of the VP3/VP1 junction was not completely blocked (Fig. 4b, 
lane 6). Furthermore, the P1-2A (VP1 Δ191-195 + 2A L2P) could be processed to generate VP0 and 
VP1-2A (Fig. 4b, lane 4). However, the VP3-VP1 intermediate produced from the P1-2A (VP1 Δ191-
195 +2A L2P) mutant was also more abundant than the intermediate seen with the P1-2A (wt + 2A 
L2P) indicating that this mutant also had a slower processing at the VP3/VP1 junction (Fig. 4b, lane 
4).    
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The cleavage of the unmodified VP1/2A junction in the P1-2A precursors with different internal 
deletions, was investigated using an anti-2A antibody. As expected, both the P1-2A (wt) and the 
positive control P1-2A (VP1 Δ142-154) generated products of approximately 85 kDa corresponding 
to the P1-2A precursor in the absence of 3Cpro (see supplementary material Fig. S1, lanes 1 and 13). 
In the presence of 3Cpro, no products were detected by the anti-2A antibodies from either the P1-
2A (wt) or the positive control P1-2A (VP1 Δ142-154) indicating that the VP1/2A junction had been 
processed (Fig. S1, lanes 2 and 14); note the 2A peptide itself is only 18 residues long and is not 
detected by immunoblotting. The two mutants, P1-2A (VP1 Δ191-195) and P1-2A (VP1 Δ194-199) 
that showed slower processing of the VP3-VP1 junction also generated products corresponding to 
the P1-2A precursor in the absence of 3Cpro (Fig. S1, lanes 9 and 11). However, in the presence of 
3Cpro, no products were detected by the anti-2A antibodies (Fig. S1, lanes 10 and 12), indicating that 
these two deletions in VP1 did not affect processing of the VP1/2A junction. Surprisingly, the non-
processable precursors, i.e. P1-2A (VP1 Δ185-199), P1-2A (VP1 Δ185-189) and P1-2A (VP1 Δ188-
192), could not be detected using the anti-2A antibody, either in the absence or presence of 3Cpro, 
and thus we cannot conclude whether cleavage of this junction was affected by the deletions (Fig. 
S1, lanes 3-8). No products were detected in the negative control (No DNA, Fig. S1, lane 15).  
  
Identification of critical residues in the P1-2A-precursor for 3Cpro processing  
Alanine-scanning mutagenesis was employed to identify individual residues within the C-terminal 
region of VP1 (between residues 185 and 199 of VP1) that are required for 3Cpro processing of the 
P1-2A precursor. The wt and mutant precursors were expressed alone and also in the presence of 
the FMDV 3Cpro as above. As expected, the P1-2A (wt) and all 15 of the single amino acid substitution 
mutants each generated products corresponding to the P1-2A precursor in the absence of 3Cpro (see 
Figs. 5, 6 and 7, odd numbered lanes). The wt and some 13 different mutant P1-2A precursors, 
excluding the mutants P1-2A (VP1 Y185A) and P1-2A (VP1 R188A), were processed by 3Cpro to yield 
VP0 and VP1 (Fig. 5, 6 and 7 even numbered lanes). In contrast, the P1-2A (VP1 Y185A) and P1-2A 
(VP1 R188A) mutants were highly resistant to cleavage by the 3Cpro (Fig. 5, lanes 4 and 10). 
Furthermore, it was again apparent that the accumulation of these mutant P1-2A products in the 
cell lysates was lower than for the wt precursor and for the other mutants that could be processed 
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(Fig. 5, lanes 3 and 9). Thus, the single amino acid substitutions VP1 Y185A and VP1 R188A were 
individually able to severely inhibit processing at both the VP0/VP3 and the VP3/VP1 junctions 
within the P1-2A precursor and had a deleterious effect on the level of the unprocessed product 
generated within cells.  
 
Surprisingly, none of the single alanine substitutions in the VP1 194-199 region had any effect on 
the processing of the junctions within the P1-2A precursor (Fig. 7, lanes 4, 6, 8, 10, 12 and 14). None 
of these produced the severe block on cleavage of the VP3-VP1 junction that was detected with the 
P1-2A (VP1 Δ194-199) mutant (Fig 4, lane 6). However, interestingly the P1-2A (VP1 V193A) was 
processed more slowly at the VP3-VP1 junction compared to the P1-2A (wt) and the other alanine 
mutants (Fig. 6, lane 12).  
 
The cleavage of the VP1/2A junction of the P1-2A precursors with different alanine substitutions, 
was also investigated using the anti-2A antibody. As expected, the P1-2A (wt) generated a product 
of approximately 85 kDa corresponding to the P1-2A precursor in the absence of 3Cpro (see 
supplementary material Fig. S2, lane 1). However, in the presence of 3Cpro, no product (containing 
2A) was observed from the P1-2A (wt) showing that VP1/2A junction had been processed (Fig. S2, 
lane 2). The two mutants, P1-2A (VP1 C186A) and P1-2A (VP1 P187A) that were correctly processed 
at the VP0/VP3 and the VP3/VP1 junction also generated products corresponding to the P1-2A 
precursor in the absence of 3Cpro (Fig. S2, lanes 5 and 7). However, as with the wt protein, in the 
presence of 3Cpro no products including 2A could be detected, indicating that these two 
substitutions individually did not prevent processing at the VP1/2A junction. Neither of these 
mutant precursors, with single amino acid substitutions, which were highly resistant to cleavage at 
the VP0/VP3 and the VP3/VP1 junctions, i.e. P1-2A (VP1 Y185A) and P1-2A (VP1 R188A), could be 
detected by the anti-2A antibody, either in the absence or presence of 3Cpro. Thus, we cannot 
conclude whether this junction was affected by these substitutions (Fig. S2, lanes 3, 4, 9 and 10). 
These results are consistent with the inability to detect the mutant capsid precursors P1-2A (VP1 
Δ185-199), P1-2A (VP1 Δ185-189) and P1-2A (VP1 Δ188-192), with the anti-2A antibody, as shown 
in Fig. S1 (see above).    
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Discussion 
The FMDV 3Cpro is able to cleave a variety of different junction sequences in the virus polyprotein 
[33]. We have shown previously that blocking cleavage of one junction in the FMDV P1-2A did not 
affect processing of the other junctions [28]. In the current studies, it has been shown that 
modifications that modify or delete a short motif in the C-terminus of VP1, can prevent processing 
of the FMDV capsid precursor P1-2A at each of the usual cleavage sites, which are far separated, in 
the linear sequence, from the site of the modifications. The VP0/VP3 cleavage site is more than 400 
amino acids away from the modified motif in the linear sequence while the VP3/VP1 junction is 
almost 200 amino acids away. It seems very likely that this reflects a major change in protein 
conformation for these mutant proteins. Viral proteins, like cellular proteins, are dependent on 
cellular chaperones for correct folding, assembly and function [24]. The viral capsid precursor must 
fold to a conformation that is soluble and recognizable by the viral protease to be processed. After 
the cleavage of the precursor, the mature capsid proteins assemble around the viral genome to 
form the protein shell, which contains 60 copies of each of the subunits. These structures must be 
stable both within, but also outside, the host cells to permit virus spread. Moreover, the virus 
particle must also be able to disassemble upon entry into cells to deliver the viral genome to initiate 
a new infection. Thus, the core structure of the capsid proteins (as distinct from the antigenic loops) 
is probably tightly constrained. 
 
Within the picornavirus family, the general structure of the capsid proteins are very similar [2]. 
Several chaperones are known to facilitate folding of picornavirus capsid proteins [23,26]. The 
mature picornavirus capsid proteins are generated by cleavage of the P1, P1-2A or L-P1-2A 
precursors. Both Hsp90 and p23, a co-chaperone of Hsp90, have been reported to be required for 
processing of the PV P1 precursor into the mature structural proteins [23]. However, interestingly, 
hepatitis A virus (HAV) is not sensitive to the inhibition of Hsp90 function [34]. This indicates that 
HAVs might employ other strategies for correct folding of the capsid precursor. However, it is 
noteworthy that HAV also has several unique characteristics that distinguish it from most other 
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members of the picornavirus family, e.g. slow growth rate, lack of capsid protein myristoylation and 
use of only a single viral protease (3Cpro) for polyprotein processing [35–38].      
 
An earlier study showed that Hsp90 mediates PV P1 folding in cells. Inhibition of this chaperone lead 
to misfolding of P1, which resulted in the targeting of the PV P1 for degradation by the cellular 
quality-control system (proteasome pathway), and thus the level of the PV P1 was strongly reduced 
[23]. These observations are consistent with the results presented here on the FMDV P1-2A. All of 
the FMDV P1-2A precursors that cannot be processed by 3Cpro accumulated to a lower level than 
the P1-2A (wt). This was apparent for the truncated precursors (VP1 Y185Stop, VP1 L158Stop, VP1 
A107Stop, VP1 L53Stop), precursors with small internal deletions (VP1 Δ185-199, VP1 Δ185-189, 
VP1 Δ182-192) and two precursors with single amino acid substitutions (VP1 Y185A and VP1 R188A). 
Thus, it may be that the mutant precursors, which cannot be processed, are misfolded and therefore 
targeted for degradation, hence the reduced level of these products within cells.  
 
Interestingly, Geller et al., [23] showed that inhibition of the Hsp90 chaperone in a cell-free system 
(rabbit reticulocyte lysate), where the proteasomal degradation system is inhibited by free hemin, 
did not reduce the yield of P1 [23]. However, even in the absence of proteasomal degradation, the 
Hsp90 was still required for P1 to fold into a processing-competent conformation, since the PV P1 
precursor, in the absence of Hsp90, adopted a misfolded conformation that could not be recognized 
by the 3CDpro and thus could not be processed into the mature capsid proteins [23].  
 
As indicated above, a critical region that is required for the correct processing of the FMDV capsid 
precursor has now been identified. This motif (YCPRP) is very highly conserved among FMDVs. 
Indeed, the YCPR sequence was found to be completely conserved in over 100 FMDV strains, with 
representatives from all 7 serotypes [15]); only variation to YCPRA has been observed (Fig. 8). 
However, previously, no function for this conserved sequence had been identified. The YCPRP motif 
is also highly conserved among other picornaviruses as well, e.g. it exists as FCPRP in cardioviruses 
and WCPRP in enteroviruses, see Fig. 9. Indeed, both Y to F and Y to W are very conservative amino 
acid substitutions, since all three amino acids have similar properties with non-polar, aromatic side 
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chains. This high conservation likely reflects its importance for correct folding of the capsid 
precursor. The high resistance to cleavage of the junctions between the structural proteins following 
substitution of residues VP1 Y185 and VP1 R188 individually indicates that correct cleavage may be 
dependent on the interaction with several amino acids in this region and thus the whole motif seems 
to be of high importance for correct folding and subsequent processing of the capsid precursor.  
 
An earlier study has showed that removing 50 residues from the C-terminus of the PV VP1 prevented 
cleavage of the two junctions, VP0/VP3 and VP3/VP1, within the capsid precursor in vitro [30]. 
Significantly, these 50 amino acids include the highly conserved motif (WCPRP) identified here, and 
thus indicates the importance of this motif, not only for FMDV, but also more widely within the 
picornavirus family. Similarly, as indicated above, removal of 42 residues (including the YCPRP) from 
the C-terminus of the FMDV VP1 protein completely prevented cleavage of the capsid precursor by 
the 3Cpro in a cell-free system [29]. Recently, we have shown that blocking cleavage of one of the 
junctions within the FMDV P1-2A precursor did not block the cleavage of the other junction within 
the capsid precursor [28]. Thus, the severe inhibition of cleavage of both junctions likely reflects a 
changed overall structure of the capsid precursor, thereby preventing cleavage of both junctions.  
 
It is interesting to note that in HAV, the equivalent region of VP1 has the sequence YFPRA, perhaps 
the two substitutions together account for the lack of sensitivity of HAV assembly to Hsp90 
inhibitors [34]. It can be proposed that the conserved motif serves as a binding site for an important 
chaperone, e.g. Hsp90 (or its partners), that are necessary for correct protein folding. A co-
chaperone of Hsp90, called p23, also seems to be involved in the correct folding of the PV P1. It has 
been reported that treatment with geldanamycin (GA) did not affect the PV P1-Hsp90 interaction, 
but abolished the P1-p23 interaction and thereby affected P1 maturation [23], thus indicating 
different possibilities for chaperone interaction at this specific site. 
 
Picornaviruses are able to adapt very rapidly since they have an RNA dependent RNA polymerase 
with a high error rate and no error correction mechanism. However, Geller et al., [23] showed that 
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PV was unable to adapt to an Hsp90-independent P1 folding pathway during several passages in 
cells in culture or in PV-infected mice when the function of Hsp90 was inhibited by the presence of 
GA. Thus it seems that for the virus to adapt to a folding pathway without the involvement of Hsp90 
requires extensive change [23].    
 
It is interesting that the deletion VP1 Δ194-199 strongly inhibited cleavage at the VP3-VP1 junction, 
without affecting the cleavage of the VP0-VP3 junction (Fig. 4, lane 6). Surprisingly, the alanine 
scanning substitutions through this specific region did not identify any individual residue that 
affected cleavage of any of the junctions (Fig. 7, lanes 4, 6, 8, 10, 12 and 14). However, interestingly 
the P1-2A (VP1 V193A) mutant, modified at a residue adjacent to the deletion, also displayed a 
slower processing rate of this VP0/VP3 junction compared to the wt and the other alanine mutants 
(Fig. 6, lane 12). However, this VP1 V193A mutant does not seem to affect the processing of the 
VP3-VP1 junction to the same extent as the VP1 Δ194-199 mutant. In addition, the VP1 Δ191-195 
mutant also showed a lower processing of this VP3/VP1 junction (Fig. 4b, lane 4) as judged by the 
elevated level of the VP3-VP1 product. These results indicate that the cleavage of the VP3-VP1 
junction, may be dependent on the interaction with several amino acids and that residues within 
the VP1 aa 193-199 region are important for optimal processing of the VP3-VP1 junction, more than 
190 aa away from the site.  
 
We have noted previously that the K210E change in VP1 that severely limited processing at the 
VP1/2A junction also enhanced the yield of VP3-VP1-2A [14]. These studies also identified a genetic 
link between the processing of the VP1/2A junction and the substitution E83K in VP1. Furthermore, 
Escarmis et al., [39] showed that the substitution M54I within the VP1 of serotype C FMDV resulted 
in less efficient processing at the VP3/VP1 junction. Thus, there are multiple, complex, interactions, 
some of which operate “at a distance”, that govern picornavirus capsid protein processing and 
assembly.      
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Methods 
Plasmid construction 
The plasmid pO1K/A22 contains a T7 promoter upstream of a full-length FMDV cDNA with the A22 
Iraq capsid coding sequence within an FMDV O1K backbone as previously described [28,40,41]. To 
investigate the effect of different modifications within the P1-2A, the FMDV cDNA was digested with 
ApaI and then religated to remove most of the sequence encoding the non-structural proteins 
(including the 3Cpro) downstream of the 2A-peptide, as described previously [28]. These constructs 
contained a modified form (W52A substitution) of the Lpro to overcome the negative effect of the L 
protease on protein expression in cells. The modified Lpro with the W52A substitution retains the 
L/P1 cleavage activity but is defective at inducing cleavage of the translation initiation factor eIF4G 
[42]; the primer sequences used to make this modification are listed in Table 1. This parental plasmid 
is referred to throughout as P1-2A (wt) and all modifications were made in this background.  
P1-2A plasmids specifying different truncations  
Variants of the plasmid, with in-frame stop codons introduced to truncate the capsid precursor at 
different sites either at the start of the 2A sequence or within the VP1 coding sequence, were 
generated using site-directed mutagenesis [43]. Briefly, fragments were amplified in PCRs using 
Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific), according to the manufacturer’s 
instructions, to create mega-primers, using the P1-2A (wt) plasmid as template and reverse primers 
specifying the  introduction of STOP codons, together with the forward primer; 14TPN9_F, see Table 
1. The PCR products (between 350 and 900 bp in length depending on where the modification was 
made) were gel purified using the GeneJET Gel purification kit (Thermo Fisher Scientific). These PCR 
products were used as megaprimers for a second round of PCR (500 ng megaprimer, and 100 ng 
template), using the P1-2A (wt) as template to produce the modified plasmids. After the PCR and 
subsequent DpnI digestion of the template plasmid, the products were transformed into chemically 
competent Escherichia coli (E. coli) cells. Plasmids were amplified from individual colonies, purified 
using the GeneJet Plasmid Miniprep Kit (Thermo Fisher Scientific) and screened by Sanger 
Sequencing using the BigDye Terminator v.3.1 Cycle Sequencing kit and a 3500 Genetic Analyzer 
(Applied Biosystems). Plasmids encoding the desired modifications were amplified and purified 
using the QIAGEN Plasmid Midi Kit (Qiagen). All of these constructs encoded P1 that was truncated 
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at different sites by introducing two STOP codons. The plasmids (listed in Table 1) were labelled to 
denote the location of the Stop codons as follows; P1-2A (2A L1Stop), P1-2A (VP1 I205Stop), P1-2A 
(VP1 D199Stop), P1-2A (VP1 Y185Stop), P1-2A (VP1 L158Stop), P1-2A (VP1 A107Stop) and P1-2A 
(VP1 L53Stop); for primer sequences, see Table 1. 
Plasmids encoding P1-2A with internal deletions within the VP1 coding region  
Variants of the P1-2A plasmid that express mutant proteins with various different deletions in the 
C-terminal region of VP1 between residues VP1 185 and VP1 199 were created using site-directed 
mutagenesis, essentially as described above; for primer sequences see Table 1. The plasmids were 
labelled as follows: P1-2A (VP1 Δ185-199), P1-2A (VP1 Δ185-189), P1-2A (VP1 Δ188-192), P1-2A (VP1 
Δ191-195) and P1-2A (VP1 Δ194-199). Furthermore, an additional positive control was included in 
which 13 amino acids within VP1 were deleted, this construct was called P1-2A (VP1 Δ142-154). An 
earlier study had shown that FMDV with this deletion is able to replicate [20,44].    
Alanine scanning mutagenesis of P1-2A 
Alanine substitutions were introduced at the codons for each residue individually between VP1 185 
and VP1 199, with the exception of VP1 A192, where the original alanine codon was substituted by 
one encoding a serine. The mutations were produced using site-directed mutagenesis, as described 
above; the primer sequences are listed in Table 1. These modifications resulted in 15 different 
plasmids: P1-2A (VP1 Y185A), P1-2A (VP1 C186A), P1-2A (VP1 P187A), P1-2A (VP1 R188A), P1-2A 
(VP1 P189A), P1-2A (VP1 L190A), P1-2A (VP1 L191A), P1-2A (VP1 A192S), P1-2A (VP1 V193A), P1-2A 
(VP1 E194A), P1-2A (VP1 V195A), P1-2A (VP1 S196A), P1-2A (VP1 S197A), P1-2A (VP1 Q198A) and 
P1-2A (VP1 D199A).  
Transient expression assays  
Baby hamster kidney (BHK) cells (originally obtained from the ATCC (CCL-10)) were grown in 35-mm 
wells to about 90% confluence, when they were infected with the recombinant vaccinia virus, 
termed vTF7-3 [45] that expresses the T7 RNA polymerase. All the various P1-2A plasmids and the 
3C plasmid (pSKRH3C [46]) express the FMDV cDNA under the control of a T7 promotor. After one 
hour incubation at 37˚C, the vaccinia virus was removed and the cells were transfected with the 
specified plasmid DNA using FuGENE 6 (Promega), as described previously [47]. To obtain the 
97
highest levels of processed capsid protein expression, 1000 ng of the P1-2A plasmid alone or with 
10 ng of the 3Cpro plasmid were used for each transfection of cells [28]. The cells were incubated in 
a CO2 incubator, at 37˚C overnight and then, after removal of the medium, lysed with 500 µl Buffer 
C (20mM Tris-HCl (pH 8.0), 125 mM NaCl and 0.5% NP-40); the cell extracts were clarified by 
centrifugation at 18,000 x g for 10 min at 4˚C. 
Immunoblot analysis  
Immunoblotting was performed using clarified cell lysates mixed with 2 x Laemmli sample buffer 
(Bio-Rad) (containing 25 mM DTT). The proteins were separated by SDS-PAGE using a 12 % Bis-Tris 
gels (Bio-Rad) and transferred to PVDF membranes (Milipore), by wet blotting, at 200 mA for 1.5 
hours. PBS containing bovine serum albumin (BSA) (5%) and Tween20 (0.1%) was used as blocking 
buffer (1 hour at room temperature (RT)) and dilution buffer for the guinea pig anti-FMDV O-Manisa 
(Man) antisera (prepared “in house”, as used previously [28]) (overnight at 4 ˚C) and their 
corresponding secondary antibodies (2 hours at RT). PBS containing skimmed milk powder (5%) and 
Tween20 (0.1%) was used as blocking buffer (1 hour at RT) and dilution buffer for the primary guinea 
pig anti-FMDV A-Iraq antisera (prepared “in house”, as used previously [28]) and the anti-2A-peptide 
antibody (overnight at 4 ˚C) and their corresponding secondary antibody (2 hours at RT). The 
proteins were detected using the following primary antibodies: guinea pig anti-FMDV O-Man 
antisera (1:1000), guinea pig anti-FMDV A-Iraq antisera (1:500) or FMDV anti-2A-peptide antibody 
(1:1000) (Rabbit, ABS31 Merck Millipore). Appropriate HRP-conjugated secondary antibodies (Dako) 
and a chemiluminescence detection kit (Pierce ® ECL Western Blotting Substrate, Thermo Fisher 
Scientific) were used to detect the proteins bound by the primary antibodies. Images were captured 
using a Chem-Doc XRS system (Bio-Rad).  
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Tables 
 
Table 1: Primers used for site-directed mutagenesis 
Primers for Megaprimers Changes  Name 
Plasmids for the Transient expression assay, introducing Leader (W52A) substitution  
SG31_Fw: CCACGACAACTGCgcGTTGAACGCC 
14TPN6_Rev: CAAACAGGTGCTTCTTGAAAAATCTTTC 
Leader (W52A) TGG-
>GCG 
P1-2A (wt) 
Plasmids for the Transient expression assay, introducing Stop codons (truncations) in VP1, note that all constructs 
contains the Leader (W52A) substitution 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK41_R: GAGCAAATCGAAGTTttattaTTGTTTTGC 
2A L1StopStop  
(CTTTTG-> TAATAA) 
P1-2A (2A L1Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK40_R: AAGTTGTTTTGCAGGttattaGATCTTCTG 
VP1 I205StopStop  
(ATTGCA -> TAATAA) 
P1-2A (VP1 I205Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK39_R: ATCTTCTGTTTGTGttattaTTGAGACGAC 
VP1 D199StopStop  
(GACAGA -> TAATAA) 
P1-2A (VP1 D199Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK38_R: CAACAGTGGTCTGGGttattaGAGTTCGGC 
VP1 Y185StopStop  
(TACTGC -> TAATAA)  
P1-2A (VP1 Y185Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK37_R: AAGTTGAAAGAAGCttattaCTGAGCGGCG 
VP1 L158StopStop  
(CTTCCT -> TAATAA) 
P1-2A (VP1 L158Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK36_R: AATGGTGCCTTGAGttattaGGTGGGGTTG 
VP1 A107StopStop  
(GCCTAC -> TAATAA) 
P1-2A (VP1 A107Stop) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK35_R: TGTTGGTGGGTTTGttattaGTCAATGACA 
VP1 L53StopStop  
(CTCATG -> TAATAA) 
P1-2A (VP1 L53Stop) 
Plasmids for the Transient expression assay, introducing small deletions in the VP1 C-terminus between VP1 185 and 
VP1 199 , note that all constructs contains the Leader (W52A) substitution 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK42_R: TGATCTTCTGTTTGTGTCTGAGTTCGGCACGC 
 P1-2A (VP1 Δ185-199) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK43_R: ACACCTCCACTGCCAACAGGAGTTCGGCACGCT 
 P1-2A (VP1 Δ185-189) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK44_R: TTGAGACGACACCTCCACGGGGCAGTAGAGT 
 P1-2A (VP1 Δ188-192) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK45_R: TTGTGTCTGTCTTGAGACGACAGTGGTCTGG 
 P1-2A (VP1 Δ191-195) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK46_R: ATGATCTTCTGTTTGTGTCTCTCCACTGCCAA 
 P1-2A (VP1 Δ194-199) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK47_R: AGCAGGAAGCTGAGCGGCCGTACCACCTGCGGA 
 P1-2A (VP1 Δ142-154) 
Positive control 
Small letters = Nucleotide changes. Bold = Deletion between the two bold nucleotides. 
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Table 2: Primers used for site-directed mutagenesis (alanine substitutions) 
Primers for Megaprimers Changes  Name 
Plasmids for the Transient expression assay, introducing alanine substitutions in the VP1 C-terminus between VP1 
185 and VP1 199 (with the exception of VP1 192 where an alanine was substituted to a serine, note that all 
constructs contains the Leader (W52A) substitution 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK48_R: CAGTGGTCTGGGGCAagcGAGTTCGGCA 
VP1 Y185A 
(TAC-> AGC) 
P1-2A (VP1 Y185A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK49_R: CCAACAGTGGTCTGGGagcGTAGAGTTC 
VP1 C186A 
(TGC-> AGC) 
P1-2A (VP1 C186A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK50_R: ACTGCCAACAGTGGTCTagcGCAGTAGA 
VP1 P187A 
(CCC-> AGC) 
P1-2A (VP1 P187A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK51_R: CCACTGCCAACAGTGGagcGGGGCAGTA 
VP1 R188A 
(AGA-> AGC) 
P1-2A (VP1 R188A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK52_R: CCTCCACTGCCAACAGagcTCTGGGGCA 
VP1 P189A 
(CCA-> AGC) 
P1-2A (VP1 P189A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK53_R: ACACCTCCACTGCCAAagcTGGTCTGGG 
VP1 L190A 
(CTG-> AGC) 
P1-2A (VP1 L190A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK54_R: CGACACCTCCACTGCagcCAGTGGTCTG 
VP1 L191A 
(TGG-> AGC) 
P1-2A (VP1 L191A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK55_R: TGAGACGACACCTCCACagaCAACAGTG 
VP1 A192S 
(GCA-> TCT) 
P1-2A (VP1 A192S) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK56_R: CTTGAGACGACACCTCagcTGCCAACAG 
VP1 V193A 
(GTG-> AGC) 
P1-2A (VP1 V193A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK57_R: GTCTTGAGACGACACagcCACTGCCAAC 
VP1 E194A 
(GAG-> AGC) 
P1-2A (VP1 E194A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK58_R: TGTCTGTCTTGAGACGAagcCTCCACTG 
VP1 V195A 
(GTG-> AGC) 
P1-2A (VP1 V195A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK59_R: TTTGTGTCTGTCTTGAGAagcCACCTCC 
VP1 S196A 
(TCG-> AGC) 
P1-2A (VP1 S196A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK60_R: CTGTTTGTGTCTGTCTTGagcCGACACC 
VP1 S197A 
(TCT-> AGC) 
P1-2A (VP1 S197A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK61_R: TCTGTTTGTGTCTGTCagcAGACGACAC 
VP1 Q198A 
(CAA-> AGC) 
P1-2A (VP1 Q198A) 
14TPN9_Fw: ATCCATGCTGAGTGGGACACAG 
1PTK62_R: TCTGTTTGTGTCTagcTTGAGACGACAC 
VP1 D199A 
(GAC-> AGC) 
P1-2A (VP1 D199A) 
Small letters = Nucleotide changes.  
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Figures 
 
Figure 1 
Schematic representation of the polyprotein processing in three different genera of 
picornaviruses. a) The RNA genome of viruses in the genus Aphthovirus, in which FMDV is the 
prototypic member, encodes a polyprotein that is processed into four primary products namely the 
Leader protease (Lpro), P1-2A, P2 and P3 during, and after, synthesis. The “cleavage” at the 2A/2B 
junction occurs during synthesis by a mechanism known as “ribosomal skipping” [8] or “StopGo” [9]. 
The Lpro mediated cleavage occurs at its own C-terminus, i.e. at the L/P1-2A junction while the 3Cpro 
is responsible for cleavage of the P2/P3 junction. The Cardiovirus polyprotein is also processed into 
the primary products, Leader, P1-2A, P2 and P3 but the Leader protein is removed from the capsid 
precursor by the 3Cpro. The Entero- and Rhinoviruses, do not have a Leader protein and the 
polyprotein is thus processed into only three primary products, namely P1, P2 and P3. In the Entero- 
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and Rhinoviruses the 2A protein is a protease that cleaves the P1/P2 junction. The 3Cpro is 
responsible for cleavage of the P2/P3 junction.     
b) The 3Cpro is sufficient for processing of the capsid precursor, P1-2A, in Aphthoviruses and 
Cardioviruses. The precursor is processed to generate VP0, VP3 and VP1, and a short 2A peptide. In 
Entero- and Rhinoviruses the 3CDpro is responsible for processing the capsid precursor P1 to VP0, 
VP3 and VP1.  
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 Figure 2 
Truncations in the C-terminus of FMDV VP1 affect capsid precursor processing.  
a) Constructs encoding the FMDV P1-2A (wt) were modified to introduce truncations at different 
sites in the VP1 coding sequence. The 2A L1Stop truncation served as a second positive control for 
processing.  
b) Cell lysates from BHK cells (infected with vTF7-3 [45]) transfected with plasmids that express the 
FMDV P1-2A (wt or truncated at the VP1) alone (odd numbered lanes) or with the plasmid pSKRH3C 
[46] encoding the FMDV 3Cpro (even numbered lanes) were analyzed by immunoblotting. Molecular 
mass markers (kDa) are indicated on the left. A negative control (No DNA) was included (lane 17). 
The different structural proteins are indicated on the right of the figure and were detected using 
guinea pig anti-FMDV O-Man antisera. Bound antibodies were visualized using the anti-guinea pig 
HRP-conjugated secondary antibodies and a chemiluminescence detection kit.  
  
108
 Figure 3 
A short region near the C-terminus of FMDV VP1 is required for capsid precursor processing 
Cell lysates were prepared from BHK cells (infected with vTF7-3 [45]) following transfection with 
plasmids that express the FMDV P1-2A wt or with small deletions as indicated either alone (odd 
numbered lanes) or with the plasmid pSKRH3C [46] encoding the 3Cpro (even numbered lanes). The 
samples were analyzed by immunoblotting. A positive control with a deletion known to be tolerated 
in infectious FMDV [20] was included, P1-2A (VP1 Δ142-154), lanes 13 and 14. Molecular mass 
markers (kDa) are indicated on the left. A negative control (No DNA) was used in lane 15. The 
structural proteins corresponding to the different bands are indicated on the right of the figure and 
were detected using guinea pig anti-FMDV O-Man antisera. Bound antibodies were visualized using 
the anti-guinea pig HRP-conjugated secondary antibodies and a chemiluminescence detection kit.  
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 Figure 4 
A region near the C-terminus of FMDV VP1 required for processing of the VP3/VP1 junction. a) 
The P1-2A precursor (wt or with small deletions as indicated) was expressed alone or with 3Cpro in 
transient expression assays in BHK cells as for Fig. 3. Cell lysates were prepared and analyzed by 
immunoblotting. The structural proteins corresponding to the different bands are indicated and 
were detected using guinea pig anti-FMDV A-Iraq antisera. Bound antibodies were visualized using 
the anti-guinea pig HRP-conjugated secondary antibodies and chemiluminescence detection. The 
odd numbered lanes show the P1-2A precursors expressed alone and the even numbered lanes 
show the precursor co-expressed with 3Cpro. Molecular mass markers (kDa) are indicated on the left. 
A negative control (No DNA) is included in lane 9. A positive control with a deletion known to be 
tolerated in replicating FMDV [20] was included, P1-2A (VP1 Δ142-154), lanes 7 and 8.  
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b)  The 2A L2P substitution was introduced into the plasmids encoding P1-2A (wt), P1-2A (VP1 Δ191-
195), P1-2A (VP1 Δ194-199) and the positive control P1-2A (VP1 Δ142-154). This 2A L2P substitution 
blocks cleavage of the VP1/2A junction and increased the sensitivity of detection of VP1. The 
negative control (No DNA) is indicated.  
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 Figure 5 
Identification of amino acids between residues VP1 185 and 188 required for capsid precursor 
processing   
The P1-2A precursors (wt or having alanine substitutions between VP1 185 and VP1 188) were 
expressed alone or in the presence of 3Cpro and analyzed by immunoblotting (as above). The 
structural proteins corresponding to the different products are indicated on the right of the figure 
and were detected using guinea pig anti-FMDV O-Man antisera (a) or guinea pig anti-FMDV A-Iraq 
antisera (b). Bound antibodies were visualized using the anti-guinea pig HRP-conjugated secondary 
antibodies and a chemiluminescence detection kit. Molecular mass markers (kDa) are indicated on 
the left. A negative control (No DNA) is included in lane 11.     
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 Figure 6 
Identification of residues between VP1 189 and 193 required for processing at the VP3/VP1 
junction. The P1-2A precursors (wt or with alanine substitutions between VP1 189 and VP1 193, 
with the exception of VP1 192 where an alanine were substituted to a serine, as indicated) were 
expressed alone or in the presence of 3Cpro and analyzed by immunoblotting. The capsid proteins 
are indicated on the right of the figure. Proteins were detected using guinea pig anti-FMDV O-Man 
antisera (a) or with guinea pig anti-FMDV A-Iraq antisera (b). Bound antibodies were visualized using 
the anti-guinea pig HRP-conjugated secondary antibodies and a chemiluminescence detection kit. 
Molecular mass markers (kDa) are indicated on the left. A negative control (No DNA) is included in 
lane 13.       
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Figure 7 
Multiple residues within the VP1 194-199 region are important for processing of the VP3/VP1 
junction.  
The P1-2A precursors (wt or with alanine substitutions between VP1 194 and VP1 199, as indicated) 
were expressed alone or in the presence of 3Cpro and analyzed by immunoblotting. The different 
capsid proteins are indicated on the right of the figure. Proteins were detected using guinea pig anti-
FMDV O-Man antisera (a) or guinea pig anti-FMDV A-Iraq antisera (b). Bound antibodies were 
visualized using the anti-guinea pig HRP-conjugated secondary antibodies and a chemiluminescence 
detection kit. Molecular mass markers (kDa) are indicated on the left. A negative control (No DNA) 
is included in lane 15.  
114
VP1 aa   173                   193                     
 sat3k    GDVYYRMKRT ELYCPRPLRV RYTH.TADRY KTPLVKPEKQ  
 sat3b    GDAYYRMKRA ELYCPRPLRV RYTH.TTDRY KTPLVKPDKQ  
 sat2r    VDVYYRMKRA ELYCPRPLLP AYDHAGRDRF DAPIGV.EKQ  
 sat2k    VDVYYRMKRA ELYCPRALLP AYTHANSDRF DAPIGV.EKQ  
 sat1r    VDVYVRMKRA ELYCPRPLLT HYDHAGKDRY KTAITKPVKQ  
 sat1i    VDVYVRMKRA ELYCPRPLLT TYDHASTDRY KVSLVAPEKQ  
    ou    TELLYRMKRA ETYCPRPLLA IHPS..EARH KQKIVAPVKQ  
    ot    TELLYRMKRA ETYCPRPLLA IQPS..DARH KQRIVAPAKQ  
    or    TELLYRMKRA ETYCPRPLLA IHPD..EARH KQKIVAPTKQ  
    o6    NELLYRMKRA ETYCPRPLLA IHPA..EARH KQKIVAPVKQ  
    o2    TELLYRMKRA ETYCPRPLLA IHPT..EARH KQKIVAPAKQ  
   o10    TELLYRMKRA ETYCPRPLLA IHPS..EARH KQKIVAPVKQ  
    o1    TELLYRMKRA ETYCPRPLLA IHPT..EARH KQKIVAPVKQ  
    cs    TELLVRMKRA ELYCPRPILP IQPT..GDRR KQQLVAPAKQ  
    c5    TELLVRMKRA ELYCPRPILP IQPT..GDRH KQPLIAPAKQ  
    c4    TELLVRMKRA ELYCPRPILP VQPA..GDRH KQPLIAPEKQ  
    c3    TELLVRMKRA ELYCPRPILP IQPT..GDRH KQPLIAPAKQ  
    c1    TELLVRMKRA ELYCPRPILP IQPT..GDRH KQPLVAPAKQ  
asia1e    TELLIRMKRA ETYCPRPLLA LDTT..QDRR KQEIIAPEKQ  
asia1d    TELLIRMKRA ETYCPRPLLA LDTT..QDRR KQEIIAPEKQ  
asia1c    TELLIRMKRA ETYCPRPLLA LDTT..HDRR KQEIIAPEKQ  
asia1b    TELLIRMKRA ETYCPRPLLA LDTT..QDRR KQEIIAPAKQ  
asia1a    TELLIRMKRA ETYCPRPLLA LDTT..QDRR KQEIIAPEKQ  
    a5    HELLVRMKRA ELYCPRPLLA IEVS.SQDRH KQKIIAPARQ  
    a4    HELLVRMKRA ELYCPRPLLA IEVS.SQDRH KQKIIAPAKQ  
   a30    HELLVRMKRA ELYCPRPLLA LEVI.SQDRH KQKIIAPEKQ  
   a29    HELLVRMKRA ELYCPRPLLA VEVS.TQDRH KQKIIAPAKQ  
   a24    HELLVRMKRA ELYCPRPLLA IEVS.SQDRH KQKIIAPAKQ  
   a22    HELLVRMKRA ELYCPRPLLA VEVS.SQDRH KQKIIAPAKQ  
   a20    HELLVRMKRA ELYCPRPLLA IEVS.SQDRH KQKIIAPAKQ  
   a17    HELLVRMKRA ELYCPRPLLA IEVL.SQDRY KQKIIAPAKQ  
   a10    HELLVRMKRA ELYCPRPLLA IEVS.SQDRY KQKIIAPAKQ  
 
>97%con   .....RMKRA E.YCPRP... ........R. ........KQ 
                        
 
Figure 8 
Alignment of the VP1 C-terminus from different FMDV serotypes 
Amino acid alignment of the VP1 C-terminus of different strains of FMDV, including examples of all 
seven serotypes. The yellow color represents amino acids that are more that 97% conserved among 
the different strains. The conserved motif YCPRP (VP1 185-189) is marked with a box in the 
consensus sequence. The alignment was prepared from sequences published previously [15]. 
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  VP1 aa   173 193  
  FMDA10   HELLVRMKRA ELYCPRPLLA IKVTS.QDRY KQKIIAPAKQ 
  FMDA12   HELLVRMKRA ELYCPRPLLA IEVSS.QDRH KQKIIAPGKQ 
   FMDC1   TELLVRMKRA ELYCPRPILP IQPT..GDRH KQPLVAPAKQ  
  FMDO1K   TELLYRMKRA ETYCPRPLLA IHPT..EARH KQKIVAPVKQ   
 FMDSat2   VDVYYRMKRA ELYCPRALLP AYTHAGGDRF DAPI.GVAKQ 
 FMDSat3   GDAYYRMKRA ELYCPRPLRV RYTHTT.DRY KTPLVKPDKQ 
    EMCR   FTVYLRYKNK RVFCPRPTVF FPWPTSG.DK IDMTPRAGVL 
   EMCBd   FTVYLRYKNM RVFCPRPTVF FPWPSSG.DK IDMTPRAGVL 
   EMCBc   FTVYLRYKNM RVFCPRPTVF FPWPSSG.DK IDMTPRAGVL 
   EMCDd   FTVYLRYKNM RVFCPRPTVF FPWPSSG.DK IDMTPRAGVL 
   EMCDc   FTVYLRYKNM RVFCPRPTVF FPWPSSG.DK IDMTPRAGVL 
   Mengo   FTVYLRYKNM RVFCPRPTVF FPWPTSG.DK IDMTPRAGVL 
 TMEBeAn   ASVRIRYKKM KVFCPRPTLF FPWPTPTTTK INADNPVPIL 
  TMEGd7   ASVRIRYKKM KVFCPRPTLF FPWPTPTTTK INADNPVPIL 
   TMEDa   ASVRIRYKKM KVFCPRPTLF FPWPVSTRSK INADNPVPIL 
    HALA   SCYLSVTEQS EFYFPRAPLN SNAMLSTESM MSRIAAGDLE 
 HACr326   SCYLSVTQQS EFYFPRAPLN SNAMLSTESM MSRIAAGDLE 
 HAHas15   SCYLSVTEQS EFYFPRAPLN SNAMLSTESM MSRIAAGDLE 
 HAHm175   SCYLSVTEQS EFYFPRAPLN SNAMLSTESM MSRIAAGDLE   
HAHm175a   SCYLSVTEQS EFYFPRAPLN SNAMLSTVSM MSRIAAGDLE 
   HAMbb   SCYLSVTEQS EFYFPRAPLN SNAMLSTESM MSRIAAGDLE 
 Polio1M   IRVYLKPKHI RVWCPRPPRA VAYYGPG.VD YKDGTLTPLS 
 Polio1S   IRVYLKPKHI RVWCPRPPRA VAYYGPG.VD YKDGTLTPLS 
Polio2La   IRVYMKPKHV RVWCPRPPRA VPYYGPG.VD YKDG.LAPLP 
 Polio2W   IRVYMKPKHV RVWCPRPPRA VPYYGPG.VD YKDG.LTPLP 
 Polio2S   IRVYMKPKHV RVWCPRPPRA VPYFGPG.VD YKDG.LTPLP 
Polio3Le   VRIYMKPKHV RVWCPRPPRA VPYYGPG.VD YKNN.LDPLS 
 Polio3F   VRVYMKPKHV RVWCPRPPRA VPYYGPG.VD YKDG.LAPLS 
 Polio3S   VRIYMKPKHV RVWCPRPPRA VPYYGPG.VD YRNN.LDPLS 
   CoxA9   IRVYFKPKHT RAWVPRPPRL CQYKKAFSVD FTPTPITDTR 
  CoxA21   VRVYMKPKHI RCWCPRPPRA VLYRGEG.VD MISSAIQPLT 
   CoxB1   VRIYFKPKHV KAWVPRPPRL CQYEKQKNVN FNPTGVTTTR 
   CoxB3   IRIYFKPKHV KAWIPRPPRL CQYEKAKNVN FQPSGVTTTR 
   CoxB4   IRIYFKPKHV KAYVPRPPRL CQYKKAKSVN FDVEAVTAER 
 EV70J67   VRVYMKPKHI KAWAPRAPRT MPYTNILNNN YVGRSAAPNA   
 BEV1Vg5   FRIYAKIKHT SCWIPRAPRQ APYKKRYNLV FSGDSDRICS 
 BEV2Rm2   VRFYAKPKHL KCWMPRAPRA VPYKSRYTGV Y.DTVEKFCD 
BEV3Ps87   VRVYAKPKHV KGWIPRSPRM TPYKSRYTGV YT.DTTKFCA 
SVDJap76   VRIYFKPKHV KTWVPRPPRL CQYQKAGNVN FEPTGVTEGR 
 SVDUK72   VRIYFKPKHV KTWVPRPPRL CQYQKAGNVN FEPTGVTEGR 
 Rhino1a   THIYHKAKHT KAWCPRPPRA VPYTHSHVTN YMPETGDVTT 
 Rhino1b   THIYHKAKHT KAWCPRPPRA VPYTHSRVTN YVPKTGDVTT 
  Rhino2   TRIYHKAKHV KAWCPRPPRA LEYTRAHRTN FKIEDRSIQT 
  Rhino9   TRIYHKAKHV KAWCPRPPRA VEYIHTHVTN YKPSTGDYAT 
 Rhino14   IRVYHRAKHV EAWIPRAPRA LPYTSIGRTN YPKNTEPVIK 
 Rhino15   TRVYHKAKHV KAWCPRPPRA VEYTHTHVTN YKPQDGDVTT 
 Rhino85   TRVYHKAKHV KAWCPRAPRA VPYTHTRSTN YVPQDGEVKI 
 Rhino89   CRIYHKAKHI KAWCPRPPRA VAYQHTHSTN YIPSNGEATT 
Consensus -RVY-K-KHV K-W-PRPPR- --Y------N Y---------
Aphthovirus 
Cardiovirus 
Hepatovirus 
Enterovirus 
Genus
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Figure 9 
Alignment of different picornaviruses at the VP1 C-terminus  
Amino acid alignment of the VP1 C-terminus of diverse picornaviruses. The black box indicates the 
highly conserved motif (VP1 185-189 in FMDV) that is important for correct processing of the capsid 
precursor. The sequences are numbered according to the FMDV residues. The yellow color 
represents amino acids that are identical with the YCPRP motif found in FMDV. Conservative 
substitutions are indicated with a similar color i.e. yellow for Y, orange for F and pink for W. The C 
residue at VP1 186 (according to FMDV VP1 numbers) is conserved in 31 out of 48 aligned 
picornaviruses (marked with yellow). The P and R at VP1 187 and 188 are 100% conserved amongst 
all of the aligned picornaviruses (marked with yellow). The P at VP1 189 (according to FMDV VP1 
numbers) is conserved in 35 out of 48 of the aligned picornaviruses, differences from the P are seen 
in all of the hepatoviruses and a few of the enteroviruses. The alignment was taken from Ann 
Palmenberg’s laboratory website (http://www.virology.wisc.edu/acp/Aligns/aligns/picorna.p1) and 
highlighted manually. 
Abbreviations: FMDV = Foot-and-mouth disease virus, EMC  = Encephalomyocarditis virus, TME = 
Theiler’s murine encephalomyelitis virus, HA = Hepatitis A virus, Cox = Coxsackievirus, EV = 
Enterovirus, BEV = Bovine enterovirus, SVD = Swine vesicular disease virus.   
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 Figure 10 
Model: Potential role of chaperone binding to a conserved motif for correct capsid precursor 
folding 
a) Hsp90 (or other chaperones and co-chaperones) is believed to bind to the P1-2A precursor (or P1 
for enteroviruses) to facilitate folding into a state where the 3Cpro (or 3CDpro) is able to process the 
precursor to the mature structural capsid proteins prior to particle assembly.    
b)  It is hypothesized that the conserved motif, YCPRP, in the C-terminus of VP1 is required for the 
binding of a chaperone (or co-chaperone). In the absence of this interaction, the precursor will be 
incorrectly folded and hence 3Cpro (or 3CDpro) will not recognize the cleavage sites; the misfolded, 
intact, precursor will be degraded by the proteasome. 
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Supplementary figures 
 
Figure S1 
Effect of small deletions on processing of P1-2A at the FMDV VP1/2A junction. The P1-2A precursor 
(wt or with small deletions as indicated) was expressed alone or with 3Cpro in transient expression 
assays in BHK cells as for Fig. 3. Cell lysates were prepared and analyzed by immunoblotting using 
rabbit anti-2A antibodies. Bound antibodies were visualized using the anti-rabbit HRP-conjugated 
secondary antibodies and chemiluminescence detection. The odd numbered lanes show the P1-2A 
precursors expressed alone and the even numbered lanes show the precursor co-expressed with 
3Cpro. Molecular mass markers (kDa) are indicated on the left. A negative control (No DNA) is 
included in lane 15. A positive control with a deletion known to be tolerated in replicating FMDV 
[20] was included, P1-2A (VP1 Δ142-154), lanes 13 and 14. Note, the free 2A peptide (18 residues 
long) is too small to detect in this system. 
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Figure S2. 
Analysis of processing at the FMDV VP1/2A junction in P1-2A precursors modified at individual 
residues between VP1 185 and 188  
The P1-2A precursors (wt or having alanine substitutions between VP1 185 and VP1 188) were 
expressed alone or in the presence of 3Cpro and analyzed by immunoblotting. The P1-2A was 
detected using rabbit anti-2A antibodies and visualized using rabbit HRP-conjugated secondary 
antibodies and a chemiluminescence detection kit. Molecular mass markers (kDa) are indicated on 
the left. A negative control (No DNA) is included in lane 11. Note, the free 2A peptide (18 residues 
long) is too small to detect in this system. 
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4.   Conclusion and perspectives 
FMDV remains an important global threat to animal production and the related economy. FMD is 
still endemic in many countries worldwide, and the distribution of the disease roughly reflects lack 
of economic development. The disease has been eradicated from the more developed countries, 
but outbreaks in such countries sometimes still occur and then cause huge economic losses. Despite 
substantial information about the virus, FMD remains a major threat to the livestock industries. 
Vaccination alone is unlikely to control the disease and strict control of animal movement is also 
required. In less developed countries there are often deficiencies in submitting samples to reference 
laboratories, which makes early detection and response difficult (Jamal & Belsham, 2013). 
Alternative, strategies to control the disease may also be required to achieve eradication globally. 
 
The structural proteins, VP0, VP3 and VP1 are generated by processing of the capsid precursor P1-
2A. Correct processing of these junctions is crucial for the virus to create new infectious virus 
particles and thus this is very important in the virus lifecycle. This makes the processing of the capsid 
precursor an attractive target for antiviral drugs to interfere or block the virus lifecycle. To increase 
the knowledge about processing of the capsid precursor, this Ph.D. study has been focused on the 
features of the P1-2A precursor that affect it’s processing. 
 
In the first manuscript, we have modified the amino acid sequences at the VP1/2A junction. 
Interestingly, it was recently shown that this junction could be blocked by introducing a substitution 
VP1 K210E (at the P2 residue in the VP1/2A junction), without interfering with the virus lifecycle 
(Gullberg et al., 2013a). This finding, made it possible to introduce different substitutions near this 
junction in full-length FMDV to investigate the effect of these substitutions without blocking virus 
infectivity, even though the processing of this junction could be modified. In contrast, it was 
expected that blocking cleavage of one of the junctions between the structural proteins i.e. the 
VP0/VP3- or the VP3/VP1 junction would prevent the formation of new virus particles, and thus 
made these junctions harder to study in full length FMDVs.    
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The grouping of cleavage sites according to the Q/x or E/x junctions revealed that sites belonging to 
the Q/x group typically also had a K at the P2 position (Curry et al., 2007). The FMDV A22 Iraq VP1/2A 
junction has a Q at the P1 position and indeed has a K at the P2 position. In manuscript 1 we 
substituted the P2 lysine in the VP1/2A junction with different amino acids (Q, A, V, M, N, E and R) 
(note that the E was already known to block processing of this junction in FMDV O1 Manisa (Gullberg 
et al., 2013a)) by modifying the full-length FMDV cDNA. Interestingly, only the P2 K (wt) junction 
and the mutant with the substitution to an R could be processed by the 3Cpro, indicating that 3Cpro 
has a strong preference for a positively charged amino acid at this specific site, see manuscript 1.  
 
As mentioned, the junctions belonging to the Q/x group typically have a K at the P2 position. Results 
from manuscript 1, showed that the VP1/2A junction could be processed only when having the wt 
lysine or a substitution to an arginine at the P2 indicating that, the 3Cpro preferred a positively 
charged amino acid. In contrast, the 3Cpro can process the E/x group of sites without being very 
constrained about the P2 residue, as there are an almost equal number of E/x junctions having 
either a K, A, T, H or Q at the P2 position. However, an arginine is never observed at the P2 residue 
in the E/x junctions. The VP0/VP3 junction of the FMDV A22 Iraq belongs to the E/x group and has 
a lysine on the P2 residue (VP2 K217). However, introducing an R at this residue in a transient 
expression system expressing the P1-2A precursor together with 3Cpro, strongly reduced the 
cleavage efficiency, indicating that the R is not optimal at this site. However, some VP0 was detected 
upon the VP2 K217R substitution indicating that the 3Cpro could still process this junction but at a 
slower rate. In contrast, introducing the VP2 K217E, which is never observed at this position in any 
of the FMDV junctions (Carrillo et al., 2005; Curry et al., 2007), completely prevented cleavage of 
the VP0/VP3 junction by the 3Cpro in the transient expression assay, see manuscript 2 (Kristensen et 
al., 2018). This finding is consistent with earlier findings on the VP1/2A junction where the VP1 
K210E (P2 residue) severely blocked processing of this junction (Gullberg et al., 2013a; Kristensen 
et al., 2016). 
 
A substitution encoding VP3 I2P downstream of the VP0/VP3 junction was introduced at the P2´ 
residue. Substitutions with a proline are usually considered as very drastic substitutions, because 
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the P residue induces a kink in the amino acid chain, and thus can influence the structure. However, 
a P at the P2´residue within the E/x junction is actually the most abundant amino acid at this specific 
site, and thus it was believed that 3Cpro might be able to partially process this junction. The 
expression of the P1-2A (VP3 I2P) in the transient expression assay revealed that processing of the 
VP0/VP3 junction can occur, but at a slower rate compared to the P1-2A (wt), and equal amounts 
of the VP0-VP3 intermediate and processed VP0 were detected, see Fig.2 in Manuscript 2. 
Interestingly, even though the P1-2A (VP2 K217R) and the P1-2A (VP3 I2P) were expressed and 
cleaved, in the transient expression assay, at approximately the same rate by the 3Cpro, the full 
length FMDV (VP3 I2P) did not generate any infectious virus, whereas the FMDV (VP2 K217R) did. 
 
The P1 Q, at the VP1/2A junction in a small peptide assay forms three hydrogen bonds to the S1 
pocket of the 3Cpro (Zunszain et al., 2010). Interestingly, the P1 E binds in approximately the same 
manner, thereby explaining the broader tolerance of FMDV 3Cpro for either E or Q at the P1 residue 
compared to the 3Cpro from other picornaviruses. It was earlier shown that the Q in a short peptide 
corresponding to the VP1/2A junction could be substituted to an E, which only reduced cleavage 
activity by two-fold (Birtley et al., 2005; Zunszain et al., 2010). In contrast, changing the P1 Q to 
either asparagine (N) or aspartate (D) completely prevented cleavage. In manuscript 2, the FMDV 
A22 Iraq VP3/VP1 junction, which belongs to the Q/x group, was modified just upstream or 
downstream of the cleavage site, i.e. at P1 and P1´ in two different constructs. Since the FMDV 3Cpro 
has only been reported to be able to cleave junctions containing either an E or Q, it was expected 
that the VP3 Q221P substituting would completely prevent cleavage. The transient expression of 
this mutant revealed that cleavage of this junction had been severely blocked, since no VP1 could 
be detected but only the VP3-VP1 intermediate. 
 
Large hydrophobic amino acids (i.e. L, I or T) are required at the P1´ within the Q/x junction group 
(Curry et al., 2007). Substituting the P1´ L to either G or C, in the Q/x group, as assessed using a 
peptide cleavage assay, reduced cleavage activity of FMDV 3Cpro to around 10% and 50% 
respectively (Zunszain et al., 2010). Interestingly the binding of the P1´ L within this short peptide 
creates a pocket within the 3Cpro, where the L is incorporated (Zunszain et al., 2010). Thus, this 
125 
 
residue seems to be in close interaction with the 3Cpro. The P1´residue within the Q/x group is most 
often an L, T or I (Curry et al., 2007), however S, V, A and M are also found at this specific site (Carrillo 
et al., 2005). In manuscript 2, a proline was introduced at the P1´ residue, P1-2A (VP1 T1P), which 
completely prevented cleavage by the 3Cpro.  
 
In manuscript 1 (Kristensen et al., 2016), we showed that the VP1/2A junction could be fully 
processed by the 3Cpro following the VP1 K210R substitution in full length FMDV, and thus it was a 
bit surprising that cleavage of the VP0/VP3 junction within the P1-2A (VP2 K217R) mutant was 
clearly reduced, see manuscript 2 (Kristensen et al., 2018). However, the FMDV (VP2 K217R) was 
the only full-length FMDV mutant, with modifications at the cleavage sites (at the VP0/VP3 and 
VP3/VP1 junctions) in the capsid precursor that could be rescued. Interestingly, cleavage of the 
VP0/VP3 junction in the full length FMDV (VP2 K217R) in the later state of infection did not seem to 
be impeded to the same degree as the in the transient expression of P1-2A (VP2 K217R), compare 
Fig. 2 and 5, manuscript 2. However, at the early state of infection (3 h p.i.) there is approximately 
similar amount of the VP0-VP3 intermediate and VP0. This probably reflects that the 3Cpro is cleaving 
this mutant junction at a slower rate. However, at later stages in the FMDV infection there will be 
much more 3Cpro present, and thus more enzyme to cleave the mutant VP0-VP3 intermediate.       
 
Based on sucrose gradient analysis, separating un-assembled material, empty capsids and virus 
particles it was clear that the VP0-VP3 intermediate was neither incorporated into empty capsids 
nor into the virus particles but was only present in un-assembled material. However, based on the 
known structure from a pentamer within the FMDV A22 Iraq capsid (Curry et al., 1996), it was clear 
that the VP2 C-terminus and the VP3 N-terminus are located very far from each other in the virus 
structure, see manuscript 2, Fig. 7. It is very likely that this is the reason why the intermediate was 
not incorporated into neither the empty capsids nor the virus particles.  
 
Overall, manuscript 1 and 2 provided important information about the junctions separating the 
capsid proteins. The VP0/VP3 junction belongs to the E/x group whereas the VP3/VP1- and the 
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VP1/2A junction belongs to the Q/x group, for the FMDV A22 Iraq. For this strain, the virus has a K 
on the P2 residue, both within the VP0/VP3- and the VP1/2A junction. Substituting this K to an E 
severely impeded cleavage of both junctions. However, substituting the K to an R, which is 
considered a fairly conservative substitution since both amino acids have positively charged 
sidechains, had different effect on the two junctions. Based on the logo plot separating the two 
junction groups (Fig. 9), it was clear that the Q/x group (VP1/2A) has a high preference for a K at this 
site. Nevertheless, an R at this site allowed the junction to be fully processed, whereas for instance 
a Q or an A blocked processing of the junction. Interestingly, all of these three amino acids are all 
present at the P2 residue in different junctions belonging to the Q/x group (Carrillo et al., 2005; 
Curry et al., 2007). This clearly indicates, that the 3Cpro is very constrained about the specific amino 
acid sequences flanking the different junctions. Furthermore, it tells us that one amino acid which 
is tolerated in one junction might not be tolerated in another junction, even though the junctions 
belongs to the same group. Moreover, an arginine is never observed at the P2 position in the E/x 
group. However, introducing this amino acid at the VP0/VP3 junction caused a reduced rate of 
cleavage at this specific site but it appeared that 3Cpro was still able to recognize the junction since 
the processed VP0 was readily detected. Furthermore, the substitution could be tolerated in full-
length FMDV. 
 
Before conducting the studies described in manuscripts 1 and 2, we were aware that the FMDV 3Cpro 
was a very complex enzyme, recognizing various amino acids within different junctions all over the 
FMDV polyprotein. However, based on the results presented in manuscripts 1 and 2, we could 
conclude that some amino acids, which are present at a specific site within one of the junction 
groups, might not be tolerated at the same site in another junction within the same group. 
Moreover, we concluded in manuscript 2, that blocking processing of one junction i.e. the VP0/VP3 
or the VP3/VP1 did not prevent processing of the other junction or the VP1/2A junction. Thus, it 
seems that there is no strict order of processing within the P1-2A capsid precursor. Furthermore, in 
manuscript 2, we were able to rescue a FMDV displaying reduced cleavage of the VP0/VP3 junction. 
Interestingly, this mutant FMDV was not significantly affected in the growth rate by this reduced 
cleavage. The FMDV A22 Iraq tends to form many empty capsids during an infection (Curry et al., 
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1997), which suggests that an excess of capsids is produced. This might also explain, why this FMDV 
(VP2 K217R) is not affected in its growth rate and why adaptions did not occur.               
 
As described in manuscripts 1 and 2, the sequences flanking the junction are highly important for 
correct processing by the 3Cpro. However, the correct folding of the P1-2A precursor is also highly 
important for the processing. An earlier study showed that truncating the P1-2A precursor, by 
removing the 2A and 42 residues of the C-terminus of VP1, blocked the processing of both the 
VP0/VP3- and the VP3/VP1 junctions (Ryan et al., 1989) in a cell-free translation system . Similarly, 
truncating the PV P1-precursor, by removing 50 aa from the C-terminus of VP1 also blocked the 
processing of the capsid precursor by the PV 3CDpro (Ypma-Wong & Semler, 1987). Manuscript 2 
revealed that processing of the three junctions in the FMDV capsid precursor were mutually 
independent (Kristensen et al., 2018), indicating that the blocking of the cleavage observed in these 
earlier studies was likely due to an overall structure change in the capsid precursor, rather than 
blocking of one junction thereby affecting the other junction.  
 
Based on these two studies on different picornaviruses, Stop-codons was introduced at different 
sites within the VP1-coding region in a construct containing the coding sequence for FMDV A22 Iraq 
P1-2A. These constructs, with truncations at different sites, were expressed in a transient expression 
assay in the presence and absence of 3Cpro. Interestingly, this identified a region within the VP1 185-
199 that was important for processing. The truncation to VP1 199 resulted in processed capsid 
proteins in the presence of 3Cpro, just like the wt. In contrast, the truncation to VP1 185 resulted in 
a non-processed capsid precursor in the presence of 3Cpro. Moreover, this non-processable P1-2A 
(VP1 185Stop) mutant accumulated to a lower level in the cells lysates compared to the wt and the 
other processable mutants. After identifying this region (VP1 185-199), smaller deletions were 
introduced into this region, which clearly indicated that the sequence VP1 185-190 was required for 
capsid precursor processing. In addition, the mutants having small deletions within this region also 
accumulated to a lower level than wt. Further analysis of this critical region was carried out by 
introducing single amino acid substitutions. This identified two residues of high importance within 
the area, namely VP1 Y185 and R188. Substituting these aa to an A, individually, severely impeded 
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cleavage of precursor by the 3Cpro. In addition, these non-processable single-aa-substitution 
precursors also accumulated to a lower level compared to the wt and the mutants that could be 
processed by the 3Cpro.  
 
Based on the experiments in manuscript 3, it was found that this YCPRP motif was required for 
processing of the FMDV capsid precursor. Interestingly this motif is located more than 400 aa away 
from the VP0/VP3 junction and almost 200 aa away from the VP3/VP1 junction. An alignment 
revealed that the YCPRP motif  was highly conserved among FMDVs from all 7 serotypes. Indeed, 
this motif was conserved among more than 100 FMDV strains (Carrillo et al., 2005)); only one strain 
had a variation to YCPRA, see manuscript 3, Fig. 8).  The YCPRP motif was also found to be highly 
conserved amongst other picornaviruses. In cardioviruses, it exists as FCPRP and in enteroviruses it 
is present  as WCPRP, see manuscript 3, Fig. 9. The high conservation of this motif likely reflects its 
importance for correct folding and subsequent processing of the capsid precursor. This conserved 
motif also provided an explanation about the earlier findings with FMDV and PV where capsid 
precursor processing was prevented upon truncation of the capsid precursor (Ypma-Wong & 
Semler, 1987; Ryan et al., 1989). Indeed, this motif was removed upon the truncation used in both 
of these studies and thus the results are fully consistent.    
  
It is likely that this conserved motif is involved in the binding of different cellular factors, such as 
chaperones, required for correct capsid precursor folding. Hsp90 seems to be required for capsid 
precursor processing and assembly in different picornaviruses (Geller et al., 2007; Newman et al., 
2017). Both Hsp90 and Hsp70 have been found to interact with the PV capsid precursor (Macejak & 
Sarnow, 1992; Geller et al., 2007). The interaction between PV P1 and Hsp90 is believed to be 
required for correct folding and for protecting the PV capsid precursor from degradation by 
proteasomes (Geller et al., 2007). In the study by Geller et al., (2007), it was shown that the PV 
capsid precursor accumulated to a lower level in the cell lysate following inhibition of Hsp90, due to 
degradation by the proteasome. All of the mutants identified in manuscript 3, that were highly 
resistant to processing by the 3Cpro and displayed decreased accumulation therefore mirrors the 
known effects of blocking interaction between the capsid precursor and Hsp90 (Geller et al., 2007; 
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Newman et al., 2017). Thus, it seems likely that the conserved motif acts as an interaction site with 
a chaperone (or its co-chaperone), perhaps the Hsp90.  
 
Further investigation of the motif identified in manuscript 3, would be of high relevance in relation 
to the lifecycle of many different picornaviruses. The identification of the conserved motif and the 
effect upon changing this, was “only” carried out expressing the FMDV P1-2A precursor together 
with the 3Cpro in a transient expression assay. However, very recently we have introduced some of 
these modifications into full-length FMDVs (Kristensen & Belsham, unpublished data). We have not 
been able to rescue virus from the FMDV (VP1 Y185A) mutant (consistent with the failure to produce 
processed capsid proteins) but surprisingly we got virus back from the FMDV (VP1 R188A) mutant. 
Sequencing of the rescued mutant virus has revealed that adaptions had occurred resulting in aa 
substitutions within both the VP2 and VP3 proteins, one of them being in close contact with the 
conserved motif in the mature virus particle. Hopefully, we will be able to determine the relevance 
of these aa substitutions in the near future. Furthermore, it would also be very relevant to identify 
proteins that interact with this motif. It is likely that the Hsp90 is involved, either directly or 
indirectly through interaction with a co-chaperone. However, it is also possible that this newly 
identified motif interacts with another protein, which has not previously been associated with the 
picornavirus family. Earlier results indicate that inhibitors of hsp90  can function as an effective 
antiviral agent (Geller et al., 2007; Newman et al., 2017). However, identification of the interacting 
cellular factors with the conserved motif, might identify other important proteins which might have 
advantages as a target for new antiviral compounds.  
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